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Diabetes Mellitus is characterized by high blood sugar and is caused by resistance to 
(type 2) or insufficiency of (type 1) the pancreatic β-cell hormone insulin. Most 
commonly, type 2 diabetes is associated with obesity whereas type 1 diabetes is 
largely a result of immune-mediated destruction of the β-cell. One rare but 
significant cause of type 2 diabetes is excess blood glucocorticoid levels (Cushing’s 
syndrome). High circulating glucocorticoids potently induce metabolic disorders 
including peripheral insulin resistance in key metabolic tissues (muscle, liver and fat) 
as well as directly suppressing β-cell function and can precipitate type 2 diabetes. 
However, in common forms of metabolic syndrome (visceral obesity, type 2 diabetes, 
increased cardiovascular disease risk) it appears that amplification of local tissue 
glucocorticoid action by increased levels of the intracellular enzyme 
11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1), particularly in adipose tissue, 
is a key driver of the adverse metabolic phenotype rather than altered circulating 
glucocorticoid levels. 11β-HSD1 is also elevated in pancreatic islets from obese 
rodents. This thesis aimed to determine the role of 11β-HSD1 in pancreatic islets 
(β-cells) under normal conditions and its potential pathogenic role in the 
development of diabetes. 
 
We first determined that 11β-HSD1 acted primarily as a reductase (amplifying 
glucocorticoid action) in pancreatic islets. We then determined that islet 11β-HSD1 
transcription is under the control of the promoters that express in other tissues like 
liver. Islet 11β-HSD1 is significantly regulated by factors relevant to the diabetic 
state; high glucose and insulin suppressed whereas fatty acids and TNFα increased 
11β-HSD1 activity. To test whether the high islet 11β-HSD1 found in obese rodents 
was directly diabetogenic, we generated transgenic mice specifically overexpressing 
β-cell 11β-HSD1 under the mouse insulin promoter (MIP-HSD1 mice) in a mouse 
strain  prone to develop β-cell failure when subjected to diabetic challenge (eg. 
chronic high fat feeding). Unexpectedly, MIP-HSD1tg/+ mice (expressing ~2 fold 
elevated 11β-HSD1 activity) exhibited markedly improved β-cell insulin secretory 
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responses, whereas MIP-HSD1tg/tg mice had partially impaired β-cell insulin 
secretory function in vivo and in vitro. Moreover, MIP-HSD1tg/+ mice completely 
resisted the mild hyperglycaemia induced by multiple-low doses of the β-cell toxin 
streptozotocin (40mg/kg i.p. for 5 days) and partially resisted the profound 
hyperglycaemia induced by a single high dose of streptozotocin (180mg/kg). Notably, 
MIP-HSD1tg/+ mice exhibited lower macrophage infiltration (MAC-2) and higher 
T-regulatory cell (Foxp3) infiltration after these challenges with evidence of 
increased insulin-positive cells and maintenance of normal levels of 
proliferation-competent β-cells. Overall, MIP-HSD1tg/tg exhibited a partial protection 
from the streptozotocin challenge.  
 
Modestly increased 11β-HSD1 expression in β-cells unexpectedly supports 
compensatory insulin hypersecretion preventing type 2 diabetes and protects β-cells 
from inflammatory mediated damage in the setting of type 1 diabetes. Above a 
protective threshold, elevated β-cell 11β-HSD1 may result in β-cell dysfunction and 
diabetes. These findings have important implications for the currently advocated 
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Diabetes is a group of metabolic diseases which are characterized by, and diagnosed 
with, chronic hyperglycaemia (WHO 1985). The classical symptoms caused by 
chronic hyperglycaemia are polydipsia (increased thirst), polyphagia (increased 
hunger) and polyuria (frequent urination).  
Diabetes was first recorded in 1552 B.C. when the 3rd Dynasty Egyptian physician 
Hesy-Ra noted the symptom of polyuria. Diabetes which was derived from Greek 
“diabainein” in reference to the polyuria was constructed by Aretaeus of Cappadocia 
around the first centry AD (Dobson 1776). The word mellitus that came from Latin 
to describe the sweet taste of uria was added by Thomas Willis in 1675. Although, 
over thousands of years, diabetes was described and studied by many ancient nations, 
it was considered incurable and predicted a short and painful life (Medvei 1993). Not 
until 1921 did Banting and his colleagues purify insulin from bovine pancreas and 
subsequently used it to reverse diabetes in humans the following year (Banting et al. 
1922). By 1936, the notable two major types of diabetes were clearly distinguished 
(Himsworth 1936) according to their different characteristics. Type 1 diabetes (T1D) 
results from a failure to produce insulin and requires life-long injections of insulin 
(although recent islet transplant therapy has opened the possibility to finally 
supersede this (Langer 2010; Ludwig et al. 2010)). Type 2 diabetes (T2D) results 
from peripheral insulin resistance wherein cells fail to sense and respond to insulin 
properly. At least initially, T2D can be controlled with medications that improve 
insulin sensitivity before the need to administer insulin. 
Despite the availability of treatment, both type 1 and 2 are chronic conditions that 
usually cannot be cured. The International Diabetes Federation (IDF) reported that 
285 million people worldwide or 6.4% of the population will suffer from diabetes by 
2010, which is nearly ten times more than reported in 1985 (Shaw et al. 2009). The 
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condition is affecting more people of working age than previously predicted and no 
ethnic group has escaped from its increasing prevalence. It is predicted that if the 
current rate of growth continues, the total number will exceed 439 million in 2030 
(Shaw et al. 2009).  
1.1.1 Type 2 diabetes 
T2D or NIDDM (Non Insulin Dependent Diabetes Mellitus) is by far the most 
common cause of glucose intolerance, with 90% prevalence among all diabetic 
patients (Zimmet et al. 2001). It is primarily characterized by three pathological 
alterations: peripheral insulin resistance, increased hepatic glucose production and 
relative insulin deficiency (Efendic et al. 1984; DeFronzo et al. 1992; Kahn 1996).  
Although T2D has been studied for a long time, the etiology is still unknown in 
detail. Inheritable genetic and environmental factors, like stress (Surwit et al. 1992), 
aging (Jack et al. 2004), high fat diet (Lovejoy et al. 2002), and a less active lifestyle 
(Hu 2003), are involved in the development of T2D (Hamman 1992). Recently, a 
large genome wide association studies in the human population identified several 
candidate genes of T2D, the majority of which are associated with β-cell function 
(Dupuis et al. 2010). About 55% of T2D cases are associated with obesity (Eberhart 
2004). Indeed, obesity is considered a strong causal factor for T2D (Camastra et al. 
1999), most likely due to excessive adipose tissue acting as a source of chemical 
signals (hormones and cytokines) that promote insulin resistance and eventually lead 
to ‘exhaustion’ of the insulin secretory response.  
T2D patients can manage their condition through exercise and diet; though many will 
require medication including insulin to properly control blood glucose levels. It is 
estimated that 60% or more of T2D incidence could be prevented or delayed by 
changing life style (Knowler et al. 2002; Lindstrom et al. 2006; Raina Elley and 
Kenealy 2008). 
1.1.2  Type 1 diabetes 
T1D or IDDM (Insulin Dependent Diabetes Mellitus) is an autoimmune disease. It is 
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characterized by high blood and urine glucose levels which results from the 
permanent destruction or damage of insulin producing β-cell in the islets of 
Langerhans of the pancreas  
Although T1D has been recognized for a long time, its exact cause is still not fully 
understood. The immunological origin leading to T1D involves in part genetic 
predisposition (Maximilian 1990) and environmental factors which interact to create 
the conditions required for disease onset. Many potential environmental factors have 
been focused on, such as stress (Williams et al. 1990; Ader et al. 1991; Surwit et al. 
1992; Durant et al. 1993), food constituents (Elliott and Martin 1984; Daneman et al. 
1987; Elliott et al. 1988; Issa-Chergui et al. 1988), viral mediators (Yoon 1990), and 
bacteria (Sadelain et al. 1990). However, most people who develop T1D are 
otherwise healthy. 
Unlike T2D, T1D is rapidly lethal and there is a need for either multiple daily insulin 
injections or continuous subcutaneous insulin fusion. Pancreatic or islet transplants 
have been used to treat T1D clinically, though this approach is still at the 
experimental trial stage and requires a lifetime of immunosuppression (Langer 2010; 
Ludwig et al. 2010; Robertson 2010; Kort et al. 2011). A drive to create artificial 
glucose responsive pancreatic islet tissues is currently at the forefront of T1D 
research (Opara et al. 2010).  
1.2 The pancreas 
The pancreas, in particular the β-cell principally maintain blood glucose levels by 
secreting insulin, a protein which was named by Edward Albert Sharpey-Schafer of 
Edinburgh in 1910, it was be purified and shown to reverse high glucose effects in 
dogs by Frederick Grant Banting and Charles Herbert Best at the University of 
Toronto in 1921. For this Banting and his colleagues got the Nobel Prize in 1923. 
1.2.1 The structure and function of the pancreas 
The pancreas is a gland organ located across the back of the abdomen, behind the 
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stomach; the widest right-most side of the pancreas, called the head of pancreas, is 
connected to the duodenum by the pancreatic duct. The tapered remaining part 
extending leftward is called the body; the section near the spleen is called the tail of 
pancreas (Figure 1-1). 
The pancreas is both an exocrine and endocrine gland. The exocrine pancreas which 
corresponds to 98% of the mature organ weight secretes the pancreatic juices 
consisting of two major components into the duodenum via the pancreatic duct to 
help digest carbohydrates, protein, and fat. Pancreatic enzymes are secreted by the 
acinar cells and pass into the small intestine to breakdown dietary protein, fat and 
carbohydrates in chyme; the other is an aqueous alkaline solution rich in sodium 
bicarbonate (NaHCO3) which is secreted by duct cells to neutralize excess acidity in 
the intestines. The endocrine function is performed by islets of Langerhans, a cell 
cluster that consists of at least five different endocrine cell types. Hormones released 
from the endocrine cells enter the blood and lead to disposal of the absorbed 
nutrients (e.g. insulin from endocrine β-cells), or, alternatively, they mobilize 





Figure 1-1. The structure of the pancreas. The pancreas is an elongated organ that 
lies across the back of the abdomen behind and below the stomach. The widest right 
side of pancreas, called the head, is connected to the duodenum by the pancreatic 
duct. The end near the spleen is called the tail of pancreas. The exocrine part consists 
of grape-like clusters of secretory cells that form digestive enzymes known as acinar 
cells, which connect to the pancreatic duct. A small proportion of the gland consists 
of isolated islands of endocrine tissue known as islets of Langerhans which are 
dispersed throughout the pancreas and arranged as cords among the capillary 
channels. (Picture modified from University of Colorado at Boulder and 2009 


























3-10% PP-cell 3-5% 
Epsilon cell <1% 
1.2.2 Pancreatic islets of Langerhans 
Islets of Langerhans are cell clusters (often hundreds of cells) that are spread 
throughout the pancreas and perform the endocrine function (Henderson 1969). The 
islets consist of five major cell types which are characterized by different hormone 
secretion profiles (Figure 1-2): β-cells secrete insulin (to decrease blood glucose); 
α-cells secrete glucagon (to increase hepatic glucose production and blood glucose); 
δ-cells secrete somatostatin (to regulate α and/or β-cell hormonal secretion); PP cells 
secrete pancreatic peptide (to inhibit gall bladder contraction, increase 
gastrointestinal motility and self regulate pancreatic exocrine and endocrine 
secretion), and Epsilon cells secrete ghrelin (to increase hunger before a meal, 







Figure 1-2. Cell components of the islet of Langerhans. Islets of Langerhans 







1.2.3  Anatomical and morphological origins of the pancreas and 
progenitor cell development 
Studies of pancreatic developmental biology have shed new light on the cause of 
T2D. As the work involved in this thesis relates to the mouse, this section focuses on 
mouse pancreatic development. The origin of the pancreas is from the embryonic 
endoderm foregut which locates anterior to the duodenum and posterior to the 
developing liver. Pancreatic development starts from embryonic day e8.5-9.0 with 
the formation of dorsal and ventral buds. The dorsal bud lies in close proximity to the 
notochord and lateral to the dorsal aorta. The ventral bud comes from the hepatic 
diverticulum and becomes the head. In mice, at e9.5, the dorsal and ventral buds 
begin a differential rotation. The duodenum rotates to the right along with the ventral 
bud. By e10.5, the partially differentiated epithelium of the two buds undergoes 
branching morphogenesis into a ductal tree that by e12.5 results in the formation of 
two primordial pancreas organs consisting predominantly of an undifferentiated 
ductal epithelium. Between e13 to e14, the ventral bud fuses with the much larger 
dorsal bud to form a single definitive pancreas (Carlson 2004). (Figure 1-3) 
Mouse pancreatic endocrine progenitor cells are present from the very beginning of 
development (e9.5) and proceed through a first and secondary transition (Rutter et al. 
1968). At e9.5, before epithelial branching, glucagon and insulin can be detected 
within the developing pancreatic bud which is considered as the first developmental 
transition (Teitelman et al. 1993). The secondary transition happens at approximately 
e13-16 when a dramatic increase in the number of endocrine cells budding from the 
ductal epithelium begins, and they organise into islet-like clusters. The islets are not 
fully formed until e18.5 when the differentiated endocrine cells begin to separate 
from the ductal epithelium and migrate to the acinar-rich area then spontaneously 
organise into islets. During e14.5-e15.5, the exocrine pancreas differentiates from the 
ductal epithelium; on e15.5, acinar cells are clearly discernible from ducts. (Figure 
1-3) 
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Figure 1-3. Schematic represention of morphogenetic events and expression of 
transcription factors during embryonic pancreas development. Hlxb9 is 
expressed in dorsal endoderm before initiation of DP organogenesis; PDX-1 appears 
between e8.5 and e8.75 at the foregut domain, VP begins to form; Nkx2-2 
coexpresses with PDX-1 at e8.75, Nkx6-1 expresses at VP; by e9.0 some cells turn 
on Ngn3 expression and go through the endocrine pathway, some cells expressing 
Ptf1a and co-expressing PDX-1 enter the exocrine pathway; at e9.5, VP starts to 
rotate to the right, several transcription factors co-express at DP and Pax4 appears. 
At this stage, glucagon and insulin can be detected (first transition); from e10.5 to 
e12.5, the uniform epithelial structure of the entire pancreatic epithelium becomes 
highly branched, and by e12.5, the undifferentiated ductal epithelium forms. Nkx2-2, 
Nkx6-1, Hlxb9-positive cells segregate to the central epithelium, whereas 
Ptf1a-positive cells are specifically found in the periphery and migrate to regulate 
acinar cell maturation; from e12.5 to e14, the VP fuses with DP to form a single 
pancreas organ; the buds begin to differentiate into endocrine and exocrine cellular 
lineages by e14 and proliferate and expand extensively, acinar cells complete 
maturation; from e13.5 to e14.5 (second transition) the endocrine cells organize into 
isolated clusters that condense into the islets of Langerhans by e18.5.  
Abbreviations: A, anterior; P, posterior; st, stomach; duo, duodenum; DP, dorsal pancreas; VP, 























































































1.2.4 Essential transcription factors for pancreatic development 
in the embryo  
Certain key transcription factors are involved in the regulation of the genes expressed 
in both developing and adult pancreas. Disruption of these genes results in impaired 
pancreatic development and consequent diabetes. Transcription factors often serve 
dual functions in determining early cellular development and later in maintaining the 
phenotype of terminally differentiated cells. At an early stage, PDX1, Ptf1a and 
Hlxb9 are required for pancreatic bud development. Later, specific transcription 
factors are activated or inhibited, directing the pancreatic cell differentiation and 
proliferation towards one lineage or another, corresponding to the exocrine and 
endocrine functions of the pancreas. For example, the notch receptor system 
regulates progenitor cell differentiation to exocrine pancreas via expression of Ptf1a, 
whereas differentiation of the endocrine pancreas in the absence of notch receptor 
signaling occurs under the influence of Ngn3. The known essential transcription 
factors are listed in Table 1-1 and Figure 1-3.
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Table 1-1. Essential transcription factors in pancreatic development 
Transcription factors Expression in embryologic 
stage 




(Homeobox gene 9) 
Starts at e8.0, disappears at e10, 
reappears at e12.5 
Essential factor for dorsal pancreatic 
specification 
β-cell (Harrison et al. 1999; Li 
et al. 1999) 
MafA  
(v-maf musculoaponeurotic 
fibrosarcoma oncogene A) 
Expresses in insulin positive 
cells after 2nd transition. 
An activator of insulin gene expression;
Marker for mature β-cell, specific for 
developing and maturated β-cell. 
β-cell (Olbrot et al. 2002; 
Matsuoka et al. 2004) 
MafB  
(v-maf musculoaponeurotic 
fibrosarcoma oncogene B) 
Expresses in both insulin and 
glucagon cells before 2nd 
transition, and then restricts in 
glucagon cells at e15. 
Marker for mature α-cell. α-cell (Artner et al. 2006; Artner 
et al. 2007) 
Ngn3 
(Neurogenin 3) 
Starts at e9–e9.5, peaks on 
e15.5, diminishes at birth 
Essential for all endocrine cell 
development; 
Marker for islet cell precursor cells. 
Little or undetectable (Gradwohl et al. 2000; 
Jensen et al. 2000; 





Starts at e8.75 at DP, e9.5 at VP, 
coexpresses with Ngn3 at e10.5
Regulation of the differentiation of 
pancreatic endocrine cells; 
Essential for β-cell differentiation. 
α-cell, β-cell,     
PP cell 
(Sussel et al. 1998; 
Sander et al. 2000; Wang 





Starts at e8.75 at VP, e9.0 
express at DP, not VP, e10.5 
reappear at VP, highly 
expresses at e13.5 to e14.5  
Marker for mature β-cell; 
Regulation of the differentiation of 
pancreatic endocrine cell; 
β-cell (Jensen et al. 1996; 
Sander et al. 2000) 
Pax4 
(Paired homeodomain 
transcription factor 4) 
Starts at e9.5, peaks at 2nd 
transition, coexpresses with 
Ngn3 
Promotes the developing islet cells 
differentiation of β-and δ-cell. 
β-cell (Sosa-Pineda et al. 1997; 
Wang et al. 2004) 
Pax6 
(Paired homeodomain 
transcription factor 6) 
Starts at e9.0, peaks at e9.25, 
expresses in cluster at e11.5, 
which predominant at e12.5. 
Early marker for endocrine cells; 
Regulates the terminal steps in cellular 
differentiation of the endocrine 
pancreas; 
α-cell (predominant), 
β-cell, δ-cell, PP cell
(Sander et al. 1997; 
St-Onge et al. 1997; 
Andersen et al. 1999) 
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Regulates the promoters of the 





Starts at e8.5, after e12.5 the 
expression decreases, then 
highly re-expresses at e13.5, 
more prominent at e14.5. 
Critical transcriptional activator of 
insulin and somatostatin in adult islets; 
Necessary in the fate of endocrine cell 
types; 
Important in determining β-cell 
maturation and function. 
Insulin (β-cell) 
Somatostain (δ-cell) 
(Ohlsson et al. 1991; 
Ohlsson et al. 1993; 
Offield et al. 1996; Li et 
al. 1999; Gannon et al. 




Starts from e9.0-e9.5, migrates 
to acinar cells at e12.5. 
Important transcription factor of acinar 
cells;  
Regulates exocrine tissue gene 
transcription. 
Acinar cells (Krapp et al. 1996; Rose 
et al. 2001) 
Sox9 
(SRY/HMG box 9) 
Starts at e10.5, co-expresses 
with Ngn3 at e15.5. 
Essential factor for pancreatic growth 
and endocrine cell differentiation. 
Ductal cells (Lynn et al. 2007; 
Seymour et al. 2007) 
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1.3 The pancreatic β-cell 
The β-cells are most remarkable for their exquisitely regulated secretion of insulin. 
Both type 1 and type 2 diabetes are linked with β-cell dysfunction or loss.  
1.3.1 Pancreatic β-cell regeneration 
The specialized features of the β-cell are determined by the expression of a subset of 
genes controlled by a number of transcription factors, some of which are 
β-cell-specific and others are ubiquitous in adult mouse tissue as described before in 
Table 1-1. 
Shortly after birth the endocrine pancreas undergoes remodelling through a process 
that involves substantial apoptosis and β-cell replication (Bonner-Weir 2000). The 
first wave of new islet formation is in the first few days after birth, the second wave 
happens at weaning (Scaglia et al. 1995). In adult mouse, under normal conditions, 
the β-cell mass remains linearly related to body weight and replication is the major 
mechanism for the growth in β-cell number (Bonner-Weir 2000). There are small 
changes in β-cell number from 30 to 40 days after birth in the rat (Finegood et al. 
1995). The regulation of β-cell growth and proliferation occurs mainly through 
insulin/IGF signalling acting through IRS-2 (Augstein et al. 1998; Kubota et al. 
2000). Although the postnatal β-cell replication rate is low, like most other cell types 
β-cells have a finite lifespan. Mathematical modelling of the lifespan of rat β-cells 
has estimated they have a slow turnover rate with a half-life estimated at 30-60 days 
in young rats (Finegood et al. 1995). Physiological apoptosis is a mechanism for 
β-cell turnover and this can be observed in vitro (Rabinovitch 1994). Further, β-cell 
apoptosis occurs during the involution of the β-cell mass postpartum in vivo (Scaglia 




1.3.2 Pancreatic β-cell function 
β-cells store a large amount of insulin in mature granules and release a small 
proportion of these granules immediately following glucose stimulation. To renew 
these stores, insulin biosynthesis is immediately stimulated and occurs mainly at the 
translational level (Itoh and Okamoto 1980; Welsh et al. 1986). Under physiological 
conditions, the quantity of insulin released by β-cells is directly related to the 
prevailing glucose concentration, which may depend on the nature, quantity and 
route of administration or exposure to nutrients.  
1.3.2.1 Insulin transcription, synthesis and release 
Insulin is an important hormone in regulating metabolic homeostasis. Preproinsulin 
which is the first product of insulin mRNA translation is encoded by a single gene in 
most species including human (Harper et al. 1981). In rodents there are two 
non-allelic insulin genes present. In rats, insulin gene I and II are colocalised on the 
same chromosome 1 (Soares et al. 1985). In mouse, the insulin gene I is located on 
chromosome 19 (Davies et al. 1994), and the insulin gene II is localised on 
chromosome 7 (Duvillie et al. 1998). Physiological insulin expression is restricted to 
pancreatic β-cells, although the insulin gene I is also found moderate expression in 
rat brain predominantly in hippocampus (Gerozissis 2003). Insulin transcription is 
controlled by the insulin promoter that is a highly conserved ~340 bp region located 
upstream from the transcription start site (Poitout et al. 2006). The insulin promoter 
binds β-cell specific as well as ubiquitous transcription factors (German et al. 1995; 
Poitout et al. 2006). The most critical transcription activation elements of the insulin 
promoters are the E, A and C sites (“boxes”) (German et al. 1995) as well as 
additional sequences that may have more subtle regulatory effects. 
 
The E boxes bind proteins of the basic helix–loop–helix (bHLH) class of 
transcription factors. In β-cells, the ubiquitous bHLH protein E47 forms a 
heterodimer with NeuroD/BETA2 (β-cell E box transactivator 2, β2) which is 
expressed in neuroendocrine cells (Naya et al. 1995). There are up to five A box 
sequences within the insulin promoter. Their consensus TAAT sequence is a known 
 36
binding site for PDX-1 (Boam and Docherty 1989; Leonard et al. 1993; Ohlsson et al. 
1993; Miller et al. 1994; Marshak et al. 1996). PDX-1 interacts synergistically with 
E47/β2 (Peers et al. 1994; Peshavaria et al. 1997; Glick et al. 2000; Ohneda et al. 
2000) and this activates the insulin promoter. Histones and DNA-binding proteins of 
the high mobility group (HMG) HMG 1(Y) (Ohneda et al. 2000) can increase the 
binding of PDX-1 to the A and E sites. Another important transcription factor is 
MafA which belongs to the Maf (musculoaponeurotic fibrosarcoma oncogene) 
family and binds to the C1 site of the insulin promoter. MafA is a glucose-regulated 
and pancreatic β-cell-specific transcriptional activator of the insulin gene (Kataoka et 
al. 2002; Kataoka et al. 2004; Matsuoka et al. 2004). Members of the hepatic nuclear 
factors (HNF) and PAX families (Paired homeodomain transcription factor) (Melloul 
et al. 2002) also contribute to insulin transcription. Insulin gene transcription is 
regulated through the activation of these factors and in combination, these factors can 
exert strong stimulatory effects (Glick et al. 2000; Ohneda et al. 2000; Aramata et al. 
2005; Zhao et al. 2005). 
 
After translation of the preproinsulin mRNA, the “pre” portion of preproinsulin is 
removed by a proteinase, and proinsulin is transported in transport vesicles along the 
microtubule network system to the Golgi apparatus and packaged into 
clathrin-coated immature granules. Proinsulin is further converted to insulin and 
C-peptide by trypsin- and carboxypeptidase-like enzyme (Orci et al. 1987). The 
clathrin-coated granules then become mature granules where the insulin crystals are 
assembled in close association with Zinc and Calcium, and finally stored as a 
hexamer which is inactive (Coffman and Dunn 1988; Kadima et al. 1992). Insulin is 
released by exocytosis after glucose stimulation. The granules carrying insulin 
hexamers are released into the intercellular space where they dissolve to expose 
insulin monomers which are the active form of insulin (Orci et al. 1984).  
1.3.2.2 The role of glucose in insulin secretion 
Glucose is the main physiologic regulator of insulin transcription, translation and 
secretion. Basal insulin gene transcription occurs at low plasma glucose 
concentrations (< 5.6mM). The transcription of insulin increases at higher glucose 
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concentrations, and is sensed through increased glucose metabolism by the high Km 
glucose transporter 2 (GLUT2) and glucokinase (GK) activity within the β-cell 
(Newgard and McGarry 1995). Glucose-induced insulin transcription is modulated 
by many factors which influence insulin transcription as mentioned above, and the 
insulin promoter boxes.  
 
β-cells release insulin in response to glucose metabolism (Maechler et al. 2006). 
After entering the β-cell through the GLUT2 transporter, glucose is phosphorylated 
to glucose-6-phosphate (G6P) by glucokinase and metabolised via glycolysis to 
generate pyruvate which is then utilised by the mitochondria (Newgard and McGarry 
1995; Prentki 1996; Nolan et al. 2006). In the glucose oxidation pathway, 
approximately 50% of pyruvate is metabolised by pyruvate dehydrogenase producing 
acetyl-CoA which enters the tricarboxylic acid cycle (TCA) to generate ATP. This 
causes an increased intracellular ATP/ADP ratio (Newgard and McGarry 1995; 
Prentki 1996; Schuit et al. 1997) which results in closure of the plasma membrane 
KATP-channels that induces membrane depolarization, and triggers increased calcium 
concentrations in the cytoplasm through opening of voltage-gated calcium channels 
(Ashcroft and Rorsman 1990). The increased intracellular calcium level induces the 
insulin secretory granules to fuse with the membrane and release insulin by 
exocytosis (MacDonald and Wheeler 2003). This pathway, often termed the KATP 
channel-dependent pathway is considered to be the major triggering event for 
glucose stimulated insulin secretion (GSIS). Pyruvate can also be metabolised by 
pyruvate carboxylase to oxaloacetate, which ensures the provision of a carbon 
skeleton to the TCA cycle in the mitochondria, a process known as anaplerosis 






Figure 1-4. Glucose regulates insulin secretion. Glucose enters in the β-cell 
through the GLUT2 transporter. Glucose is metabolized through glycolysis and the 
tricarboxylic acid cycle to generate ATP, resulting in an increased intracellular ATP/ 
ADP ratio, which cause closure of KATP-channels. This depolarizes the plasma 
membrane and increases calcium concentrations in the cytoplasm through 
voltage-gated calcium channels. The increased calcium causes insulin secretory 
granules to be released by exocytosis. Fatty acids influence insulin release by both 
directly activating GPR40 and through formation of malonyl-CoA to generate long 
chain acyl-CoAs (LC-CoA) which stimulate insulin granule exocytosis, either 


























1.3.2.3 The role of fatty acids in insulin secretion 
Free fatty acids (FFAs) are important to the pancreatic β-cell for its normal function, 
its capacity to compensate for insulin resistance, and its failure in type 2 diabetes 
(Prentki et al. 2002; Nolan et al. 2006). FFAs alone do not stimulate insulin secretion, 
however, they potentiate insulin release in response to glucose (Stein et al. 1996; 
Dobbins et al. 1998). This might involve two different mechanisms. The first relates 
to the binding of FFAs to the G protein-coupled receptor GPR40 which is a 
transmembrane receptor highly expressing on the islet β-cell membrane (Itoh et al. 
2003). Activation of GPR40 by FFAs outside the β-cell causes the activation of 
intracellular signalling and a subsequent increase in intracellular calcium levels, and 
secretory granule exocytosis (Itoh et al. 2003; Shapiro et al. 2005). GPR40 
contributes approximately half of the effect of FFAs to augment GSIS. The other 
mechanism involves malonyl-CoA formation during anaplerosis. Malonyl-CoA 
forms as a consequence of citrate exit from mitochondria which blocks carnitine 
palmitoyltransferase 1 (CPT-1), inhibiting the removal of long chain acyl-CoAs 
(LC-CoA) via their mitochondrial β-oxidation (Prentki and Corkey 1996; Roduit et 
al. 2004; Nolan et al. 2006). This permits the generation of LC-CoA that then 
increases insulin secretion both by directly stimulating secretory granule exocytosis 
and by protein kinase C (PKC) activation (Prentki et al. 2002). (Figure 1-4) 
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1.3.3 The β-cell and diabetes 
Plasma glucose levels are tightly controlled by the interplay of tissue insulin 
sensitivity, insulin independent glucose metabolism and pancreatic β-cell insulin 
release. There is a feedback loop between the insulin-sensitive tissues and the β-cell, 
with β-cells increasing insulin supply in response to demand by the liver, muscles 
and adipose tissue (Kahn et al. 1993). Failure of this feedback loop results in a 
deviation from normal glucose tolerance and underlies the development of diabetes. 
T2D subjects lack the first phase of insulin secretion, which constitutes the initial 
glucose sensing response of the pancreatic β-cell to altered circulating glucose 
concentrations. 
1.3.3.1 β-cell failure 
Unlike other cell types, the β-cell can not protect itself by blocking uptake of excess 
nutrients (particularly glucose and FFAs). Rather, the β-cells consistently enhance 
insulin secretion, responding to chronically increased glucose and FFA loading, so 
that excess glucose and FFA can be stored as glycogen in liver and triacylglycerols 
(TG) in adipose tissue, respectively. This adaptation allows maintainenance of 
normal glycaemia even in individuals that are insulin-resistant in several metabolic 
tissues (liver, adipose tissue, muscle). In this β-cell hyperinsulinaemic compensation 
stage the increased metabolism within the β-cell leads to high levels of oxidative 
damage and the ER stress response.  
 
The ER is a critical intracellular organelle with a vast network of membranes which 
plays an important role in the biosynthesis of secretory proteins, assembling the 
secretory and membrane proteins into secondary and tertiary structures, and is an 
important reservoir for Ca2+ (Nielsen and Petersen 1972; Chevet et al. 2001). Any 
misfolded or unfolded proteins are removed and degraded through the ER (Schroder 
and Kaufman 2005; Marciniak and Ron 2006). When there is an accumulation of 
unfolded proteins, energy and nutrient fluctuation, or a disruption of Ca2+ 
homeostasis, increased perturbations in the ER occur and activate the ER stress 
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response, known as the unfolded protein response (UPR) (Schroder and Kaufman 
2005; Marciniak and Ron 2006). When this response fails to preserve and restore ER 
function, cell apoptosis occurs (Marciniak and Ron 2006; Eizirik et al. 2008). 
 
Under physiological conditions, the ER is highly developed in β-cells to maintain 
their continuous insulin secretory potential. Due to their glucose responsive, highly 
oxidative nature, the β-cell is susceptible to the accumualtion of mis/unfolded and 
premature proteins which are the consequences of reactive oxygen species (ROS) 
(Kaneto et al. 2005) and excessive nitrous oxide (NO) (Oyadomari et al. 2001), 
which results in ER stress (Harding et al. 2001; Weir et al. 2001). Indeed ER stress in 
β-cell is induced by FFA in obesity and T2D (Ozcan et al. 2004). The increased ER 
stress activates the JNK and CHOP pathway (Oyadomari et al. 2001; Kaneto et al. 
2005), both of which are involved in β-cell apoptosis. Initially, increased ER stress 
responses in the β-cell may preserve β-cell function to compensate for the apoptotic 
loss of β-cells. However, finally, exaggerated ER stress responses lead to β-cell 
dysfunction (Weir et al. 2001; Poitout and Robertson 2002). 
 
β-cell failure occurs when islets are unable to sustain β-cell compensation for 
insulin resistance and may result from inadequate expansion of β-cell mass or failure 
of the existing β-cells to respond to glucose. Glucotoxicity (Unger and Grundy 1985), 
lipotoxicity (Unger 1995), and glucolipotoxicity (Poitout and Robertson 2002; 
El-Assaad et al. 2003) have all been proposed to increase the risk of β-cell damage 
from mitochondrial or ER stress. When β-cell failure is present, impaired glucose 
tolerance, elevating fasting glucose and type 2 diabetes result. Furthermore, the 
natural history of type 2 diabetes entails a progressive deterioration in β-cell function 
(Kahn 2001) associated with β-cell loss by apoptosis (Butler et al. 2003; Yoon et al. 











Figure 1-5. β-cell failure and the natural history of Type 2 Diabetes. Type 2 
diabetes is associated with both insulin resistance (and/or hyperinsulinemia) and 
β-cell dysfunction. A progressive decline in β-cell function leads to loss of islet 
β-cell compensation for the insulin resistance. As a consequence, progress from 
normal glucose tolerance (NGT) to impaired glucose tolerance (IGT) and finally to 
established type 2 diabetes occurs. Even after diagnosis of type 2 diabetes, β-cell 
function continues worsening and eventually insulin can not maintain glucose 
homeostasis. Green circles represent normal β-cells that increase in number (NGT), 
then becomes dysfunctional (hypertrophic β-cell: dark green oval shapes, IGT) and 
finally undergo failure (failing β-cells: brown oval shapes with green central spots). 
Picture adapted from (Prentki and Nolan 2006).  
 
1.3.3.2 β-cell compensation 
In the diabetic condition, hyperglycaemia initially increases both β-cell function 
(Chen et al. 1994) and islet mass (Bonner-Weir and Smith 1994; Alonso et al. 2007) 
as a protective action. The adult islet mass expansion increases islet volume but not 
numbers (Bock et al. 2003), with hypertrophy of existing β-cells (Jonas et al. 1999). 
However, this view was challenged by the finding that β-cell proliferation was a 
major source of new β-cells under both normal physiological conditions and after 
70% or 50% pancreatectomy (Dor et al. 2004; Teta et al. 2007). PDX1 acts as a 
critical regulator of β-cell replication that occurs during the compensatory response 
to insulin resistance (Kulkarni et al. 2004). Generation of β-cells from 
undifferentiated or partially differentiated precursors may also be involved in the 
maintenance of β-cell mass, a process called neogenesis (Xu et al. 2006). Although, 
very little is known about these putative stem cells, several cell types are proposed as 
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and Capecchi 2009); ductal epithelial cells (Bonner-Weir 2000; Xu et al. 2008); 
centroacinar cells which lie at the junction between acinar cells and the adjacent 
terminal ductal epithelium (Rovira et al. ; Hayashi et al. 2003; Nagasao et al. 2003); 
mesenchymal-like nestin-expressing cells (Zulewski et al. 2001) and intra-islet δ 




Glucocorticoids (GCs) are a group of corticosteroid hormones which are synthesised 
primarily in the adrenal gland. The primary glucocorticoid in man and most 
mammals is cortisol, whereas in rodents and lower vertebrates it is corticosterone.  
 
GCs were first discovered in the 1940s and in the years that followed, synthetic GCs 
soon became one of the most effective medicines to treat inflammation (Hench et al. 
1949). GCs have pleiotropic effects on physiological functions in the body including 
those involved in energy balance and metabolism, immune function, cardiovascular 
function, circadian rhythmicity, growth and development, cognitive processes and 
the modulation of various types of behaviour. For example, GCs regulate energy 
storage by participating in glycogenic and glycolytic pathways (Villar-Palasi and 
Larner 1970; Nyirenda and Seckl 1998). GCs are also a powerful 
immunosuppressant in high doses, which led to the development of therapeutic 
applications for the treatment of asthma (reviewed in Stellato 2007) and rheumatoid 
arthritis (reviewed in Gaffo et al. 2006). In foetal development, GCs are necessary 
for survival at birth: mice with disruption of the glucocorticoid receptor (GR) gene 
die at birth because of a lack of normal lung maturation (Cole et al. 1995; Nemati et 
al. 2008).  
1.4.1 Glucocorticoid synthesis and secretion 
Endogenous GCs are produced mainly in the adrenal gland from the common 
precursor cholesterol through a series of enzymatic reactions which are located in 
either the smooth endoplasmic reticulum or mitochondria. The basic structure of 
cholesterol is maintained throughout the steroid biosynthetic pathways which contain 
a cyclopentane ring and 3-cyclohexane rings. Specifically, GCs are synthesized in the 






















Figure 1-6. Corticosteroid bio-synthesis. In the adrenal gland, humans synthesize 
cortisol from cholesterol, whereas, rodents synthesize corticosterone as they lack 




Circulating GC levels are regulated by a negative feedback loop: the 
hypothalamus-pituitary-adrenal gland (HPA) axis (Aguilera 1998). The HPA axis is 
activated either by a circadian rhythm or stress stimulus. Under non-stress conditions, 
circulating levels of GCs are released both in an ultradian and diurnal manner. The 
suprachiasmatic nucleus, which is considered as an endogenous biological ‘clock’ 
sets the circadian rhythm by recurring daylight and darkness (Takahashi and Zatz 
1982). In mammals, the peak secretion of GCs happens just before the active period, 
whereas the nadir occurs during the rest (quiescence/sleep) period. 
 
Upon stimulus (e.g. stress, such as pain, trauma or emotional stress), neural inputs 
which perceive these signals converge at the main HPA axis control centre, the 
hypothalamus, to initiate adrenocorticotropin hormone (ACTH) secretion. The 
parvocellular cells of the paraventricular nucleus in the hypothalamus rapidly release 
corticotropin-releasing hormone (CRH) and arginine vasopressin (AVP) into the 
portal circulation to target the anterior pituitary where CRH and AVP then act 
synergistically to stimulate the secretion of stored ACTH into the bloodstream 
(Figure 1-7). Circulating ACTH binds to its receptor located at the cell surface of the 
adrenal cortex to stimulate the synthesis and secretion of GCs (Axelrod and Reisine 
1984). Meanwhile, GCs exert a negative feedback on the HPA axis by suppressing 
the production of CRH and ACTH (Ma et al. 1997), to prevent excess synthesis of 
GCs and restore the normal basal levels (Dallman et al. 2004). Only five percent of 
active GCs circulate free in the plasma, most are bound to plasma proteins. 
Approximately 90% of cortisol and 80% of corticosterone is bound to corticosteroid 
binding globulin (CBG) (Heyns and Coolens 1988), much of the remaining GCs are 




Figure 1-7. Glucocorticoid (GC) secretion is regulated by a negative feed-back 
loop HPA axis and GCs modulate the target cell gene expression. CRH/AVP is 
released in the hypothalamus after stimulation, and subsequently stimulates ACTH 
release from the anterior pituitary which then induces the GC synthesis in the adrenal 
cortex and release into the circulation. The increased GCs execute feedback 
inhibition on the HPA axis at both pituitary and hypothalamus, suppressing the 
synthesis of GC. GCs cross the cell membrane to exert their biological effects by 
binding to the GR, which exists as a multiprotein complex bound with HSP in the 
cytoplasm. GC/GR translocates into the nucleus binding to GRE to regulate target 
gene transcription. 
 
Abbreviations: CRH/AVP, corticotropin-releasing hormone/arginine vasopressin; ACTH, 
adrenocorticotropin hormone; GCs, glucocorticoids; GR, glucocorticoid receptor; HSP, heart 
shock protein; GRE, glucocorticoid response element; Nu, nucleus; Pr, protein. Adapted from 






















1.4.2 Glucocorticoid receptors (GR) 
GCs are lipophilic, they can easily cross cell membranes. They then bind to two 
structurally related intracellular receptors to exert their effects. The glucocorticoid 
receptor (GR) which is the main receptor in stress and metabolic-regulated tissues is 
present in almost all cell types, including pancreatic β-cells (Fischer et al. 1990; 
Matthes et al. 1994). In a few cell types, such as epithelial cells of the kidney 
(Krozowski et al. 1989), colon (Rafestin-Oblin et al. 1984), mainly those concerned 
with fluid or electrolyte balance, GCs bind to the mineralocorticoid receptor (MR) 
(de Kloet 2003). Both receptors act as transcriptional factors that can activate and/or 
inhibit the transcription of both overlapping and distinct target genes either after 
binding to DNA or through protein-protein interactions (Datson et al. 2008). 
1.4.2.1 Structure of GR 
As for other nuclear receptors, GR contains three functional domains. The 
N-terminal domain consists of sequences responsible for gene activation (Giguere et 
al. 1986). The DNA binding domain consists of two zinc fingers which are essential 
for GR binding of target gene promoters through their recognition of specific DNA 
sequences, glucocorticoid responsive elements (GRE) (Tsai et al. 1988). The ligand 
binding domain (LBD) is present in the C-terminal which is responsible for hormone 
binding (Giguere et al. 1986; Warriar et al. 1994), nuclear translocation (Picard and 
Yamamoto 1987), ligand-dependent transactivation (Webster et al. 1988), and heat 
shock protein (HSP)-90 binding (Dalman et al. 1991; Pratt 1993). 
1.4.2.2 Mechanism of GR action 
In the absence of ligand, GR is held in an inactive state in the cytoplasm by its 
predominant interaction with HSP-90, HSP-70 and immunophilins (FKBP51) (Pratt 
1993; Pratt and Dittmar 1998; Pratt et al. 2004). After binding to the ligand, GR 
undergoes a series of conformational changes that leads to dissociation from the 
multiprotein complex. This exposes a nuclear localisation signal (Grad and Picard 
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2007) which activates the GC/GR translocation into the nucleus and subsequent 
binding to the GRE domain in target genes (Figure 1-7) and regulation of their 
transcription (Bamberger et al. 1996).  
 
The GR can exert either activating or suppressive effects on target gene transcription. 
Transactivation occurs when GR binds to the “positive” GRE, and then recruits 
co-activators to cause chromatin remodelling and facilitation of transcription (Michas 
et al. 2010). The mechanisms of transrepression of GR are less clear, although it has 
been proposed that GR binds to a specific “negative” GRE (nGRE), which has a 
sequence more variable than the canonical GRE (Truss and Beato 1993; de Kloet 
2003). GR can either inhibit the target gene transcription directly (Guay et al. 2007) 
or indirectly by occluding adjacent/overlapping binding sites for the positively acting 
transcription factors (Schoneveld et al. 2004). The indirect mechanism can also be 
achieved by protein-protein interaction in which binding to the nGRE is not required 
(de Kloet 2003; Schoneveld et al. 2004). For example, monomers of GR interact with 
pro-inflammatory transcription factors, in particular the activator protein 1 (AP-1) 
and nuclear factor-κB (NF-κB) to prevent pro-inflammatory gene transcription by 
inhibiting their binding to cognate DNA binding sites (Newton and Holden 2007).  
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1.4.3 Physiological functions of glucocorticoids and their role in 
the pancreas 
GCs are essential for development, immune responses, energy homeostasis, stress 
responses, cognition and behaviour. They have wide and profound physiological 
effects in maintaining homeostasis under physical and emotional stress. The control 
of GC action within cells is therefore critical. Persistent exposure to 
supra-physiological GCs causes Cushing’s syndrome (Dorn et al. 1995); Deficiency 
of GCs is found in Addison’s disease (Bamberger et al. 1996). Moreover, GC action 
alteration is typical in the pathogenesis of some diseases states such as Metabolic 
Syndrome (Seckl and Walker 2004; Reaven 2006). 
1.4.3.1 Development 
GCs are essential for the organ structure development and tissue maturation (Fowden 
et al. 1998), especially for lung (Garbrecht et al. 2006) in foetal development. 
Clinically, GCs are used at late gestation for premature birth to accelerate prenatal 
lung maturation (Liggins and Howie 1972). However, excess GCs retard foetal 
growth in both humans (Reinisch et al. 1978) and rodents (Nyirenda and Seckl 1998). 
Administration of dexamethasone to pregnant rats in the third trimester results in 
offspring with a low birth weight, which develop hypertension, glucose intolerance 
and insulin resistance in later life (Benediktsson et al. 1993). Previous studies 
showed β-cell development is sensitive to GC action. Excessive exposure of the 
rodent foetus to GCs during the last week of gestation induces impaired glucose 
tolerance (Lindsay et al. 1996; Nyirenda et al. 1998) and reduction of functional 
islets (Nyirenda et al. 2009). Both maternal and fetal GCs are increased in 
undernourished rats, which further results in reduction of foetal β-cell mass and 
number (Garofano et al. 1997; Garofano et al. 1998). Dexamethasone decreases 
e15.5 embryonic pancreas progenitor cell differentiation to β-cell and, conversely, 
increases acinar cell number in vitro and in vivo, (Gesina et al. 2004). 
 
GR deficient mice die within a few hours after birth from respiratory failure and 
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atelectasis of the lung which is consistent with GC functions (Cole et al. 1995; 
Nemati et al. 2008). During mouse embryo development, GR gene expression clearly 
increases before e13.5 in the gastrointestinal tract, upper respiratory tract, and 
discrete areas of the central nervous system and in liver. Later, increased expression 
occurs in lung, muscle, pituitary and thymus (Speirs et al. 2004). In pancreas, GR is 
expressed at a very low level up to e13·5–e14, increases at e14.5-e16.5 in both islet 
progenitor cells and the majority of ductal cells, then falls sharply (Speirs et al. 2004). 
Studies in mice with GR deleted in whole pancreas showed GR was not required for 
the early induction of pancreatic development and differentiation, although it was 
necessary for pancreatic morphogenesis during late foetal development through 
indirect effects (Gesina et al. 2006). A precise GR gene-dosage was important in 
controlling β-cell expansion during development (Gesina et al. 2006). Moreover, 
transgenic mice which overexpress GR under the rat insulin I promoter exhibit 
impaired insulin release which may have developmental origins (Delaunay et al. 
1997). 
1.4.3.2 Inflammation 
As the anti-inflammatory effects of pharmacological levels of GCs are well known, 
they are commonly used clinically to treat a range of immune/inflammatory disorders, 
such as allergies, acute inflammation, asthma and rheumatoid arthritis (McEwen et al. 
1997; Chapman and Seckl 2008). Endogenous GCs can either potently enhance or 
suppress immune reactions to shift innate and adaptive immune responses depending 
on the timing and concentration of exposure (Wilckens 1995; McEwen et al. 1997; 
Smoak and Cidlowski 2004; Yeager et al. 2004). Thus, GCs exert 
immunomodulatory effects rather than simply anti-inflammatory effects at 
sub-pharmacological doses. In innate immunity progression, GCs are essential to 
reverse the lethal effects of proinflammatory cytokines (IL-1, TNFα) (Bertini et al. 
1988) which are secreted by resident macrophages during initiation of the 
inflammatory response (Topley et al. 1993; Borish and Steinke 2003). Thus, GCs 
alter leukocyte distribution, differentiation and transcription of numerous genes in 
GC sensitive leukocytes, monocytes, neutrophils and granulocytes (McEwen et al. 
1997) which are recruited by proinflammatory mediators. Moreover, GCs restrain 
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oedema, increase blood viscosity and haematopoietic differentiation programmes in 
the response of the innate immune system (McEwen et al. 1997). Notably, GCs also 
promote adaptive immunity by regulating Th1/Th2 balance (Kovalovsky et al. 2000). 
T lymphocytes (T-cells) are classified into two broad subsets. The pathogenic 
cellular immune response is mediated by Th1 cells, a subset of T cells characterized 
by secretion of IL-2 and INFγ which induce macrophages and CD8+ cells to secrete 
proinflammatory cytokines. Alternately, the protective humoral immune response is 
mediated by Th2, a subset of T cells that synthesize IL-4 and IL-10 which are 
considered as anti-inflammatory effectors (Rabinovitch 1994). GCs suppress action 
of the Th1 cellular immune response and may help to explain the shift toward the 
Th2 humoral immune response (Blotta et al. 1997; Ramirez 1998). GCs also both 
increase macrophage secretion of IL-10 (Ramirez et al. 1996) and induce the 
development of T regulatory cells (Barrat et al. 2002), thus suppressing immune 
responses, and promoting the resolution of inflammation. The anti-inflammatory and 
immunosuppressive action of GCs is mainly due to the inhibition of several 
transcription factors (TF) activity such as NF-κB, AP-1 and STAT proteins, through 
direct interaction with GR (Cippitelli et al. 1995; Scheinman et al. 1995; Liu et al. 
2001).  
 
Inflammation is a key feature of the autoimmune disease T1D. Further, over the last 
decade, a close link between inflammation and T2D has been established (Wellen 
and Hotamisligil 2005). T2D rodent models have an increased number of immune 
cells both in the circulation (Kolb and Mandrup-Poulsen 2005; Wellen and 
Hotamisligil 2005) and within key metabolic tissues such as adipose (Weisberg et al. 
2003) and pancreatic islets (Ehses et al. 2007). Considering GCs have diabetogenic 
properties, promoting insulin resistance, and other side effects (Detailed in 1.4.3.3), 
they are not an optimal clinical treatment for long-term suppression of inflammation. 
However, notably, GCs were recently used for preconditioning islet preparations 
prior to islet transplantation to reduce later potential immunorejection responses 
through careful modulation of the dose (Lund et al. 2008). 
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1.4.3.3 Metabolism 
GCs are essential for maintaining glucose homeostasis under normal conditions and 
contribute to dysregulated glucose homeostasis in pathological conditions 
(McMahon et al. 1988; Friedman et al. 1996; Andrews and Walker 1999; Jacobson et 
al. 2006). In the prolonged fasted state the glucose levels fall and active GCs are 
released into the circulation to promote hepatic glucose production. In contrast, when 
the glucose level increases after food intake, GCs assist glycogen synthesis (a form 
of energy storage) by activating the glycogen synthesis pathway in the presence of 
insulin (Stalmans and Laloux 1979; Ruzzin and Jensen 2005). However, chronic 
elevation of GCs through exogenous administration or excessive production of 
endogenous GCs (e.g. Cushings syndrome) is associated with dyslipidaemia, 
hypertension, glucose intolerance and insulin resistance (Landy et al. 1988; Chrousos 
1995; Reynolds et al. 2001; Andrews et al. 2002) which contribute to the 
development of T2D and cardiovascular disease.  
 
GCs regulate glucose metabolism in several tissues and organs, the mechanism 
involves increasing gluconeogenesis in the liver, mobilising lipids and glycerol from 
adipose tissue and amino acids from muscle as well as decreasing glucose uptake in 
muscle (reviewed in (Vegiopoulos and Herzig 2007)). In general, GCs are described 
as diabetogenic hormones for their potent effect to stimulate glucose production and 
induce insulin resistance in both humans and rodents, although notably most studies 
have used pharmacological doses of the potent sythetic GR agonist dexamethasone 
(Tappy et al. 1994; Nicod et al. 2003; Buren et al. 2008; Rafacho et al. 2008). 
1.4.3.3.1 Glucocorticoids and liver 
In liver, GCs promote gluconeogenesis resulting in the generation of glucose from 
non-carbohydrate carbon substrates such as amino acids and glycerol. They address 
this mainly by activating two critical enzymes: phosphoenol pyruvate carboxykinase 
(PEPCK) (Hanson and Reshef 1997) and glucose-6-phosphatase (G6Pase) (Garland 
1986). PEPCK is a rate limiting enzyme in gluconeogenesis. The PEPCK promoter 
contains two positive GC response elements (GRE) and three accessory factor 
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elements (Hanson and Reshef 1997). G6Pase catalyses the terminal step in 
gluconeogenesis and its promoter contains two potential GREs (Lin et al. 1998) 
which enable GCs to elevate its activity (Nordlie and Arion 1965; Garland 1988).  
1.4.3.3.2 Glucocorticoids and adipose tissue 
In adipose tissue, GCs regulate lipid metabolism according to the level of the GR, 
which is fat depot selective, and the prevailing nutritional state, fasting or fed. GCs 
increase lipolysis through activating hormone sensitive lipase and inhibiting 
lipoprotein lipase in peripheral fat in the fasted state (e.g. subcutaneous, gluteal and 
thigh) (Ong et al. 1992; Slavin et al. 1994; Mattsson and Olsson 2007). The released 
FFAs are essential for oxidation in other tissues, particularly muscle, to generate 
energy. The released glycerol is a substrate for hepatic gluconeogenesis. 
Glucocorticoids also promote pre-adipocyte differentiation, induce lipogenic activity, 
and increase hypertrophy in central fat (e.g. abdominal, visceral adiposity) (Gaillard 
et al. 1991; Samra et al. 1998; Masuzaki et al. 2001; Morton and Seckl 2008). 
Consistent with these effects, Cushing’s syndrome patients show a marked 
redistribution of body fat, with fat and muscle wasting in subcutaneous and limbs, 
but accumulation in the depots of the abdomen, the nape of the neck and face where 
GR levels are higher. 
1.4.3.3.3 Glucocorticoids and muscle 
In skeletal muscle, GCs modulate protein metabolism by promoting protein 
degradation, inducing the mobilization of amino acids, increasing amino acid export 
and inhibiting protein synthesis (Vegiopoulos and Herzig 2007). The metabolised 
amino acids serve as substrates for liver gluconeogenesis in times of prolonged fast, 
or with GC excess. Furthermore, GCs suppress glucose oxidation by direct inhibition 
of the glucose transport system (Olefsky 1975). Peripheral glucose uptake depends 
on the cell membrane translocation of the GLUT4 transporter, which is expressed 
mainly in skeletal muscle. GCs suppress GLUT4 expression and translocation to the 
cell membrane from an internal location which suppress glucose uptake (Horner et al. 
1987; Oda et al. 1995; Weinstein et al. 1995; Coderre et al. 1996; Dimitriadis et al. 
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1997). 
1.4.3.3.4 Glucocorticoids and pancreas 
Numerous studies have examined GCs effects on pancreatic islet glucose-stimulated 
insulin secretion (GSIS). However, no consensus has emerged due to the divergent 
results found across different species and methodologies. In vitro, GCs inhibit GSIS 
from perfused rat pancreas (Billaudel and Sutter 1979; Barseghian et al. 1982) 
isolated rodent islets (Billaudel et al. 1984; Pierluissi et al. 1986; Wang et al. 1994; 
Gremlich et al. 1997; Lambillotte et al. 1997; Zawalich et al. 2006; Sandberg and 
Borg 2007; Swali et al. 2008), and in a mouse model of obesity (Chan and Lejeune 
1992; Davani et al. 2000; Ortsater et al. 2005). The inhibitory effects were only 
present with high physiological to supraphysiological GC exposure (10 and 100 
nmol/l dexamethasone, a potent synthetic GC or 50 and 100 nmol/l 
11-dehydrocorticosterone (11DHC), the inactive GC in rodent) and led to both 
suppression of insulin release (Davani et al. 2000; Jeong et al. 2001; Swali et al. 
2008) and insulin biosynthesis (Jeong et al. 2001). Evidence for GC-mediated 
increases in GSIS has been found in normal C57BL/6J mouse islets (Brunstedt and 
Nielsen 1981; Hult et al. 2009). (Table 1-2) 
 
However, the direct effects of GCs on islet function is difficult to address in vivo, 
because GCs have diverse effects on other key metabolic tissues (see 1.4.3.3). Thus 
because GRs are widely distributed in many cells; the multiple influences of GCs in 
the whole body makes the results hard to interpret. Notably, GCs may enhance vagal 
stimulation of insulin secretion by their central action (Stubbs and York 1991; 
Angelini et al. 2010), adding further complexity to the overall in vivo effects of GC 
excess.  
 
In vivo, GC treatment induces peripheral insulin resistance in humans (Beard et al. 
1984; Tappy et al. 1994; Nicod et al. 2003; Ahren 2008) and rats (Severino et al. 
2002; Holness et al. 2005; Buren et al. 2008; Rafacho et al. 2008), which elicits a 
secondary compensatory response from the pancreatic β-cell to promote insulin 
secretion by increasing β-cell mass and/or function (Beard et al. 1984; Karlsson et al. 
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2001; Choi et al. 2006; Rafacho et al. 2008). Accordingly, the isolated islets from 
dexamethasone treated rats display an increase of GSIS due to increased 
mitochondrial function, Ca2+ signaling, PKC activity, and changes in exocytotic 
capacity (Rafacho et al. 2010). It is difficult to unravel whether some, none or all of 
these changes are due to direct effects of the GCs on β-cell function. (Table 1-2) 
 
In contrast leptin deficient obese Lepob/ob and normal mice treated with GCs in 
comparable dose to the rats (Rafacho et al. 2008) exhibit reduced GSIS in vivo (Khan 
et al. 1992; Ling et al. 1998). Mice with GR overexpression which is under the 
control of the rat insulin I promoter also exhibit impaired insulin release (Delaunay et 
al. 1997; Ling et al. 1998; Davani et al. 2004). The mechanism by which increased 
GC sensitivity (higher β-cell GR) directly inhibit GSIS in mice remains unclear but 
likely involves regulatory factors of the glucose metabolism pathway, such as 
increased glucose cycling through G6Pase activity (Khan et al. 1992; Khan et al. 
1995; Ling et al. 1998), decreased GLUT2 transporter stability (Gremlich et al. 1997), 
and augmented α2-adrenergic receptor level which inhibits insulin secretion (Davani 
et al. 2004). (Table 1-2) 
 
For human, intravenous administration of cortisol increases the first phase of β-cell 
function (Vila et al. 2010) and oral administration of dexamethasone increases 
insulin secretion (Abdelmannan et al. 2010). Overall, it has been difficult to discern 
the primary effects on β-cell function from those arising from peripheral insulin 











Table 1-2. GCs effects on pancreatic islet glucose-stimulated insulin secretion  
In 
vivo/vitro 
Species Source Type of GCs Dose Method Effects Reference 
Rat Perfused 
pancreas 
Cortisone 1mM Repeated pulse 
administration 




Inhibition. Only 2nd 
phase disturbed. 






0.02, 0.2 or 
20mg/l 
 
Pre-incubated for 1hr. 
4.2mM and 16.7mM 
glucose 
 Inhibition. Inhibitory 





Rat   
(male albino) 
Isolated islets Corticosterone 0.6μM Pre-incubation for 
40-44mins 
Inhibition by reduce 
Ca2+ influx. 













Pre-incubation for 2hrs, 
2mM and 20mM 
glucose 
Inhibit GSIS. Delayed 
1st phase, reduced 2nd 
phase. 




Isolated islets Dexamethasone 1μM Pre-incubation for 
48hrs, 2.8mM and 
16.7mM glucose 
Inhibit GSIS by 
reduce GLUT2 
(Gremlich et al. 
1997) 
Rat  Isolated islets Dexamethasone 1μM Pre-incubation for 3hrs, 
15mM glucose 
Inhibit both 1st phase 
and 2nd phase 




Pre-incubation for 6hrs, 
3.3, 16.7mM glucose 






1nM Pre-incubation for 1hr No effect 
(Jeong et al. 
2001) 
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10, 100nM  Inhibition 
Pre-incubation for 5hrs, 
15mM glucose 





18hrs, 3mM and 15mM 
glucose 
Inhibition in both 
glucose  












Isolated islets Corticosterone 1, 10, 100 
μM 













3 or 20mM 
glucose 
Inhibition. (Swali et al. 
2008) 
Rat (fa/-) 1nM Pre-incubation for 24, 




10nM Pre-incubation for 
72hrs, 27.5mM glucose
Inhibition. (Chan and 
Lejeune 1992) 
Mouse (Lepob/ob) Isolated islets 11-DHC  50, 500nM 3.3, 8.3, 16.7mM 
glucose 
Inhibition in a 
dose-dependent 
(Davani et al. 
2000) 
Mouse (Lepob/ob) Isolated islets 11-DHC 5nM  Pre-incubation for No effect (Ortsater et al. 
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50, 500 nM 48hrs, 3,11mM glucose Inhibition 
Mouse 
(C57BL/6J) 
50nM Pre-incubation for 
48hrs 




Isolated islets Hydrocortisone 1nM Islet cultured for 1 to 
3weeks. 




Isolated islets Corticosterone 200nM Pre-incubation for 
18hrs, 3,11mM glucose
Increase 1st and 2nd 
phase during 120hrs 
(Hult et al. 
2009) 
Rat Isolated islets Dexamethasone 4mg/kg ip. For 10 days, 2.8mM 
glucose and 20mM 
glucose 
Inhibition (Wang et al. 
1994) 
ip. For 12 days, 3.3mM 
and 8.3mM glucose 
Increase GSIS.  
ip. For 12 days, 
0-20mM glucose 
Increase insulin 
secretion at 1.8mM to 
11.1mM glucose  
Rat (female 
Sprague-Dawley) 




secretion at 1.8 to 
3.3mM glucose, 
inhibit at 11.1 to 
20mM glucose 







Rat (male Wistar) Isolated islets Dexamethasone
1mg/kg 
ip. for 5 days, 
2.8-22mM glucose 
Increase GSIS, can 
not counteract 
metabolic disorder 
(Rafacho et al. 
2008) 
In vivo 
Rat (male Wistar) Isolated islets Dexamethasone 1mg/kg/day ip. for 5 days, 2.8, 
11.1mM glucose 
Increase insulin 
secretion in both 2.8 
and 11.1mM glucose 
(Rafacho et al. 
2010) 
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Rat (male Wistar) Isolated islets Dexamethasone 1mg/kg/day ip. For 5 days. 8.3mM 
glucose 
Increase (Angelini et al. 
2010) 
Mouse (Lepob/ob) Isolated islets Dexamethasone 25μg/day ip. For 1 or 2 days, 5.5 
and 16.7mM glucose 





Isolated islets Dexamethasone 100μg/ml ip. For 3 days, 5.5 and 
16.7mM glucose 
Inhibit GSIS (Ling et al. 
1998) 
Human (men) Circulation 
plasma 
Dexamethasone 6mg/day. 3 mg twice daily for 2 
days, 
Increase (Beard et al. 
1984) 




0.6mg/kg iv. 4 mins before 
administrate 330mg/kg 
glucose 
Increase 1st phase 
insulin secretion 
(15mins) 
(Vila et al. 2010)
Human Circulation 
plasma 




effects of 2, 4mg. 
significant effects in 
8mg. 
(Abdelmannan 
et al. 2010) 
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1.5 11β-hydroxysteroid dehydrogenases (11β-HSDs) 
Besides GR density, the primary determinants of physiological GC action depends 
on the intracellular concentration of the ligand which is regulated by the activity of 
the HPA axis, by the level of the corticosteroid binding globulin, and by the activity 
of the intracellular 11β-hydroxysteroid dehydrogenase enzymes. The intracellular 
11β-HSD activity was discovered by Amelung and colleagues (1953). 11β-HSD 
activity is found in a broad range of cells and tissues (reviewed in Seckl and Walker 
2004). There are two isozymes of 11β-hydroxysteroid dehydrogenase, 11β-HSD1 
and 11β-HSD2, that catalyze the interconversion of hormonally active GC (cortisol 
in humans and corticosterone in rodents) and inactive GC (cortisone in humans and 
11DHC in rodents) to regulate intracellular GCs levels (reviewed in Tomlinson et al. 
2004). 11β-HSD1 acts as a bi-directional (the reductase usually being predominant) 
enzyme and it is largely expressed in the tissue and organs associated with high GR 
expression, such as liver, lung, adipose tissue, and brain (Moisan et al. 1990; Tannin 
et al. 1991; Ricketts et al. 1998; Jamieson et al. 2000; Brereton et al. 2001; 
Dzyakanchuk et al. 2009). In contrast, 11β-HSD2 functions solely as a 
dehydrogenase and is expressed mainly in kidney and other mineralocorticoid target 
tissues where it prevents inappropriate activation of GCs (Cook et al. 1988; van Uum 
et al. 2004). Notably, MR and GR have indistinguishable affinities for active GCs 
and as such the 11β-HSD enzymes fullfil a critical pre-receptor ligand access 
function in these tissues (Seckl and Walker 2004). 
1.5.1 11β-hydroxysteroid dehydrogenases type 1 (11β-HSD1)  
The 11β-HSD1 gene in rat contains an 861bp open reading frame encoding a protein 
of 288 amino acids (Lakshmi and Monder 1988). Analysis of the mouse cDNA 
shows extensive conservation of nucleotide (91%) and amino acid (86%) sequences 
with rat 11β-HSD1 (Rajan et al. 1995). Fetal mouse 11β-HSD1 mRNA expression is 
first observed at e15 in lung and liver, and its expression increases markedly from 
 62
this time (Speirs et al. 2004). 
 
11β-HSD1 is an NADP(H)-dependent enzyme which is a major regulator of GC 
metabolism in mammals (Agarwal and Auchus 2005). In tissue homogenates 
(Lakshmi and Monder 1988) and some transfected cells (Agarwal et al. 1989; 
Bujalska et al. 1997; Atanasov et al. 2004; Dzyakanchuk et al. 2009) 11β-HSD1 
exerts a bi-directional function. However, in intact cells and in vivo, 11β-HSD1 
mainly acts as a reductase (Low et al. 1994; Jamieson et al. 1995; Kotelevtsev et al. 
1997; Jamieson et al. 2000). 11β-HSD1 is an integral membrane protein of the 
endoplasmic reticulum (ER) with its N-terminus anchor in the ER membrane and 
with the C-terminus inside the ER lumen (Ozols 1993; Mziaut et al. 1999; 
Dzyakanchuk et al. 2009). 11β-HSD1 activity highly depends on the ratio of 
NADPH/NADP+ within the ER lumen (Atanasov et al. 2004; Banhegyi et al. 2004; 
Bujalska et al. 2005; Dzyakanchuk et al. 2009). Because the ER membrane is 
relatively impermeable to pyridine nucleotides, the NADPH/NADP+ ratio within the 
ER is regulated by other enzymes, key among which is hexose-6-phosphate 
dehydrogenase (H6PDH) which is untethered and resides in the ER lumen (Ozols 
1993). The H6PDH is the microsomal counterpart of the cytosolic 
glucose-6-phosphate dehydrogenase (G6PDH). NADP+ and G6P are the two 
essential substrates for H6PDH to generate NADPH by catalyzing the first two steps 
of the endoluminal pentose-phosphate pathway. Generation of NADPH thereby 
drives 11β-HSD1 reductase activity (Lavery et al. 2006). Unlike NADP+, G6P is 
transported into the ER lumen by the glucose-6-phosphate transporter (G6PT) (Chou 
et al. 2002). Deficiency of the G6PT in liver results in a loss of 11β-HSD1 reductase 
activity (Walker et al. 2007). Numerous in vitro studies have demonstrated a key link 
between 11β-HSD1 reductase activity and H6PDH (Atanasov et al. 2004; Banhegyi 
et al. 2004; Bujalska et al. 2005; McCormick et al. 2006). Critically, H6PDH 
knock-out mice exhibit a switch in 11β-HSD1 activity from reductase to 
dehydrogenase in liver, strongly suggesting the enzyme is the key co-factor provider 
for 11β-HSD1 in vivo (Lavery et al. 2006). Furthermore, H6PDH expression is 
stimulated by dexamethasone in both adipocytes in vitro and rat adipose tissue in 
vivo (Balachandran et al. 2008), suggesting regulation of H6PDH as well as 
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Figure 1-8. The interaction between 11β-HSD1 and H6PDH. Glucose is taken up 
by the cell and metabolised to generate G6P which enters the ER lumen through 
G6PT. G6P can be utilized by H6PDH in the presence of NADP+ to provide NADPH 
which is a cofactor that permits reductase (cortisone to cortisol) activity of 
11β-HSD1. The active cortisol subsequently binds to GR to exert its effects in the 
nucleus.  
 
Abbreviations: ER, endoplasmic reticulum, H6PDH, hexose-6-phosphate dehydrogenase, NADP, 
Nicotinamide adenine dinucleotide, NADPH, Nicotinamide adenine dinucleotide phosphate, G6P, 
glucose-6-phosphate; G6PT, Glucose-6-phosphate transporter; 6PG, 6-phosphogluconolactonate 





















1.5.2 The promoter of the 11β-HSD1 gene 
Different promoter usage and alternate splicing mechanisms make alternate 
11β-HSD1 mRNA transcripts in distinct tissues. Although two different cDNAs were 
cloned from mouse liver (Oppermann et al. 1995; Rajan et al. 1995), that encode 
identical proteins, the cDNA sequences differ in the 5′ untranslated region (UTR), 
suggesting alternate transcription starts. Previous studies (Bruley et al. 2006) have 
used 5′ rapid amplification of cDNA ends (RACE) to identify an alternate promoter, 
P1, which is located 23kb upstream to the commonly used promoter, P2. Both 
promoters are expressed in liver, lung, adipose tissue, and brain. However, P1 
(encoding exon 1A) predominats in lung and P2 (encoding exon 1B) predominates in 
liver, adipose tissue, and brain. P1 and P2 derived transcripts encode the same 
protein, 11β-HSD1 A. Importantly, this implies distinct regulatory mechanisms may 
control 11β-HSD1 transcription in a tissue-specific manner. A further promoter, P3 
has been described in kidney which initiates the transcription at another site in rat; 
264 bp further 5′ as well as within the first intron (Moisan et al. 1992). The latter 
start site transcribed an 11β-HSD1 mRNA encoding a nonfunctional protein 





Figure 1-9. The promoter region of the 11β-HSD 1 gene. Organisation of the 
rodent 11β-HSD1 gene, P1, encoding Exon 1A; P2 encoding Exon 1B; Exon 1A is 
23kb upstream of the Exon 1B; P3, encoding an intron. When transcription begins 
from promoter 1, Exon 1A is spliced with the Exon 2; from promoter 2, the Exon 1B 
is spliced with the Exon 2, however translation begins from the same ATG, so they 
encode the same protein 11β-HSD1 A. In kidney, transcription begins at another 
promoter close to Exon 3, encoding the non-functional protein 11β-HSD1 B. 
Adapted from (Bruley et al. 2006).  
 
1.5.3 Factors regulating 11β-HSD1 
The regulation of 11β-HSD1 transcription and activity is highly tissue-specific and 
influenced potently by hormones such as GCs, insulin, as well as cytokines such as 
proinflammatory IL-1 and TNF-α (Jamieson et al. 2000; Tomlinson et al. 2004). 
GCs temporally regulate 11β-HSD1 expression and activity in rat liver and 
hippocampus in vivo (Moisan et al. 1990; Jamieson et al. 2000) and 
dose-dependently increase 11β-HSD1 expression in human skeletal muscle 
(Whorwood et al. 2002) GCs generally act to stimulate 11β-HSD1 in skin fibroblasts 
(Hammami and Siiteri 1991), testis (Nwe et al. 2000), human coronary artery smooth 
muscle cells (Michas et al. 2010), preadipocytes (Kim et al. 2007), and hepatocytes 
(Liu et al. 1996; Voice et al. 1996). However, in adipocytes, GCs down-regulate 
11β-HSD1, at least in vitro (Napolitano et al. 1998; Balachandran et al. 2008) whilst 
up-regulating 11β-HSD1 in vivo (Livingstone et al. 2000; Balachandran et al. 2008). 
Insulin inhibits 11β-HSD1 expression and/or activity in many cells (Moisan et al. 
1990; Hammami and Siiteri 1991; Liu et al. 1996; Jamieson et al. 1999; Nwe et al. 
2000; Sandeep et al. 2005; Kim et al. 2007). In contrast, insulin can stimulate 
3’ 
P 1 P 2
104 bp 67 bp 
      
114 bp 
P3 
64 bp 131 bp 
Exon 1A 5’ Exon 1B ATG Exon 2 Intron Exon 3 Exon 6 
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11β-HSD1 expression and activity in adipocytes in vivo and in vitro (Wake et al. 
2006; Westerbacka et al. 2006; Balachandran et al. 2008). Taken together, both GCs 
and insulin regulate 11β-HSD1 possibly in a concentration-dependent and 
cell-specific manner. Proinflammatory IL-1 and TNFα increase 11β-HSD1 mRNA 
levels in several cell types (Escher et al. 1997; Tetsuka et al. 1999; Cai et al. 2001; 
Cooper et al. 2001; Tomlinson et al. 2001; Yong et al. 2002). The TNFα effect is 
attenuated by insulin in human adipose stromal cells (Handoko et al. 2000). Growth 
hormone (GH) (Liu et al. 1997; Moore et al. 1999), liver X receptor (LXR) and 
peroxisome-proliferator-activated receptor-γ (PPARγ) (Berger et al. 2001; Stulnig et 
al. 2002) inhibit 11β-HSD1 expression and activity. Moreover, high fat diet 
decreased 11β-HSD1 activity in adipose tissue without effects in liver though the 
mechanisms for this remain unknown (Morton et al. 2004). 
 
Members of the CAAT/enhancer-binding protein (C/EBP) family are the major 
transcription factors regulating 11β-HSD1 (McKnight et al. 1989; Darlington et al. 
1995; Croniger et al. 1998; Poli 1998). The 11β-HSD1 P2 promoter contains 10 
C/EBP binding sites between 2812 and 176 (Williams et al. 2000). Among the 
C/EBP isoforms expressed in liver and adipose C/EBPα, which is important in 
energy metabolism (McKnight et al. 1989) and haematopoietic lineage determination 
(Iwasaki et al. 2006), acts as a potent activator of the 11β-HSD1 P2 promoter in 
hepatocytes both in vivo and in vitro (Williams et al. 2000; Bruley et al. 2006). In 
vitro, several cell lines, such as preadipocytes (Napolitano et al. 1998; Gout et al. 
2006; Arai et al. 2007), lung epithelial cells (Sai et al. 2008) and skin fibroblasts 
(Hammami and Siiteri 1991), 11β-HSD1 activity is elevated through C/EBPβ 
binding to the P2 promoter. Furthermore, 11β-HSD1 expression is increased by 
TNFα in hepatoma cells (Ignatova et al. 2009), and IL-1 in human foetal lung 
fibroblasts (Yang et al. 2009) through the P2 promoter and C/EBPβ. C/EBPβ plays a 
role in inflammatory and innate immune functions, so it can be a link between 
inflammation and metabolism (Poli 1998). In addition, GCs are important regulators 
of C/EBP transcription, markedly inducing C/EBPβ and C/EBPδ mRNAs (Matsuno 
et al. 1996; Breed et al. 1997; Gotoh et al. 1997) and with differing temporal and 
 67
tissue-specific effects on C/EBPα mRNA (MacDougald et al. 1994; Ramos et al. 
1996). However, the regulation of P1 and P3 remains poorly understood. The P1 
promoter is not regulated by C/EBPα in transfected cells (Bruley et al. 2006), and is 
expressed independently of C/EBPα in lung.  
1.5.4 11β-HSD1 in obesity and lessons from transgenic mouse 
models 
GCs play an important role in the development of obesity and metabolic disease in 
rodents as evidenced by the correction of all metabolic abnormalities with 
adrenalectomy (ADX) and re-instatement of the aberrant phenotype with GC 
replacement in the ADX animals (Shimomura et al. 1987; Dallman et al. 2004). 
However, circulating GC levels are normal or even low in common or idiopathic 
human obesity (Pasquali et al. 1999) whereas tissue 11β-HSD1 activity, particularly 
adipose tissue, is elevated (Bujalska et al. 1997; Wake et al. 2003; Wake et al. 2006). 
This led to the concept that amplification of tissue GCs may explain the similarities 
between certain aspects of excess GC action (e.g. the visceral obesity, type 2 diabetes 
and increased cardiovascular risk) found in Cushings syndrome with that found in 
common obesity.  
1.5.4.1 11β-HSD1 in the adipose tissue 
11β-HSD1 is highly expressed in fat and its expression and activity increases with 
differentiation from pre-adipocytes to mature adipocytes (Napolitano et al. 1998). 
11β-HSD1 expression and/or activity increased in adipose tissue of obese humans 
(Rask et al. 2001; Rask et al. 2002; Lindsay et al. 2003; Wake et al. 2003; Kannisto 
et al. 2004; Sandeep et al. 2005; Goedecke et al. 2006; Michailidou et al. 2007) and 
rodents (Livingstone et al. 2000; Masuzaki et al. 2001; Morton et al. 2004). In 
rodents, 11β-HSD1 is particularly increased in visceral fat (Livingstone et al. 2000; 
Morton et al. 2004), whereas, it increased in the subcutaneous fat in humans 
(Sandeep et al. 2005). 11β-HSD1 overexpression specifically in adipose tissue under 
the aP2 promoter (aP2-HSD1) achieved a level of 11β-HSD1 activity that was 
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comparable (2-3 fold higher than lean) to that found in obese humans. Crucially, as 
with idiopathic human obesity corticosterone levels in the blood were normal but 
corticosterone was higher in adipose tissue and the portal circulation draining from 
the visceral fat (Masuzaki et al. 2001). aP2-HSD1 mice developed glucose 
intolerance, insulin resistance, dyslipidemia, leptin resistance and a “metabolic 
syndrome” (Masuzaki et al. 2001) as well as hypertension (Masuzaki et al. 2003), 
making a causal link between elevated adipose 11β-HSD1 and metabolic syndrome. 
1.5.4.2 11β-HSD1 in the liver 
In contrast to adipose tissue, in liver, the organ with the highest level of 11β-HSD1 
expression (>10-fold compared to adipose tissue (Tannin et al. 1991)) 11β-HSD1 
expression is decreased in obese humans (Stewart et al. 1999; Rask et al. 2001; Rask 
et al. 2002; Sandeep et al. 2005) and rodents (Livingstone et al. 2000; Liu et al. 
2003). However, the aP2-HSD1 transgenic mice display a high level of 
corticosterone and FFAs in the hepatic portal vein (Masuzaki et al. 2001), which 
suggests overexpression of 11β-HSD1 in visceral adipose tissue could cause a 
detrimental delivery of elevated GCs to liver, at least in mice. The liver-specific 
overexpression of 11β-HSD1 was generated by utilizing the ApoE promoter 
(ApoE-HSD1) (Paterson et al. 2004) to investigate the effects of excess hepatic GCs 
on metabolic syndrome. ApoE-HSD1 mice exhibited modest insulin resistance, 
increased liver fat content, and dyslipidaemia in the absence of glucose intolerance, 
obesity or changes of adipose distribution (Paterson et al. 2004). Along with an 
improvement in liver insulin sensitivity in humans after treatment with the 
11β-HSD1 inhibitor carbenoxolone (Walker et al. 1995; Rosenstock et al. 2010), 
these data indicated that elevated hepatic 11β-HSD1 activity, as is found in certain 
rare conditions such as myotonic dystrophy (Johansson et al. 2001), makes a 
pathogenic contribution to metabolic disease (Liu et al. 2005; Morton et al. 2005). 
1.5.4.3 11β-HSD1 in the skeletal muscle 
Although skeletal muscle is an important target for GC-induced insulin resistance 
(describe in 1.4.3.3), the expression of 11β-HSD1 is relatively low in skeletal muscle 
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in mice (Itoh et al. 2004). In contrast, 11β-HSD1 is expressed in vascular smooth 
muscle (Walker et al. 1992). Human skeletal muscle cells express 11β-HSD1, and its 
activity is down regulated by insulin in vitro (Whorwood et al. 2001). 11β-HSD1 is 
increased in skeletal muscle of a diabetic rat model, but decreased in diabetic 
subjects (Zhang et al. 2009). The role of skeletal muscle 11β-HSD1 remains to be 
clarified, although recent work has demonstrated that 11β-HSD1 inhibitors have 
direct beneficial effects in rodent skeletal muscle (Morgan et al. 2009).  
1.5.5 The 11β-HSD1 knock out mouse model  
Absence of regeneration of active corticosterone after complete disruption of the 
11β-HSD1 gene in tissues of 11β-HSD1 knockout mice (11β-HSD1-/-) confirmed 
that 11β-HSD1 was a reductase in most intact cells, and that only the 11β-reductase 
was capable of locally reactivating 11-dehydrocorticosterone to corticosterone in 
mice (Kotelevtsev et al. 1997). To compensate the low production of active GCs, 
11β-HSD1-/- mice exhibit adrenal hypertrophy, higher secretion of corticosterone, 
hyper-responsiveness to acute restraint stress, and low sensitivity to the negative 
feedback on HPA axis (Kotelevtsev et al. 1997; Harris et al. 2001).  
 
11β-HSD1-/- mice are resistant to diet-induced metabolic syndrome (visceral obesity, 
insulin resistance, type 2 diabetes, and dyslipidemia), which resembles Cushing's 
Syndrome of plasma GC excess. Thus 11β-HSD1-/- mice had increased hepatic and 
adipocyte insulin sensitivity (Morton et al. 2001; Morton et al. 2004). 11β-HSD1-/- 
mice on a high fat diet gain less weight and preferentially accumulated peripheral 
rather than visceral fat mass, in part due to an increase PPARγ expression and 
activation in visceral fat (Morton et al. 2001; Morton et al. 2004; Wamil et al. 2011). 
Moreover, 11β-HSD1-/- mice exhibit improved lipid and lipoprotein profiles 
associated with increased HDL cholesterol and reduced VLDL triglyceride levels 
(Morton et al. 2001; Morton et al. 2004). 11β-HSD1-/- mice also exhibit improved 
glucose tolerance, in part through lower fasting induction of PEPCK and G6Pase, 
thereby decreasing gluconeogenesis in liver (Kotelevtsev et al. 1997). 11β-HSD1-/- 
mice are insulin-sensitized, particularly in adipose tissue, and show a reduction of 
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leptin, resistin and TNFα, but elevation of adiponection and PPARγ (Morton et al. 
2001; Morton et al. 2004; Densmore et al. 2006). Moreover, 11β-HSD1-/- mice 
display a transient hyperphagia (Morton et al. 2004; Densmore et al. 2006), enhanced 
angiogenesis after myocardial infarction (Small et al. 2005), are resistant to cognitive 
decline in old age (Sooy et al. 2010) and have an exaggerated inflammatory response 
and altered inflammatory resolution (Gilmour et al. 2006; Zhang and Daynes 2007). 
Taken together these studies show that intracellular amplification of GC action by 
11β-HSD1 has a profound effect on many of the fundamental processes ascribed to 
GC (see 1.4.3) clearly emphasising the importance of tissue-level regulation of GC 
action, often in the face of or independently of HPA control. 
1.5.6 11β-HSD1 inhibitors 
Given the protective effects of 11β-HSD1 deficiency in metabolic disease, a strategy 
to develop a therapeutic inhibitor of 11β-HSD1 has been considered as a treatment 
for metabolic syndrome and T2D (Boyle 2008; Morton and Seckl 2008; Morton 
2010; Tomlinson et al. 2010). Carbenoxolone, a compound purified from liquorice is 
a non-selective 11β-HSD1 inhibitor with major efficacy in liver, poor efficacy within 
adipose tissue, but with capacity to improve insulin sensitivity in humans and rats 
(Walker et al. 1995; Livingstone et al. 2000). However, the weight of evidence 
suggested that dysregulation of 11β-HSD1 clearly occurs in the adipose tissue in 
obesity. Thus, compounds that would be efficacious across a number of tissues were 
sought. Arylsulfonamidothiazoles (BVT.14225 and BVT.2733) were the first 
reported selective 11β-HSD1 inhibitors and they enhanced insulin action in liver, as 
well as lowering blood glucose concentrations in diabetic and obese mice (Alberts et 
al. 2002; Barf et al. 2002; Alberts et al. 2003). To date, a number of other 11β-HSD1 
inhibitors are under development for potential clinical purposes (Alberts et al. 2003; 
Hermanowski-Vosatka et al. 2005; Webster et al. 2007; Bujalska et al. 2008). 
Recently, the first data using an 11β-HSD1 inhibitor for the clinical treatment of T2D 
has been reported (Rosenstock et al. 2010). Patients treated with INCB13739 added 
to ongoing metformin monotherapy had significantly reduced hemoglobin A1C, 
fasting glucose, total cholesterol, LDL, cholesterol, and triglycerides, while the basal 
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cortisol level was unchanged. The prospects for therapeutic inhibition of 11β-HSD1 
are therefore good, although the downstream effects of these inhibitors in tissues 
where elevated 11β-HSD1 may play a beneficial functional role (e.g. macrophage 
inflammation resolution) remains to be clarified. 
1.5.7 11β-HSD1 in the pancreas and diabetes 
11β-HSD1 is expressed in rodent (Davani et al. 2000; Duplomb et al. 2004; Ortsater 
et al. 2005; Swali et al. 2008) and human pancreatic islets (Davani et al. 2000). 
Recently 11β-HSD1 expression was found to be highest in the α cells suggesting a 
paracrine modulation on insulin secretion exists (Swali et al. 2008). 11β-HSD1 
expression is higher in pancreatic islets of obese/diabetic rodents and is more 
sensitive to 11-dehydrocorticosterone (11DHC) mediated suppression of GSIS, an 
effect reversed by 11β-HSD1 inhibitors (Davani et al. 2000; Duplomb et al. 2004; 
Ortsater et al. 2005; Swali et al. 2008). Curiously, however, exposure of normal islets 
to 200nM corticosterone produced a stimulation of first phase GSIS, a finding that 
was not interpreted in the publication, although the suppressive effect of 
corticosterone on second phase GSIS was discussed (Hult et al. 2009). Furthermore, 
the high glucose and lipid levels typical of metabolic disease were assessed for their 
potential regulatory effects on islet 11β-HSD1 in vitro, but no clear effect on 
11β-HSD1 mRNA levels on isolated islets of prediabetic ZDF rats was found 
(Duplomb et al. 2004). Thus, the increased GC action mediated by elevation of 
11β-HSD1 expression may modulate the onset of diabetes by amplifying the 
inhibitory effect of GCs in β-cell. However, according to inconsistent and 
controversial effects of GCs on islet GSIS (details in 1.4.3.3), it is equally possible 
that the altered β-cell 11β-HSD1 could be secondary to the β-cell failure, or even a 
mechanism invoked to protect the β-cell from further damage. Therefore, overall, the 
physiological role of islet 11β-HSD1 and its impact upon the etiology of diabetes is 
unclear. 
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1.6 Hypothesis and Aims 
Hypothesis 
This thesis was based upon the over-arching hypothesis that: 
 
Elevated β-cell 11β-HSD1 levels promote β-cell failure and type 2 Diabetes.  
 
Aims 
The overall aim of this thesis was to investigate the role and regulation of 11β-HSD1 
in the pancreatic β-cells. To accomplish this goal, investigations were carried out by 
generating a β-cell-specific 11β-HSD1 overexpression model in mice. The specific 
aims were: 
 
1. To investigate what regulates 11β-HSD1 in pancreatic islets, including: 
i) Which activity directionality of 11β-HSD1 is predominant in islets; 
ii) Which promoter controls 11β-HSD1 expression in islets; 
iii) Which factors regulate islet 11β-HSD1 activity in diabetes. 
2. To determine the effects of β-cell-specific overexpression of 11β-HSD1 on β-cell 
failure in type 2 diabetes. 
3. To determine the effects of β-cell-specific overexpression of 11β-HSD1 on β-cell 
failure in type 1 (streptozotocin-induced) diabetes. 
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Chapter 2    
 
Materials and Methods 
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2 Materials and Methods 
2.1 Animals and animal care 
Diabetes-susceptible C57BL/KsJ mice were obtained from Jackson laboratory 
(Jackson laboratory, USA) at 4 to 6 weeks of age, and were subsequently bred in the 
biomedical research facility (Little France, University of Edinburgh). Mice were 
housed in a temperature controlled room maintained with a 12hour light/dark cycle 
(7am-7pm light, 7pm-7am dark). Mice were given standard chow (RM, Special Diets 
Services) and autoclaved water ad libitum. Conditions and diets changed for specific 
experiments (described below). All studies were approved by the local ethical 
committee of the University of Edinburgh and were performed within the guidelines 
of the United Kingdom Animals Scientific Procedures Act, 1986 and under the 
auspices of the approved project license PPL 60/3962.  
2.1.1 Creation of a β-cell-specific 11β-HSD1 overexpressing mice 
A model of β-cell 11β-HSD1 overexpression was created using a β-cell specific 
promoter (Mouse insulin-I (Hara et al. 2003), a gift from Dr. Mark Magnusson, 
Vanderbilt University, USA). The sequence of the mouse insulin promoter (8.3kb) 
was cloned upstream of the rat 11β-HSD1 cDNA (1.265bp) in a pGEM11Zf (+) 
vector (constructed by Lynne Ramage) before being purified and micro-injected into 
blastocysts from C57BL/KsJ (performed by Genetic Intervention and Screening 
Technologies Biomedical Research Resources, University of Edinburgh) and 
implanted in pseudo-pregnant females. The creation of the transgenic mice model 
had been performed by Nicholas M. Morton, Sophie Turban and Lynne Ramage. 
Control C57BL/KsJ mice were bred in house. Only male C57BL/KsJ mice were used 
for the experiments in this thesis. 
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2.2 Experimental diets 
Mice were fed a hypercaloric (high-fat) diet (58 kcal% fat w/sucrose Surwit Diet, 
Research diet, New Brunswick, USA) for 12 weeks to induce glucose intolerance, 
and hypocaloric (low-fat) diet (11 kcal% fat w/cornstarch Surwit Diet, Research diet) 
to be control. 
  
2.3 Glucose tolerance test (GTT) 
The GTT was used to determine how quickly glucose was cleared from the blood 
after glucose administration. This method gives a crude measure of insulin sensitivity 
(glucose disposal) and β-cell function (where insulin evolution curves act as a 
surrogate for β-cell responsiveness to glucose load).  
2.3.1 Oral glucose tolerance test (oGTT)/ intraperitoneal glucose 
tolerance test (ipGTT) 
Mice were housed individually several days before the experiment to allow them to 
equilibrate to their environment and reduce undue stress/HPA activation. Prior to 
glucose administration, mice underwent a 6 hour fast to achieve a ‘baseline’ blood 
glucose level. Blood glucose levels were measured in a drop of blood after 
venesection of the tail vein using a handheld glucometer (OneTouch Ultra, LifeScan, 
USA). Further blood samples were collected in a Microvette CB 300 (Sarstedt, 
Leicester, UK) at time zero (T0) to determine baseline plasma insulin levels. A bolus 
of glucose solution (2g glucose/kg bodyweight using 25% (w/v) D-glucose in 0.9% 
NaCl solution for ipGTT, in dH2O for oGTT) was either injected into the 
intraperitoneal cavity or delivered into the stomach by a gavage needle (20-gauge, 38 
mm long curved, with a 21/4 mm ball end; Able Scientific, Canning Vale, Western 
Australia, Australia). Blood was collected at 1, 3, 5, 10, 15, 30, 60, and 120 minutes 
after glucose administration for glucose and insulin analysis. 
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2.3.2 Intravenous “long” glucose tolerance test (lGTT)  
Due to the variability in absorption in the ipGTT and, to a lesser extent the oGTT, we 
developed an intravenous glucose tolerance test (IvGTT, lGTT). The lGTT closely 
reports the critical first (1 to 3 minutes) and second phase of insulin secretion after 
glucose challenge. This improves the accuracy of our interpretation compared to 
intraperitoneal GTT and oral GTT which can exhibit marked variation in time of 
glucose absorption, especially when there are large anatomical variations in body fat; 
e.g. in obese compared to lean animals. The lGTT also used a continuous infusion of 
a higher dose of glucose than ipGTT or oGTT in order to cause sustained maximal 
insulin release (5g/kg BW for one hour) to help distinguish β-cell function from 
peripheral glucose disposal effects. In the absence of euglycaemic/hyperinsulinaemic 
clamps, this gave us improved insight into β-cell capacity/function. 
2.3.2.1 Jugular vein cannulation: 
Each mouse was anaesthetized by injection of 1mg/ml Medetomidine (Domitor) and 
100mg/ml Ketamine (Vetalar), (0.1ml/10 grams body weight, ip), and placed on its 
back on a pre-warmed hot pad. With the aid of a dissecting microscope (Zeiss Semi 
2000), a vertical incision was made above the jugular vein. The jugular vein was 
found and isolated. Four pieces (approximately 2cm each) of 5-0 braided silk suture 
material were placed under the vein. The upper ligature was tied to occlude the vein. 
The centre ligatures were left loose. The catheter was prepared by attaching a 10 cm 
length of Micro-Renathane tubing 025" O.D. x .012" I.D (Sandown Scientific, 
Hampton, UK) to a 25G needle. A needle was attached to a 1ml syringe filled with a 
saline heparin mix (heparin: saline: 1:10). The bent needle tip was then used to cause 
a small puncture in the jugular vein and the catheter was subsequently fed into the 
vessel until it reached the pectoral muscle. Any occlusions were checked by 
aspirating the syringe catheter assembly gently; blood from the vein flows freely in 
and out of the catheter when a good insertion is achieved. Ligatures were tied to 
firmly secure the catheter, and any excess thread was trimmed off. One small drop of 
surgical glue (3M™ Vetbond™ Tissue Adhesive, 3M, US) was placed to make sure 
the catheter remained stable. The catheter was taken off from the needle and closed 
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at the needle end by tightly knotting. The mouse was turned on its stomach and a 
small incision was made through the skin around the back of the neck. Thin blunt 
end forceps were fed subcutaneously toward the right shoulder to create a path to 
exteriorize the catheter. The excess catheter was folded and stored under the skin of 
the back to prevent it being damaged by the mouse (biting) upon recovery. All 
wounds were then closed using mouse surgery clips (A-75， Perfect, Bruneau, 
France). Reversal agent 5mg/ml antipamezole (antisedan, 0.05ml/10g) was 
administered, Vetegesic analgesic was administered as a diluted solution in sterile 
water (1:10, 0.05ml/30g), and 1ml saline was injected intraperitoneally to counteract 
any dehydration from the hotplate. Mice were put in a 30 °C warm-box overnight 
and observed for 2 days for full recovery. Surgery routinely lasted less than 30 
minutes per mouse. 
2.3.2.2 Infusion procedure: 
After a minimum 48h of surgical recovery the mice were fasted for 4 hours on the 
morning of the experiment. An infusion pump CMA/102 microdialysis pump (CMA 
Microdialysis; Phymep) was used to infuse either saline or glucose solution (25% 
(w/v) D-glucose dilute in 0.9% NaCl solution) into the jugular vein and hence 
directly in a carefully time-controlled fashion into the blood circulation. The saline 
was loaded in a 1ml syringe attached a 25G needle and run through P10 tubing 
(Jencons pls, Leighton Buzzard, UK) to a 25G needle connector, which was 
connected to the catheter. A small portion of the mouse tail tip was clipped and blood 
glucose level was measured by OneTouch Ultra Blood Glucose Monitoring System 
(Johnson and Johnson Company, Lifescan, Bucks, UK). Initially, a constant low flow 
rate (0.2μl/min) of saline was infused for 2 hours (to allow any stress effects on basal 
glucose to subside) blood glucose was sampled before starting the infusion pump 
(time 0). The glucose solution was infused with a flow rate of 10μl/min/30g 
bodyweight. Blood glucose was measured and blood samples were taken for insulin 
measurement with a Microvette CB 300 (Sarstedt, Leicester, UK) at 1, 3, 5, 10, 15, 
30, 60 minutes. The glucose bolus was stopped at 60 minutes and final glycemia was 
measured at 120 minutes. 
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2.4 Analysis of plasma corticosterone  
Age-matched (10 to 20 weeks) animals were housed singly several days prior to 
blood sampling. Mice were given standard chow diet or high fat diet (58% calories as 
fat for 12 weeks, as described before in 2.1.2) ad libitum.  Blood samples were 
obtained from a tail venesection within 1 minute of disturbing the cage to avoid 
confounding stress-mediated elevation of corticosterone. Samples were taken during 
the diurnal nadir of the HPA cycle (between 8:30 and 9:00am). 
2.5 Streptozotocin (STZ) experiments  
Streptozotocin (STZ) is a naturally occurring chemical from a strain of the soil 
microbe Streptomyces achromogenes (Malcolm 1962) and has been widely used in 
animal experiments to induce type I like diabetes (Mansford and Opie 1968; Wang 
and Gleichmann 1998). 
2.5.1 High-dose STZ experiment 
Age matched mice were given a single bolus i.p. injection of either 10mM citrate 
buffer (PH4.5) or STZ (180mg/kg body weight, dissolved in 10mM citrate buffer, 
Sigma-Aldrich). Blood glucose was monitored by sampling a single drop of fresh 
blood from a single tail venesection (tail nick; re-opened gently with a damp paper 
towel) everyday at around 2pm. Mice were monitored until being killed at either 3 or 
10 days after STZ treatment. Trunk blood samples were collected on the last day and 
pancreata were harvested and either frozen or fixed in 10% formalin (Sigma-Aldrich, 
Company Ltd, Dorset, UK) for further investigation. 
2.5.2 Multiple low-dose STZ experiment 
The mice were treated either with i.p. injection of saline or STZ (40mg/kg body 
weight) dissolved in saline for 5 consecutive days. Induction of diabetes was 
assessed by taking tail blood glucose measurements at day 0, 4, 12, and 15. 
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2.6 Measurement of key factors in plasma 
Blood samples were placed immediately on ice and then centrifuged at 2000rpm for 
10mins. The plasma was separated and stored at -80°C until assayed.  
2.6.1 Plasma glucose measurement 
Enzymatic glucose assay: A standard curve (33.3, 22.2, 11.1, 5.55 and 2.8mM) was 
made from a stock solution at the reference standard of 11.1mM (Thermotrace, 
Leeds, UK) by adding different volumes (3μl, 2μl, 1μl, 0.5μl, 0.25μl) using 96-well 
plates. Glucose concentration was measured by adding 2μl of standards or samples in 
10μl water, then supplementing with 200μl of glucose infinity reagent (Thermotrace) 
into each well. The plate was incubated at 37°C for 3 min and glucose concentration  
was calculated based on the absorbance of the standards and samples measured by a 
Spectrophotometer at a wavelength of 340nm. 
 
Glucose meter blood glucose measurement: blood glucose level was measured in a 
single drop of blood from a tail tip or venesection using OneTouch Ultra Blood 
Glucose Monitoring System (Johnson and Johnson Company, Lifescan, Bucks, UK) 
2.6.2 Plasma insulin measurement by ELISA 
Plasma insulin level was measured using a Mouse insulin ELISA kit (Crystal chem, 
Downers Grove, US) according to the manufacturer’s protocol. The standard curve 
(12.8, 6.4, 3.2, 1.6, 0.8, 0.4, 0.2, 0.1, 0ng/ml insulin) was made by diluting stock 
standard solution of 25.6ng/ml mouse insulin provided in the kit. 95μl of sample 
diluents were dispensed in each well of a 96 well plate, and 5μl of sample or standard 
curves was added and incubated for 2 hours at 4°C. Contents were aspirated and 
washed 5 times with appropriate buffer solution (300μl of washing buffer per well), 
then 100μl per well of anti-insulin enzyme conjugate was added and incubated for 
30mins at room temperature. Well contents were aspirated and the wells were 
washed 7 times using 300μl of washing buffer per well. 100μl per well of enzyme 
substrate solution was added and the solution was allowed to react for 40mins at 
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room temperature without exposure to light. The reaction was stopped by adding 
100μl per well of enzyme reaction stop solution. The insulin concentration of the 
samples was calculated with reference to the standard curve by measuring the 
absorbance within 30minutes using a platereader (Spectrophotometer) at A450. 
Background was accounted for by subtracting A630 values. Sample blanks and 
interassay controls were routinely used to compare between experiments, although 
all results presented were from self-contained experiments in this thesis (i.e. relative 
values are compared between groups within a given experiment). 
2.6.3 Insulin measurement by RIA 
Insulin released into the medium from isolated pancreatic islets (large experimental 
groups dictated a more practical choice of assay for the in vitro work) was measured 
using an rat insulin RIA kit (Linco Research, Milipore Missouri, USA) according to 
the manufacturer’s protocol. On the first day, 100µL of hydrated 125I-Insulin was 
added in “total activity” tubes, 200 µL of assay buffer plus hydrated 125I-Insulin was 
added to the “Non-Specific Binding” (NSB) tubes and 100 µL of assay buffer plus 
100µL of rat anti-insulin antibody plus hydrated 125I-Insulin to “Reference tubes”. 
Duplicated 100 µL of “Standards” and “Quality Controls”, then 100 µL of each 
sample were combined with 100 µL of hydrated 125I-Insulin along with 100 µL of rat 
anti-insulin antibody. Samples were then vortexed, covered, and incubated overnight 
at 4°C. On day 2, 1 ml of cold (4°C) precipitating reagent was added to all tubes 
except Total Count tubes and samples were vortexed and incubated for 20 minutes at 
4°C. All tubes except Total Count tubes were centrifuged at 4°C for 20mins. The 
supernatant of all tubes except Total Count tubes were immediately decanted, drained 
for at least 15-60 seconds, and excess liquid was blotted from the lip of the tubes. All 
tubes were counted in a gamma counter for 1 min. (This work has been done by 
Sophie Turban and Lynne Ramage, Edinburgh) 
2.6.4 Plasma corticosterone measurement by radioimmunoassay 
Plasma corticosterone was measured by RIA using a 3H-corticosterone tracer and a 
polyclonal anti-corticosterone antibody (a gift from Dr C.J. Kenyon, Edinburgh). 
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Plasma was diluted in borate buffer 1:10 and denatured at 75°C for 30mins. 2μl of 
3H-corticosterone (62.2 Ci/mmol; Perkin-Elmer Life Science, Boston, USA) was 
added into 9ml of borate buffer, and then antibody was added for a final dilution 
1:104. 50μl of the mixture dilution buffer and 20μl standard or samples were added to 
each assay well of a 96-wells plate, gently swirled/mixed and then incubated at room 
temperature for at least one hour. 50μl SPA (Scintillation proximity assay beads, GE 
Healthcare) was added to each well, samples were inverted continuously for several 
times and then incubated at room temperature for 24hrs. A scintillation (1450 Liquid 
Scintillation Counter, Wallac, Boston, USA) was used to measure the radioactive 
counts (cpm, counts per minute). The antigen-antibody reaction was competitive 
meaning that the more radioactive counts the less corticosterone was present in the 
wells. 
2.7 Isolation of islets from mouse pancreas 
Mice were anesthetized with sodium pentobarbital (30mg/kg). Pancreas was inflated 
with 3ml of a 1mg/ml collagenase ΧΙ (Sigma Aldrich) disolved in Hank’s balanced 
salt solution (HBSS, Lonza, Slough, UK) via the bile-pancreatic duct to aid rapid 
digestion the surrounding exocrine pancreas (Salehi et al. 1996). Whole pancreas was 
removed, and further digested in collagenase for 20mins at 37°C. Digested pancreata 
were then incubated on ice for 15min with 1v/v HBSS containing 10% fetal bovine 
serum (FBS, Lonza). The debris-containing supernatant was discarded and the cell 
suspension was washed 2 times with HBSS containing 10% FBS and then 
centrifuged at 1000rpm for 3min to gentle pellet the islets between washes. Islets 
were hand picked manually under a binocular microscope at 10× magnification in a 
blackened Petri dish. 
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2.8 Genotyping of transgenic mice 
2.8.1 DNA extraction from tail 
Genomic DNA was extracted from the tail of each mouse to determine its genotype. 
The tail was incubated in 600μl tail buffer (see table 2-3) containing 35μl 10mg/ml 
proteinase K (Sigma-Aldrich). The tails were gently rotated at 55°C in an oven 
overnight. The next day and 20μl of 20μg/ml RNase A (Sigma-Aldrich) was added 
into each tube, and incubated at 37°C in a hotblock for one hour. 37.5μl of 2M 
β-mercaptoethanol (Sigma-Aldrich) and 600μl phenol (Fisher Scientific, 
Leicestershire, UK) was added into each tube. The tubes were rotated for 15mins and 
then centrifuged at 12,000g for 2mins. The aqueous phase was removed into a fresh 
tube (using cut-off pipette tips to avoid genomic DNA shearing). 300μl of phenol 
and 300μl of chloroform: isoamyl alcohol (24:1, Sigma-Aldrich) was added, and the 
tubes were rotated for 5mins then centrifuged at 12,000 for 2mins. The aqueous 
phase was transferred to a fresh tube. 600μl chloroform: isoamyl alcohol (24:1) was 
added, and the tubes were rotated for 5mins then centrifuged at 12,000g for 2mins. 
The aqueous phase was transferred to a fresh tube. 600μl isopropanol (Fisher 
Scientific) was added, and the tubes were inverted several times to precipitate the 
DNA. DNA was pelleted by centrifuging at 12,000g, for 2mins. The supernatant was 
removed and discarded. The pellets were resolubilised after brief drying in 200μl TE 
buffer by warming at 37°C for 30mins (or leaving at 4°C overnight). 100μl of 6M 
ammonium acetate which removed the free nucleotide and protein plus 600μl 
isopropanol were added to purify the DNA. Samples were centrifuged at 12,000g for 
2mins to pellet the DNA. The supernatant was removed carefully. The pelleted DNA 
was washed with 180μl 70% ethanol (VWR, Leicestershire, UK), and centrifuged at 
high speed for 2mins, the ethanol was removed and air dried briefly. 30μl TE buffer 
was added to resolubilise the DNA and it was stored at 4°C.  
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2.8.2 Polymerase Chain Reaction (PCR) 
The PCR reactions (50μl) contained 0.2μg DNA, 1.25U GoTaq (Promega, 
Southampton, UK), and 30pmol of each primer (Manufactured by Invitrogen, 
Renfrew, UK). Primers for genotyping were MIP-HSD1: 5’-GGA ACT GTG AAA 
CAG TCC AAG G-3’, and MIP-HSD1: 5’-TTT GCT GGC CCC AGT GAC AAG 
CTT T-3’. (Figure 2-1) 
 
PCR program was 98°C for 3 mins, then 40 cycles of 90°C for 45secs (denaturation), 
60°C for 30secs (annealing), 72°C for 90secs (extension), then finally 72°C for 
5mins and 4°C for 10mins.  
 
Figure 2-1. PCR site of the MIP-r11β-HSD1 transgene. The product of PCR is 
650bp long including part of MIP gene, part of the r11β-HSD1 gene, and a restriction 
enzyme EcoR I site (designed by Sophie Turban). 
2.8.2.1 Restriction enzyme digestion of cDNA to identify the presence of the 
transgene (MIP-HSD1) insert 
20μl of cDNA from the PCR amplification mouse tail DNA was incubated with the 
specific MIP primers containing a restriction site for EcoR I along with 1μl EcoR I, 
2μl buffer (H) (Promega), in a total reaction volume of 25μl and the reaction was 
incubated at 37°C for 2 hours to identify the existence of the specific transgene.  
Mouse Insulin Promoter (MIP- 8.3kb) r-HSD1 (1.265bp) 
EcoR I 
5’-   650 bp   -3’  
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2.8.2.2 Agarose gel electrophoresis 
2% agarose gels were prepared for analysing the PCR DNA fragment restriction 
digestion patterns by electrophoresis. Agarose (Lonza, Slough, UK) was dissolved in 
0.5x TBE buffer by boiling the solution in a microwave oven. Ethidium bromide 
(final concentration 0.2μg/ml, Sigma-Aldrich) was added to the melted agarose and 
cast in horizontal gel trays. Set gels were submerged in 0.5x TBE in standard gel 
electrophoresis tanks and samples was loaded into wells. DNA was separated by 
electrophoresis under constant voltage conditions of 140V. Sizes of DNA fragments 
were determined by comparison with a 100bp DNA ladder (Invitrogen) run in 
parallel. Resolved DNA fragments were visualized and pictured by placing agarose 
gels on a UV transilluminator using a wavelength of 254nm.  
2.8.3 Southern Blotting 
2.8.3.1 DNA digestion 
Genomic DNAs (10-30μg) from mouse tail was restriction enzyme digested with 4μl 
Afl III (5000 units/ml, Biolab, Herts, UK) restriction enzyme which has two sites 
present in MIP-HSD1 transgene (Figure 2-2), 4μl Buffer 3, 4μl BSA (1mg/ml), and 
proper dH2O to make a final volume of 40μl. Samples were incubated overnight in at 
37°C.  
 
Figure 2-2. Afl III enzyme restriction sites of the MIP-HSD1 transgene. There 
are two digestion sites for Afl III in MIP transgene. One site is in the MIP (2861) and 
the other one was at the end of r-HSD1 cDNA (9758). The length between two Afl 
III sites was 6.897kb which included most of the MIP-HSD1transgene. 
M  I  P (8.3kb) r-HSD1 (1.265kb) 
Afl III  Afl III  
6.897 kb 
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2.8.3.2 Gel electrophoresis of restriction digested genomic DNA 
After digestion was completed, DNA samples were run on a 0.7% agarose gel; 
agarose was dissolved in 1× TAE buffer. Samples were loaded with 4μl DNA 
loading buffer and run in 1× TAE buffer at 40V for 40mins, then at 100V until the 
bromophenol blue dye arrived around a ¾ of the total length of the gel. The gel was 
removed and cut to a suitable size for transfer. 
2.8.3.3 Transfer of DNA to nylon membranes 
The DNA was depurinated by exposing the gel to 0.15M HCl for 10 mins; then 0.5M 
NaOH, 1.5M NaCl for 45mins. This was neutralized by submerging the gel in 1.5M 
Tris, 1.5M NaCl, 1mM EDTA (PH 7.2) for 30 mins, and again in fresh buffer for 15 
mins. The transfer blot was set up by laying 3 pieces of 3M paper, soaked in 10× 
SSC on top of an inverted gel tray. The gel was placed on top and a sized piece of 
Zeta-Probe GT Genomic Tested Blotting membrane (Bio-Rad Laboratories Ltd. 
Hertfordshire, UK) was placed directly onto the gel. This was followed by 2 pieces 
of pre-wetted 3M paper. A stack (about 10cm thick) of folded blotting paper was 
placed on the top to initiate capillary transfer and the DNA was transferred for 24 
hours.  
2.8.3.4 Pre-hybridization 
After transferring for 24 hours, the membrane was rinsed briefly in water to remove 
excess salt and then baked at 80°C for 2 hours to fix the DNA. The membrane was 
then pre-hybridized with 5× Denhard’s (Sigma-Aldrich) reagent containing 100ug/ml 
denatured salmon testes DNA (Sigma-Aldrich) (boiled for 15 minutes at 100oC and 
rapidly cooled on ice or added directly to the hybridisation vessel), 0.5% SDS, and 
6×SSC, and incubated at 65°C for at least 6 hours.  
2.8.3.5 Hybridization 
2.5μl of probe DNA (10ng/μl, rat 11β-HSD1, 1.265kb) and TE buffer 42.5μl were 
mixed and heated at 95°C for 5 min then put on ice for 5 min. The mixture and 5μl of 
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α-32P CTP (3000 Ci/mmol, GE Healthcare, Buckinghamshire, UK) were added into 
Amersham Ready to go DNA Labelling Beads (-dCTP, GE Healthcare) mixed well 
and incubated at 37°C for 15 min. A Nick column (Sephadex, G-50 DNA Grade, GE 
Healthcare) was equilibrated with TE buffer. The mixture was pipetted directly onto 
the column. 400μl of TE buffer was applied, and this first eluate fraction 
(unincorporated) was discarded. Another 400μl TE buffer was added to elute the 
probe and the labeled probe was collected in another tube. The denatured and chilled 
probe was added to 20ml of hybridization buffer (0.5% SDS; 6×SSC) at 65°C. 
Pre-hybridisation buffer was removed and hybridisation buffer was added and the 
membrane was incubated overnight at 65°C. 
2.8.3.6 Washes and Exposure 
After overnight hybridization, the probe mixture was discarded and the membrane 
was washed in the hybridisation bottle with 20 ml of washing solution in the 
following steps, 15 min twice with 2× SSC, 0.1% SDS; 65°C, 15 min twice with 1× 
SSC, 0.1% SDS. The membrane was wrapped in saran wrap and placed against 
autoradiographic film (MS, Kodak, US) and exposed at -80°C for a week before 
being developed in a dark room. Alternatively the membrane was exposed to a 
phosphor imager 32P-sensitive screen overnight and read on a radioimaging detector 
(FLA-2000, Fujifilm) and analysed by quantitative phosphorimager software Aida / 
2D densitometry (Aida 344, Raytek Scientific, Sheffield, UK) 
2.9 11β-HSD1 Activity Assay  
Thin Layer Chromatography (TLC) is used to separate different compounds in a 
mixture. Here it was used to detect levels of either 11-dehydrocorticosterone (11DHC, 
A compound) or corticosterone (B compound) newly made by 11β-HSD1 using 
tritiated tracer A or tritiated B. The relative amount of both tritiated compounds 
within the same sample reveals the rate of conversion from one to the other which 
reflects the activity of 11β-HSD1. Thus reductase activity is measured in cells by 
treatment with tritiated 11DHC and dehydrogenase activity with tritiated 
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corticosterone. The compounds are identified by their migration with respect to pure 
cold 11DHC or B added to the samples before loading TLC plates. Cold compounds 
can be visualised under UV light and their migration pattern marked and 
cross-referenced with the tritium signal from the samples.  
 
Routinely, 100 Isolated islets were cultured in 24 wells plates and incubated in 500μl 
RPMI 1640 (Lonza) with 10% FBS, supplemented with 10nM [3H] tracer A or B and 
200nM cold A or B in order to measure the reductase or dehydrogenase activity 
respectively. Different concentrations of cytokines and factors according to 
experiment design (see below) were added to the culture medium. Islets were then 
incubated at 37°C for 24 hours. 
 
11DHC and corticosterone were extracted from the medium using ten volumes of 
ethyl acetate. The ethyl acetate fraction was collected and evaporated using both air 
flow and a heating plate at 70°C, leaving steroid residues in the tubes. Samples were 
resuspened in 40μl 100% ethanol, and spotted in 5μl aliquots at 2cm from the bottom 
line of TLC plates (TLC Silica Gel60 F254, Merk, Germany). Samples were placed 
1.5cm apart. The plates were placed in a pre-equilibrated chamber containing 92ml 
chloroform and 8ml ethanol as a mobile phase and allowed to run for one hour. 
Steroids were separated by capillary action, the fast migrating spot was identified 
with the cold standard 11DHC, and the slower migrating spot was corticosterone. 
Plates were dried and then exposed to a phosphorimager tritium detection film 
(BAS-TR2040, Fujifilm) in a cassette for at least 48 hours. The conversion of 
steroids was calculated after scanning analysis using a radioimaging detector (see 
2.6.2) that measured 3H signal with densitometry using quantitative phosphorimager 
software Aida / 2D densitometry (see 2.6.2). Conversion was calculated with the 
densitometry data from the signal of the newly generated 3H steroid as a percentage 
of the whole steroid in the sample. Activity was interpreted as accurate if it was 
within a linear range with respect to the sample protein concentration and conversion 
(usually below 40%). With isolated islets, the activity assay applied in this thesis did 
not go beyond the linear range. 
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2.10 Insulin release from isolated islets 
Mouse islets were isolated and prepared in batches of 10 islets, chosen to reflect a 
similar mean size (100μm) between genotypes. Islets were placed on a Millicell 8.0 
μm insert (Milipore, Billerica, USA) within a 24 well plate and treatments were 
performed in triplicate. Islets were equilibrated in 500μl KREBS solution (0.1% BSA) 
with 2.8mM glucose at 37°C in a 5% CO2 incubator. After 2 hours, KREBS buffer 
was replaced with 500µL of fresh KREBS solution with 2.8mM glucose every 10min 
for 30min followed by 500μl KREBS solution with a stimulatory glucose 
concentration at 25mM every 5 min for 30min and by 500µL KREBS solution with 
2.8mM glucose every 10 for 30min to demonstrate the full capacity of the islets to 
return to basal levels of insulin production. Media were collected and frozen for 
further analysis of insulin secretion. The insulin concentration was measured by RIA 
kit (Linco research, Missouri, USA) according to the manufacturer’s protocol as 
described in 2.6.3 and this work was performed by Sophie Turban and Lynne 
Ramage. 
2.11 Insulin content in whole pancreas 
Pancreas were taken and weighed, 2ml lysis buffer was added and each pancreas was 
homogenized using a motorized homogenizer (IKA). 100ul of homogenate was then 
diluted in 2ml acidified ethanol (1.5% HCl in 70% ethanol) overnight at -20°C. The 
next day samples were centrifuged at 2000rpm for 15mins at 4°C. The aqueous 
solution was transferred to new tubes and neutralized by the addition of 100μl 1M 
Tris (PH7.5). Insulin content was measured by RIA kit (see 2.6.3) and corrected for 
the appropriate dilution factor. 
2.12 Protein content in whole pancreas 
Bio-Rad Dye Reagent Concentrate (Bio-Rad Laboratories, Britain) was diluted 1:4 in 
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distilled water. 2mg/ml BSA was diluted to make a standard curve (2, 1, 0.5, 0.25, 
0.125, and 0.0625mg/ml). 200μl of diluted Bio-Rad Dye Reagent and 5μl standard 
curve or diluted samples (containing ~1-2mg of protein, samples from plasma was 
diluted 1 in 104) were added in to 96 wells plates and reacted at room temperature for 
15mins. Protein content was assessed from the absorbance of the sample with respect 
to the standard curve at 570nm using a plate reader spectrophotometer.  
2.13 RNA Extraction  
2.13.1 Extraction of RNA from whole pancreas 
RNA extraction was extracted with the TRIzol (Invitrogen, Paisley, UK) method. 
Briefly 1ml TRIzol was added to pancreas (~100-200mg) and the tissue were 
homogenised using a motorized homogenizer (see 2.11). Homogenates were 
incubated at room temperature for 5min before the addition of 0.2v/v of chloroform 
(Sigma, Gillingham, UK). The tubes were briefly shaken to mix and then incubated 
at room temperature for 3min. Samples were then centrifuged at 12,000g for 15min 
at 4°C. This produces a lower red phenol-containing phase (containing proteins), an 
interphase (containing DNA and denatured proteins), and an upper aqueous phase 
(containing RNA) which was transferred to a fresh eppendorf tube. Isopropanol 
(0.5v/v, Sigma) was then added to precipitate the RNA. Samples were incubated at 
room temperature for 10min and then centrifuged at 12,000g for 10min at 4°C. The 
supernatant was discarded and the RNA pellet was then washed with 1ml 75% 
ethanol. Samples were inverted and centrifuged at 12,000g for 5min at 4°C. The 
RNA pellets were allowed to air dry at room temperature for 5-10min. Pellets were 
resuspended in 15μl DEPC water (0.1% diethylpyrocarbonate, Invitrogen), RNA 
concentration was determined using a GeneQuant spectrophotometer (Pharmacia 
Biotech, Sweden).   
2.13.2 Extraction of RNA from pancreas by RNeasy mini column 
Pancreas (~10-20mg) was homogenised in 0.5ml TRIzol by using a motorized 
 90
homogenizer. Homogenates were incubated at room temperature for 5min. 0.2v/v of 
chloroform (100μl) was added and then the tube were briefly shaken to mix before 
incubation at room temperature for 3min. Samples were then centrifuged at 12,000 
rpm for 15min at 4°C to separate RNA. The upper aqueous phase (containing RNA) 
was transferred to a fresh eppendorf tube. 1v/v of 70% ethanol was then added to the 
cleared lysate and mixed immediately. Up to 700μl of samples was applied to an 
RNeasy mini column (QIAGEN, Crawley-West Sussex) placed in a 2ml collection 
tube. The mini-column was centrifuged for 15s at 12,000 rpm and the flow-through 
was discarded. 700μl BW1 buffer (applied with the RNeasy mini column kit) was 
added in the column and it was centrifuged for 15s at 12,000 rpm. Flow-through was 
discarded. 500μl RPE buffer (applied with the RNeasy mini column kit) was added 
in each column and the column was spun, spin for 2mins at 12,000 rpm to wash the 
spin column membrane. The column was placed in a new 2ml collection tube and 
centrifuged at full speed for 1min. The RNeasy column was placed in a new 1.5ml 
collection tube. 30-50μl RNase-free water was directly added to the spin column 
membrane, incubated for 1min, and then centrifuged for 1min to elute. The RNA 
concentration was measured using a Nanodrop spectrophotometer (Thermo, 
Wilmington, USA) 
2.13.3 Extraction of RNA from isolated islets (Matrix method) 
Around 200 islets were added directly to 100μl Trizol. 20μl chloroform per 100μl 
Trizol was added to each sample and this was vortexed for 15 seconds and allowed to 
stand at room temperature for 2 to 3mins. Samples were transferred to ice for another 
15mins and then centrifuged at 12000rpm at 4°C. The upper aqueous phase was 
transferred to a fresh eppendorf tube and 12μl Matrix (Rnaid matrix, Anachem, Texas, 
US) was then added and mixed to bind the RNA. To allow RNA binding to RNA 
matrix, samples were vortexed and gently agitated for 5mins and then centrifuged at 
12,000g for 1min at 4°C to pellet the matrix. The supernatant was removed and the 
RNA pellet was then washed in 500μl RNA wash concentrate (Anachem, Luton, UK) 
diluted to contain 30% v/v absolute ethanol. The washed matrix was pelleted at 
12,000g for 1min at 4°C. The washing step was repeated for three times. Following 
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washing the ethanol was discarded and the RNA pellets were allowed to air dry at 
room temperature for 5min. Pellets were resuspended in 12μl DEPC water and 
incubated in 55°C hotblock for 12mins to elute the RNA from the matrix. The RNA 
was separated from the matrix by centrigugation at 12000rpm for 2 minutes. RNA 
concentration was measured by Nanodrop spectrophotometer prior to reverse 
transcriptase reaction. 
2.14 Reverse transcriptase reaction (RT) 
Reverse transcriptase reactions were carried out using the Super Script III 
First-Strand Synthesis System to synthesize cDNA from total RNA. 1μl 10x DNase I 
buffer (Invitrogen) was added to 20μg RNA per sample in order to eliminate all 
genomic DNA contamination from RNA samples. Ultrapure water was used to adjust 
the final volume to 10μl and the samples were incubated at 22°C for 15mins. 1μl of 
EDTA was added to each tube and incubated at 65°C for another 15mins to inhibit 
DNase I. Samples were then kept on ice. Reverse transcription was carried out in a 
total volume of 20μl, containing 5μl RNA, 15μl cDNA synthesis mix consisting of 
1μl Oligo dT primers (Promega) for specific hybridising to 3′ poly A tails in mRNA, 
1μl dNTPs (Promega), 3μl 10x RT buffer (100mM Tris-HCl, 500mM KCl, 1% 
Triton-X100, Promega), 4μl 25mM MgCl (Promega), 2μl 0.1M DTT (Promega), 1μl 
RNase OUT, and 1μl SuperScript III (Promega). Samples were incubated at 50°C for 
50mins. The reaction was terminated at 85°C for 5mins and then chilled on ice. 
Samples were stored at -20°C for further experiments (2.15). 
2.15 PCR for 11β-HSD1 promoter expression 
PCR reactions (50μl) contained 2μl RT reactions, 1.25U GoTaq (Promega), 30pmol 
of forward and reverse primer for each promoter or gene studied (promoter primers 
were kindly provided by Pr. Karen Chapman) (Bruley et al. 2006). GAPDH and 
11β-HSD1 primers were used to control the quality of the RNA. 
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Primers were: 
Promoter1 (P1): 5′- GGAGCCGCACTTATCTGAA -3′ (upstream exon1A, forward 
primer P1), 
Promoter2 (P2): 5′- GGAGGTTGTAGAAAGCTCTG -3′ (upstream exon 1B, 
forward primer P2), 
Promoter3 (P3): 5′- GTATGGAAAGCAAGACAAGG -3′ (upstream an intron before 
exon 3, forward primer P3) 
P868: 5′-AGGATCCAGAGCAAACTTGCTTGCA-3′ (reverse primer for P1, P2, 
P3), 
PHSD: 5′-AAAGCTTGTCACTGGGGCCAGCAAA-3′ (forward primer for HSD1), 
P869: 5′- AGGATCCAGAGCAAACTTGCTTGCA-3′ (reverse primer for HSD1) 
PGAP: 5′- GCCAAGGTCATCCATGACAAC-3′ (forward primer for GAPDH) 
PGAP: 5′- AGTGTAGCCCAAGATGCCCTT-3′ (reverse primer for GAPDH) 
The PCR program was 95°C for 45secs, then 40 cycles of 90°C for 45secs, 60°C for 
30secs, 72°C for 90secs, then finally 72°C for 5mins and 4°C for 10mins. Samples 
were run on a 2% agarose gel in 0.5x TBE buffer and compared to negative and 
positive controls and a 100bp DNA ladder (Invitrogen). 
2.16 Immunohistochemistry (IHC) 
Pancreata were fixed in 10% formalin (sigma) for 24 hrs and transferred to 70% 
ethanol, and automatically dehydrated in a tissue processor TP1050 (Leica, Ramsey, 
USA) that embedded tissue fragments in paraffin by Histocentre 3 (Thermo 
Shandon). Tissue sections were cut by microtome. Tissue sections were 
deparaffinized and rehydrated by incubating twice in xylene for 5mins, then placed 
in sequential washes of 100% (2x), 95%, and 80% ethanol solutions for 20 seconds 
each with a final wash in water. Sections were then put in a pressure cooker and 
boiled in 10mM citrate buffer (pH 6.0) for 5mins for antigen retrieval (breaking the 
protein cross-links formed by formalin), and cooled at room temperature for another 
20mins. Sections were incubated for 30mins in 3% hydrogen peroxide in methanol 
which is commonly used to block endogenous peroxidase activity. Sections were 
then blocked by blocking buffer (20% goat serum with 5% BSA, in TBS (table 2-3)) 
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for 30mins, followed by Avidin and Biotin (Vector Lab, Peterborough, UK) blocking 
for 15mins each, and between each block sections were washed twice with washing 
buffer (TBS, pH 7.4). Sections were incubated with primary antibodies (Table 2-1, 
described in chapter 5) at 4°C overnight. Antibodies were diluted in blocking buffer. 
Slides were washed twice in washing buffer, and then incubated with secondary 
antibodies diluted in blocking buffer. Secondary anti-bodies were biotinylated 
anti-guinea pig (1:400, Abcam) or biotinylated goat anti-rabbit (1:500, Dako, 
Cambridge, UK) and incubation was at room temperature for 30mins, followed by 
two washing cycles. Slides were incubated with Vectastain ELITE ABC-Peroxidase 
Kit (Vector lab) for 30mins, rinsed with washing buffer as before. Signal was 
developed in freshly prepared diaminobenzidine (DAB) solution (DAB Peroxidase 
Substrate Kit, Vector lab) following the manufacturer’s instructions. The reaction 
was stopped by washing in TBS until a uniform brown color became visible on the 
sections. Sections were counter-stained with Haematoxylin Solution (Sigma), rinsed 
under running water, decolorized with 1% acid alcohol for 2 seconds, washed with 
running water, blue-stained by Scotts tap water, washed under running water and 
then rehydrated, followed by incubating in 70%, 80%, 95%, 100% (2x) ethanol, and 
finally xylene for 5mins. Slides were mounted with a cover glass (VWR) in an 
aqueous medium. 
All negative controls were used the appropriate same original serum as the staining 
first antibody at the same concentration. 
2.17 Immunofluorescence (IF) 
Sections were fixed in paraffin and processed with the following steps. Sections were 
deparaffinized, rehydrated, subjected to antigen retrieval, inactivated by peroxidase 
and then blocked by blocking buffer. Sections were then incubated with primary 
(table 2-3) rabbit anti-ki67 (1:3000) antibody at 4°C overnight. Slides were washed 
twice with washing buffer (TBS, PH 7.4), and then incubated with goat anti-rabbit 
peroxidase (Abcam) at room temperature for 30mins, followed by 2 further washes. 
Slides were incubated with Tyramide green 488 (Tyramide signal amplification kit, 
Cambridge, UK) to amplify the signal at room temperature for 10mins, followed by 
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two washes, and then slides were stored in the dark. 10mM citrate buffer was boiled 
by microwave for 4mins, and then the slides were added to the boiled citrate buffer 
for another 2.5mins, cooled for 30mins, and then washed with washing buffer for 
5mins. The slides were blocked for 30mins and then incubated with a second primary 
antibody rabbit anti-PDX-1 (1:1000) antibody at 4°C overnight. On the third day, 
slides were washed twice, incubated with goat anti-rabbit Alexa Fluor 546 
(Molecular probes, Paisley, UK) at a 1:200 dilution in PBS at room temperature for 1 
hour. Slides were washed twice. Dapi (Sigma, diluted 1:1000 in PBS) was used to 
stain nuclei by incubating sections for 10mins. The slides were mounted with 
PermaFluor (Thermo) and visualised using a Leica fluorescence microscope.   
2.18 Quantification of IHC/IF 
Quantification of Foxp3 was carried out by using computerized image analysis. 
Three sets of paraffin sections from each pancreas were made for Foxp3 and each 
section was cut at intervals of 100μm. The number of Foxp3 positive cells was 
determined from light microscopic image and counted using Zeiss (KS300, 3.0) 
software throughout the section. Pancreas section area was measured by MCID Basic 
7.0 software. 
 
Quantification for PDX1 and Ki67 was performed using Image J software on light 
microscopic images. PDX1 and Ki67 positive cells were measured within the islets 
as defined morphologically by the islet capsule boundary. PDX1 and Ki67 
double-positive cells were counted on each section. The rate of proliferating β-cells 
was presented as the ratio of PDX1 and Ki67 double-positive cells to PDX1-positive 
cells in each islet and this was then averaged for each mouse within each group.  
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Table 2-1. List of primary antibodies for IHC and IF 
IHC Anti-Insulin Guinea pig anti-mouse (Abcam, Cambridge, 
UK) 
1:300 
IHC Anti-PDX1 Rabbit anti-mouse (Chemicon international 
inc) 
1:6000
IHC Anti-Mac-2 Rabbit anti-mouse (Cedarline, ON, Canada) 1:150 
IHC Anti-Foxp3 Rat anti-mouse (eBioscence, Hatfield, UK) 1:150 
IHC Anti-sox9 Rabbit anti-mouse (Chemicon) 1:8000
IHC Anti-Neurogenin 
3 
Rabbit anti-mouse (Chemicon) 1:1000
IHC Anti-Caspase3 Rabbit anti-mouse (Cell signaling, 
Hertfordshire, UK) 
1:100 
IF Anti-PDX1 Rabbit anti-mouse (Chemicon international 
inc) 
1:1000
IF Anti-ki67 Rabbit anti-mouse (DAKO) 1:3000
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2.19 TUNEL assay for apoptosis in pancreatic sections 
Slides were incubated at 60°C for 15mins, dewaxed, rehydrated and subjected to 
antigen retrieval as described in 2.2.10. After washing with PBS for 3 times, five 
minutes each wash, slides were fixed with 4% (v/v) formaldehyde in PBS for 15 min 
at room temperature and then washed twice with PBS. 100µl of Proteinase K 
(20µg/ml) was added to each slide in a humidity chamber, ensuring the tissue section 
was fully covered. Incubation was for 10min at room temperature and was stopped 
by washing in PBS once. Slides were then fixed with 4% (v/v) formaldehyde in PBS 
for another 5 min at room temperature, and then washed with PBS. The DeadEnd™ 
Fluorometric TUNEL assay kit (Promega) was used. 100µl of the equilibration buffer 
was added to each slide in a humidity chamber and incubated at room temperature 
for 10min. During this time, reaction mixtures were prepared. 5µl of nucleotide mix 
and 1µl of rTdT enzyme was mixed with 45µl equilibration buffer for each slide, and 
a negative control was prepared by mixing 5µl nucleotide mix and 46µl equilibration 
buffer. Equilibration buffer was drained off and 50µl of the reaction mixture was 
added to each slide and covered with a plastic coverslip. Slides were incubated in a 
humid dark chamber for 1 hour at 37°C. Slides were kept in the dark. After reacting, 
coverslips were removed and the slides were incubated in 2× SSC for 15mins 
followed by washing in PBS for 5min. Dapi was used to stain nuclei. The slides were 
mounted with PermaFluor using and images visualised using Leica fluorescence 
microscope (2.18). 
2.20 Western Blot 
0.5ml lysis buffer (table 2-3) was added to each pancreas and they were 
homogenized using a motorized homogenizer (as above 2.11). The homogenates 
were centrifuged at 12000rpm for 15mins at 4°C. The aqueous solution was 
transferred to new tubes. A protein assay was used to measure protein concentration 
(2.12). Equal amounts of protein were mixed with 2μl of 6x loading buffer (table 2-3) 
and water was used to adjust the final volume to 10μl. Samples were heated at 100°C 
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for 5mins, cooled on ice, quickly spun and then kept on ice. Samples and 10μl 
molecular weight marker (See Blue, Invitrogen) were loaded onto SDS-PAGE gels 
(table 2-3) and run at 100 Volts for 2hours to separate proteins. Proteins were 
electrotransfered from the gel to a PVDF membrane (GE Healthcare) in transfer 
buffer (1x, table 2-3) at 200mA for 2 hours. The transfer system was kept cool during 
electrotransfer with an inset ice-block (previously chilled to -20°C). After transfer, 
the membrane was washed in TBS-T (table 2-3) 0.1% for 5mins and then incubated 
in TBS-T with 5% milk for 1 hours at room temperature to block. The membrane 
was rinsed 3 times for 5mins each with TBST-T and incubated with a rabbit primary 
antibody (anti-cleaved caspase-3 at 1:1000, Cell Signaling) in TBS-T 5% BSA 
overnight at 4°C. The membrane was washed three times for 5mins with TBS-T, 
then incubated with an anti-rabbit HRP-conjugated secondary antibody (1:2000, cell 
signaling) in TBST-T with 5% milk with gentle agitation for 2 hours at room 
temperature. The membrane was washed 3 times for 5mins each with TBS-T. The 
membrane was incubated with 1ml developing solution (Supersignal West Pico kit, 
Pierce, Thermo) for 1 minute. Excess developing solution was drained; the 
membrane was wrapped in saran wrap and then exposed to X-Ray film for 3mins. 
Signal was developed by exposing the film through a Konica X-Ray developer 
(Konica, FL, US).   
2.21 Data analysis and statistics  
Streptozotocin experiments, plasma assays, IHC and IF were analysed with an initial 
blinding step with subsequent code-breaking after quantification. Data are presented 
as the mean ± S.E.M. Statistical analysis was performed by Graph Pad (GraphPad 
Prism 4 Demo). The groups were compared using either Student’s t-test (for a simple 
comparison of two groups) or one-way ANOVA (Tukey comparison all groups). 
Two-way ANOVA (Holm-Sidak, pairwise multiple comparison) was used to compare 
glucose and treatment interactions. A P value of <0.05 was considered to show a 
statistically significant difference between groups. 
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Table 2-2. List of equipment 
TECHNE TC-512 PCR machine Techne Inc. 
UV transilluminator Uvitec Ltd 
Hybridization oven Weiss-Gallenkamp 
Optical light microscope Zeiss 
Spectrophotometer Molecular Device 
Radioimaging detector ,FLA-2000 Fujifilm 
Gene Quant RNA/DNA calculator  Pharmacia 
Motorized homogenizer  IKA 
Fluorescence microscope Leica 
Konica SRX-101A X-Ray developer Konica 
LightCycler 480 thermocycler  Roche 
Nanodrop spectrophotometer  Thermo 
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Table 2-3. List of buffers and solutions 
Tail Buffer 0.5ml 1M Tris, 4ml 250mM EDTA, 0.2ml 5M 
NaCl, 1ml 10% SDS, 4.3ml dH2O 
TE Buffer 606mg Tris, 18.6mg EDTA, make up to 500ml 
6M ammonium acetate 4.62g ammonium acetate was dissolved in 10ml 
dH2O 
10x TBE buffer 108g Tris base, 55g Boric acid, 40ml 0.5M EDTA 
were dissolved in 1L dH2O 
50 x TAE buffer 121g Tris, 28.5ml glacial acetic acid and 50ml 
0.5M, EDTA (pH8.0) were dissolved in 500ml 
dH2O 
DNA loading buffer 39ml 2M NaH2PO4, 61ml 2M Na2HPO4, Glycerol 
1v/v, Bromophenol Blue 
0.15M HCL 6.48ml HCL was diluted in 500ml dH2O  
0.5M NaOH, 1.5M NaCl 20g NaOH, 87g NaCl, were dissolved in 1L dH2O
1M Tris, 1.5M NaCl, 1mM 
EDTA 
121g Tris, 87g NaCl, 0.372g EDTA, were 
dissolved in 1L dH2O, pH 7.2 
20x SSC 175.3g NaCl, 88.22g Citrate Na, were dissolved in 
1L dH2O. 
10% SDS 10g SDS was added into 80ml dH2O and heated to 
60°C until completely dissolved. pH was adjusted 
to 7.5 and the volume was up to 100ml with dH2O
PBS buffer (10x) 80g NaCl, 29g Na2HPO4, 2g KH2PO4, 2g KCl, 
were dissolved in 1L dH2O, pH 7.4 
0.1MCitrate buffer 42.02g citric acid, made up to 2L, pH6.0 
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Borate buffer 8.25g boric acid, 2.7g NaOH, 5g BSA, make up to 
1L, pH 7.4 
KREBS Ringer Phosphate 
buffer 
6.9g NaCl, 373mg KCl, 296mg MgSO4, 800ml 
dH2O; 
120ml Na2HPO4 (7.1g Na2HPO4 dissolved in 
500ml dH2O), 3ml NaH2PO4 (6g NaH2PO4 
dissolved in 500ml dH2O) were mixed into the 
above solution, pH 7.4; 
2.28ml was taken from freshly prepared 6.1% 
CaCl2 (0.61g CaCl2 dissolved in 10ml dH2O); 
Made up to 1L dH2O, stored at 4°C, 0.1% BSA 
was added before use. 
0.1M citrate acid 1.92g Citric acid was dissolved in 100ml dH2O, 
0.1M Nacitrate dihydrate 14.7g Nacitrate dehydrate was dissolved in 500ml 
dH2O 
10mM citrate buffer 5ml 0.1M citrate acid, 5ml 0.1M Nacitrate 
dehydrate were dissolved in 100ml dH2O, pH4.5 
0.5M Tris-HCl 121.14g Tris methylamine, made up to 2L, pH 7.4
50mM TBS (Tris buffered 
saline) 
100ml 0.5M Tris-HCl, 8.5g NaCl, made up to 1L 
Lysis buffer 50mmol/l Tris, pH 7.4, 0.27 mol/l sucrose, 
1mmol/l sodium orthovanadate, pH 10, 1mmol/l 
EDTA, 1mmol/l EGTA, 10mmol/l sodium 
β-glycerophosphate, 50mmol/l NaF, 5mmol/l 
sodium pyrophosphate, 1%[wt/vol] Triton X-100, 
0.1% [vol/vol] 2-mercaptoethanol, and protease 
inhibitors—EDTA free tablets (Roche) 
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SDS-PAGE gel 12% separating gel: 3.35ml dH2O, 2.5ml 1.5M 
Tris (PH 8.8), 0.1ml 10%SDS, 4ml 
30%Acrylamide, 0.75ml 10%APS, 0.01ml 
Temed; 
Stacking gel: 2.85ml dH2O, 1.25ml 0.5M Tris (PH 
6.8), 0.05ml 10%SDS, 0.85ml 30%Acrylamide, 
0.025ml 10%APS, 0.005ml Temed. 
Running buffer (10x) 30g Tris, 144g Glycine, 10g SDS, made to 1L 
dH2O. 
Loading buffer (6x) 1.8ml 2M Tris (PH 6.8), 3ml Glycerol, 0.3ml 
0.5% Bromophenol Blue, 1.8g SDS, 925mg DTT, 
made up to 10ml with dH2O.  
Transfer buffer (10x) 24.2g Tris, 112.3g Glycine made to 1L dH2O. 
Transfer buffer (1x) 100ml transfer buffer (10x), 800ml dH2O, 100ml 
Methanol 





Chapter 3    
 
The Role and Regulation of 11β-HSD1 
in Pancreatic Islets 
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3 The role and regulation of 11β-HSD1 in pancreatic islets  
3.1 Introduction 
Glucocorticoids play a critical role in regulating glucose homeostasis. The 
mechanisms of their effects involve in increasing hepatic gluconeogenesis and 
glucose output (Barthel and Schmoll 2003) and diminishing insulin sensitivity in 
muscle (Dimitriadis et al. 1997; Smith and Muscat 2005) and adipose tissue (Sakoda 
et al. 2000).  
 
GC access to its nuclear receptor GR is tightly regulated by the intracellular enzyme 
11β-HSD1 which catalyses the local reactivation of GCs within tissues when 
H6PDH is abundant. This enzyme is expressed in both rodent and human pancreatic 
islets, and it is highly expressed in β-cells (Turban et al. unpublished), although it has 
been found expressed in α-cells (Swali et al. 2008). Little is known about the 
regulation of 11β-HSD1 in pancreatic islets, although 11β-HSD1 activity in isolated 
islets is increased by 11DHC in vitro (Davani et al. 2000; Ortsater et al. 2005). As 
described in chapter 1.5.2 there are three promoters which regulate 11β-HSD1 
transcription. P1 predominates in lung, P2 predominates in liver, adipose tissue, and 
brain and P3 is utilized in the kidney and is believed to encode a non-enzymatically 
active 11β-HSD1 protein. However, the predominant promoter used to drive 
11β-HSD1 gene expression in pancreatic islets is unknown. Although the regulation 
of P1 and P3 promoters has not been yet characterized, the C/EBP families are the 
major transcription factors regulating the 11β-HSD1 P2 promoter (McKnight et al. 
1989; Darlington et al. 1995; Croniger et al. 1998; Poli 1998). The proinflammatory 
IL-1 and TNF-α cytokines increase 11β-HSD1 mRNA levels in glomerular 
mesangial cells (GMC) (Escher et al. 1997), granulosa cells (Tetsuka et al. 1999), 
human aoric smooth muscle cells (Cai et al. 2001), human bronchial smooth muscle 
cells (Cai et al. 2001), osteoblast cells (Zulewski et al. 2001), human ovarian surface 
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epithelial cells (Yong et al. 2002), and human preadipocytes (Tomlinson et al. 2001). 
Furthermore, TNFα and IL-1 increase 11β-HSD1 expression by inducing the binding 
of C/EBPβ to the P2 promoter in hepatoma (HepG2) cells (Ignatova et al. 2009) and 
human fetal lung fibroblasts (Yang et al. 2009). The regulation of 11β-HSD1 by 
insulin and GCs has been extensively studied. However, the literature is inconsistent 
and incomplete suggesting differential effects that are highly tissue specific and 
duration dependent in operation. In general, GCs act as a stimulator of 11β-HSD1, 
while insulin is an inhibitor of the enzyme expression and/or activity in skin 
fibroblasts (Hammami and Siiteri 1991), testis (Nwe et al. 2000), preadipocytes (Kim 
et al. 2007), and hepatocytes (Liu et al. 1996; Voice et al. 1996). GCs dose 
-ependently increase 11β-HSD1 expression in human skeletal muscle (Whorwood et 
al. 2002), and temporally regulate 11β-HSD1 expression and activity in rat liver and 
hippocampus in vivo (Moisan et al. 1990; Jamieson et al. 2000). In adipocytes, GCs 
down-regulate 11β-HSD1 in vitro (Napolitano et al. 1998; Balachandran et al. 2008) 
but up-regulate 11β-HSD1 in vivo (Livingstone et al. 2000; Balachandran et al. 
2008). Insulin has also stimulates 11β-HSD1 expression and activity in adipocytes 
both in vivo and in vitro (Wake et al. 2006; Westerbacka et al. 2006; Balachandran et 
al. 2008).  
 
Previous studies report 11β-HSD1 mRNA and activity were elevated in islets of 
obese and diabetic rodent models such as ob/ob mice (Davani et al. 2000; Ortsater et 
al. 2005) and ZDF rats (Duplomb et al. 2004). This suggested altered glucose 
metabolism itself may regulate the expression of 11β-HSD1. Nevertheless, these 
studies failed to find a direct regulatory effect of glucose, leptin, or a convincing 
effect of free fatty acids on islet 11β-HSD1 (Duplomb et al. 2004). Only the 
treatment with a PPARγ agonist thiazolidinedione (troglitazone), which also inhibits 
the expression of 11β-HSD1 in preadipocytes (Berger et al. 2001), showed a small, 
direct effect to suppress 11β-HSD1 in ZDF islets (Duplomb et al. 2004). Therefore 
11β-HSD1 regulation by cytokines and hormones remains unclear and it is of key 
importance to address this question to fully understand the physiological role of this 
enzyme in islet function. The present work was undertaken to obtain a better 
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understanding of the role and regulation of 11β-HSD1 activity, in pancreatic islets, in 
particular in response to known diabetogenic factors. 
3.2 Aims 
1. To determine the predominant enzyme directionalty of 11β-HSD1 in pancreatic 
islets; 
2. To identify which promoter of 11β-HSD1 is used in pancreatic islets; 
3. To investigate which factors regulate 11β-HSD1 activity in pancreatic islets. 
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3.3 Experimental design 
3.3.1 11β-HSD1 activity and directionality in pancreatic islets 
11β-HSD1 possesses both reductase and dehydrogenase activities in its purified form 
and in tissue homogenates. The reductase is the predominant function in most intact 
cells and in vivo (Low et al. 1994; Jamieson et al. 1995) when the predominant 
co-factor providing enzyme H6PDH is also expressed. To find out which activity of 
11β-HSD1 is predominant in pancreatic islets, batches of 100 islets were isolated 
(Described in 2.7), and incubated with [3H] labeled 11-dehydrocorticosterone (A 
compound) to measure reductase activity; while [3H] labeled corticosterone (B 
compound) was incubated to test the dehydrogenase activity. Furthermore, to 
determine the potential effect of glucose metabolism on islet 11β-HSD1 reductase 
and dehydrogenase activities, islets were incubated in either low glucose 
concentration (2.8mM) or high glucose concentration (16.8Mm). Islets were 
incubated for 24 hours and medium was extracted to measure the conversion of A to 
B, or B to A by TLC methods (Described in 2.9). 
3.3.2 Determining the 11β-HSD1 promoter use (P1, P2 or P3) in 
pancreas and isolated islets  
For a better understanding of the regulation of 11β-HSD1 in pancreas and islets, it 
was important to determine which promoters are employed to regulate 11β-HSD1 
expression in pancreas and islets. There are three known promoters that have been 
found to regulate 11β-HSD1 transcription (Described in 1.5.2). Although the 
regulators for P1 and P3 are still largely unknown, the P2 is regulated by C/EBP 
transcription factors (Described in 1.5.3). RNA was extracted from whole mouse 
pancreas or isolated islets. Reverse transcription followed by PCR with specific 
designed primers for the three different promoters (a gift from Dr. Karen Chapman). 
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3.3.3 The effects of glucose, fatty acids, insulin, dexamethasone 
and cytokines on islet 11β-HSD1 reductase activity in vitro 
Obesity and T2D are characterized by high plasma glucose, fatty acids, insulin, and 
certain cytokines (Boden and Shulman 2002). Glucocorticoid action is also elevated, 
at least within certain tissues (Morton and Seckl 2008). These diabetes-associated 
factors might be directly responsible for excessively increased islet 11β-HSD1 
activity found in some diabetic rodents (Davani et al. 2000; Livingstone et al. 2000; 
Masuzaki et al. 2001). To investigate this, islet 11β-HSD1 activity was measured by 
incubating pancreatic islets with different factors. 
 
In this case, a physiological glucose concentration (5mM) and a stimulatory (with 
regards to insulin secretion, 20mM) were used to assess glucose effects on islet 
11β-HSD1 activity. To control for potential confounding osmotic effects of the 
higher glucose concentration, sorbitol, a glucose “analogue” without a key hydroxyl 
group was used at the same concentration (20mM). 11β-HSD1 activity was measured 
from the cultured medium by TLC. 
 
Fatty acids potentiate glucose-stimulated insulin secretion from normal pancreatic 
β-cells and also play a role in the pathogenesis of β-cell dysfunction when they 
accumulate (lipotoxicity) within the islets in T2D (McGarry and Dobbins 1999; 
Poitout and Robertson 2002). Palmitate which is an abundant dietary-derived fatty 
acid in human plasma, was used as a reference compound to study the influence of 
fatty acids on islet 11β-HSD1 activity in vitro (Warnotte et al. 1999). Islets were 
isolated from the mice, and cultured in the absence or presence of 0.5mM palmitate 
(high physiological level in obese, diabetic range) (Jacqueminet et al. 2000) along 
with basal (5mM) or high (20mM) glucose concentrations to mimic the combination 
found in the type 2 diabetic condition.  
 
Plasma TNFα is increased with morbid obesity (Hotamisligil et al. 1993) and 
stimulates 11β-HSD1 activity in many cell lines (details in chapter 1.5.3). Its 
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regulatory effect was mediated by C/EBPβ on the P2 promoter of 11β-HSD1 in 
HepG2 cells (Ignatova et al. 2009). To evaluate TNFα effect on islets 11β-HSD1 
activity, 1ng/ml TNFα was used, a concentration that stimulated 11β-HSD1 activity 
in human adipose stromal cells (Handoko et al. 2000).  
 
Although plasma glucocorticoids are largely normal during obesity and the early 
stage of diabetes, they are elevated in the later stages of diabetes, at least in rodents 
(Shimomura et al. 1987). Glucocorticoids regulate 11β-HSD1 activity in several 
tissues and cells apart from islets (Tomlinson et al. 2004). Dexamethasone is a 
synthetic glucocorticoid widely used as an anti-inflammatory drug (reviewed in 
(Swartz and Dluhy 1978; Holland and Taylor 1991; McEwen et al. 1997)). The 
concentration of dexamethasone chosen to test effects on islets 11β-HSD1 activity 
was 100nM, comparable to that used for investigating 11β-HSD1 expression in 
adipocytes (Napolitano et al. 1998). 
 
Circulating insulin is elevated secondary to insulin resistance in T2D. In insulin 
resistant states, insulin levels can reach up to 10nM or greater (Hollenbeck et al. 
1984). The effects of insulin on regulating 11β-HSD1 expression and activity is not 
clear and seems to depend on the tissue or cell types studied (Moisan et al. 1990; 
Hammami and Siiteri 1991; Liu et al. 1996; Napolitano et al. 1998; Jamieson et al. 
1999; Handoko et al. 2000; Nwe et al. 2000; Koistinen et al. 2004; Sandeep et al. 
2005; Wake et al. 2006; Kim et al. 2007; Balachandran et al. 2008). 10nM insulin 
was chosen to reflect a supraphysiological level found in compensatory 
hyperinsulinaemia of insulin resistance. 
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3.4 Results 
3.4.1 11β-HSD1 is predominantly a reductase in pancreatic islets  
The reductase activity of 11β-HSD1 was significantly higher (ten-fold) than the 
dehydrogenase in pancreatic islets. 16.8mM glucose had no significant effect on 
either reductase or dehydrogenase activities of 11β-HSD1 in islets in this studies, and 





















Figure 3-1. 11β-HSD1 activity is predominantly reductase in pancreatic islets. 
11β-HSD1 activities were measured by TLC. The reductase activity is represented by 
conversion of A to B, while dehydrogenase by the conversion of B to A. Reductase is 
significantly higher than dehydrogenase of 11β-HSD1 in islets in both low glucose 
concentration (A) and high glucose concentration (B). The islets were isolated from 
C57BL/KsJ (KsJ) mice. Values represented the mean ± S.E.M, **P<0.01 (One-way 

































Glucose(mM)     2.8    16.8           2.8    16.8 
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Reductase           Dehydrogenase 
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3.4.2 The P1 and P2 11β-HSD1 promoters are predominantly used 
for 11β-HSD1 expression in pancreas and islets  
Pancreas and pancreatic islets were isolated from mice and RNA was extracted. 
Reverse transcription followed by PCR with specific primers for the three different 
promoters were run to find out which promoters are predominant in whole pancreas 
and islets. For islets and pancreas the PCR produced a strong band at the expected 
size of 600bp using primers specific for P1 (encoding exon 1A) and P2 (encoding 
exon1 B), indicating the robust expression of promoters 1 and 2 in pancreas and 
islets (Figure 3-2). Both GAPDH and 11β-HSD1 controls were positive indicating 
the RNA was of good quality. 
 
            Pancreas         Islets              Liver 
              
      M  G  H  P1  P2     G  H   P1  P2      G   H  P1  P2  B  
 
 
Figure 3-2. P1 and P2 are the predominant promoters in pancreas and islets. 
PCR gel visualized by UV trans illuminator showing P1 and P2 specific bands at 
600bp from pancreas and islets RNA. Liver was used as a positive control 
showing P1 and P2; negative controls (B) contain no RNA (H2O); GAPDH (G) 
and 11β-HSD1 (H) primers were used as a control for the RNA quality.100bp 






3.4.3 The effects of nutrients, hormones and cytokines on 
pancreatic islet 11β-HSD1 activities in vitro 
To address the effects of glucose on 11β-HSD1 activity, islets were isolated from 
KsJ mice, and cultured with basal (5mM) glucose level, or a maximal stimulatory 
high glucose concentration (20mM) for 24 hours. 20mM sorbitol was used as an 
osmotic control. Compared to low glucose, there was a significant decrease of 
11β-HSD1 activity with high glucose. 11β-HSD1 activity was not affected by 20mM 
sorbitol compared to low glucose concentration, but was higher than 20mM glucose 
(Figure 3-3).  
 
To investigate the effect of free fatty acid on 11β-HSD1 activity, 0.5mM palmitate 
was used. 0.5mM palmitate significantly increased islet 11β-HSD1 activity with low 
glucose incubation and reversed high glucose-mediated inhibitory effects on islet 
11β-HSD1 activity (Figure 3-3). 
 
To determine the effect of TNFα on 11β-HSD1 activity, 1ng/ml TNFα was used. 
TNFα (1ng/ml) had no significant effect on 11β-HSD1 activity in the presence of 
low glucose. However, TNFα clearly prevents high glucose-induced inhibition of 
11β-HSD1 activity (Figure 3-3).  
 
To evaluate the effect of active GCs on 11β-HSD1 activity, 100nM dexamethasone 
was used. 100nM dexamethasone had no effect on islet 11β-HSD1 activity either 
with low or high glucose (Figure 3-3) 
 
10nM insulin clearly inhibited islet 11β-HSD1 activity in the presence of low 









Figure 3-3. Effects of glucose, palmitate, TNFα, dexamethasone and insulin on 
islet 11β-HSD1 reductase activity. Islets were isolated from KsJ mice, incubated in 
basal glucose condition (5mM Glucose, blank bars) or high glucose level (20mM 
Glucose, solid bars) with 20mM Sorbitol (strip bars), 0.5mM palmitate, 1ng/ml 
TNFα, 10nM insulin, and 100nM dexamethasone. Values represent the mean ± 
S.E.M, *** P<0.0001, *P<0.05 vs. 5mM glucose without treatment, Two-way 
ANOVA, n=6, §§§ P<0.0001, §§ P<0.01, vs. 20mM glucose without any treatment, 









































Glucocorticoids have profound effects on glucose metabolism under both normal and 
pathologic conditions. Considering the free unbounded inactive glucocorticoids 
(11DHC in rodents) are predominant in the circulation (Harris et al. 2001), they can 
be locally activated by the action of 11β-HSD1 in tissues. There is growing evidence 
that 11β-HSD1 is a bidirectional enzyme, in some cells (Lakshmi and Monder 1988; 
Agarwal et al. 1989; Bujalska et al. 1997; Atanasov et al. 2004; Lavery et al. 2006; 
Dzyakanchuk et al. 2009). Therefore, demonstrating which activity of this enzyme 
predominates in islets is important. 11β-HSD1 is expressed in pancreatic islets of 
KsJ mice as previously reported in C57BL/6J, Lepob/ob mice and human islets 
(Davani et al. 2000; Ortsater et al. 2005; Swali et al. 2008). Islet 11β-HSD1 activity 
is predominantly reductase. We found the reductase activity of 11β-HSD1 was ten 
fold higher than dehydrogenase activity in isolated islets of KsJ wild type mice in 
vitro. Furthermore, increasing glucose in the culture medium did not affect the 
directionality of this enzyme, suggesting the reductase activity is the predominant 
activity of 11β-HSD1 in pancreatic islets and this is not changed in obesity or 
diabetic conditions. 
 
11β-HSD1 activity is higher in some obesity induced diabetes animal models, such 
as Lepob/ob mice (Ortsater et al. 2005) and ZDF rats (Duplomb et al. 2004). Thus, the 
regulation of 11β-HSD1 in pancreatic islets is important to understand. RT-PCR 
analysis revealed that P1 and P2 were both involved in regulating 11β-HSD1 
transcription of the isolated islets from KsJ mice as in liver or adipose tissue (Bruley 
et al. 2006). This suggests that 11β-HSD1 expression might be regulated in a similar 
way as shown in liver and adipose tissues and comparably by inflammatory factors, 
cytokines and nutrients (Liu et al. 1996; Voice et al. 1996; Napolitano et al. 1998; 
Jamieson et al. 2000; Livingstone et al. 2000; Tomlinson et al. 2004; Kim et al. 2007; 
Balachandran et al. 2008). However, whilst this work shows that both promoters are 
used, the relative level of each promoter remains to be quantified.  
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We have attempted to look at the effect of several diabetogenic factors on islet 
11β-HSD1 activity. There is a significant inhibitory effect of high glucose on 
11β-HSD1 activity in isolated islets. The lack of effect of sorbitol, a glucose 
“analogue”, indicates the specific effect of glucose or one of its metabolites and not 
an osmolarity effect. This suggests that hyperglycaemia is not the cause of elevated 
11β-HSD1 activity in islets (Duplomb et al. 2004; Ortsater et al. 2005). This also 
contrasts with the stimulatory effect of high glucose on 11β-HSD1 reductase activity 
in HEK-293 cell, hepatoma cells and unaltered 11β-HSD1 activity in 3T3-L1 
adipocytes in vitro (Dzyakanchuk et al. 2009). Although this may be explained by 
different species and glucose levels used, it is more likely that high glucose regulates 
11β-HSD1 activity differentially in distinct tissues and suggests a unique effect of 
glucose metabolism in this specialised glucose-response cell type (islets). A 
reduction in 11β-HSD1 activity is observed in high fat diet induced β-cell failure in 
KsJ mice (see 4.5.9). This is also in accordance with the fact that the presence of a 
high glucose concentration in the islet environment induces glucotoxicity by 
increasing ROS formation that suppresses insulin production (Robertson and Harmon 
2006) which might interfere with the ER lumen environment where 11β-HSD1 is 
localised  (Turban et al. unpublished).  
 
Although three days in the presence of fatty acids (oleate/palmitate) failed to modify 
11β-HSD1 mRNA level in isolated islets of pre-diabetic ZDF rats (Duplomb et al. 
2004), increased saturated fatty acids (palmitate) elevated the 11β-HSD1 activity 
within 24hr in isolated islets from KsJ mice. This suggests that lipids have the ability 
to increase 11β-HSD1 activity and this might account for the increased level of 
activity seen in islets of obese mouse models (Davani et al. 2000; Ortsater et al. 2005) 
where high levels of FFA are present in the systemic circulation (Ingalls et al. 1950). 
Interestingly, high free fatty acid levels reverse the glucose-mediated suppression of 
islet 11β-HSD1 activity, suggesting lipid mediated regulation is dominant. It is 
currently unclear why KsJ islets show a lower 11β-HSD1 level on high fat diet, 
however, it is possible their increased β-cell failure susceptibility alters their 
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response to glucotoxicity and lipotoxicity.  
 
TNFα is elevated in morbid obesity and stimulates 11β-HSD1 transcription through 
P2 in many cell lines (details in 1.5.3). No such work has been carried out on 
pancreatic islets. We show that TNFα reverses the inhibitory effects caused by high 
glucose on islet 11β-HSD1 activity. TNFα alone had no effect at physiological 
glucose concentration. This suggests the TNFα might contribute to the elevation of 
islet 11β-HSD1 activity in obesity and diabetes and is consistant with the increased 
inflammatory state of obesity and diabetes (Kolb and Mandrup-Poulsen 2005; 
Wellen and Hotamisligil 2005). Moreover, the increased 11β-HSD1 activity in islets 
by TNFα  could activate GCs which may locally exert immunomodulatory effects 
(see 5.5.1.3).  
 
Dexamethasone had no effects on islet 11β-HSD1 activity in both physiological and 
high glucose conditions. This lack of effect is surprisingly different from findings 
that GCs increase 11β-HSD1 activity in other tissue and cell types such as skin 
fibroblasts (Hammami and Siiteri 1991), testis (Nwe et al. 2000), preadipocytes (Kim 
et al. 2007), hepatocytes (Liu et al. 1996; Voice et al. 1996), human skeletal muscle 
(Whorwood et al. 2002), and adipocytes in vivo (Livingstone et al. 2000; 
Balachandran et al. 2008). Further in adipocytes in vitro (Napolitano et al. 1998; 
Balachandran et al. 2008) and rat liver in vivo (Nwe et al. 2000), GCs decrease the 
11β-HSD1 activity. This important observation suggests that increased local 
generation of GC does not initiate a feed forward GC regulation of 11β-HSD1, and 
that elevated circulating GC (e.g. Cushing syndrome) may not alter islet 11β-HSD1 
directly. Indeed, this finding implicates other factors as being responsible for altered 
11β-HSD1 levels in islets in obesity and diabetes. 
 
Insulin showed a significant inhibitory effect on 11β-HSD1 activity only at low 
glucose concentration. This is in agreement with the negative regulatory effects of 
insulin found in many other tissues and cell types (Moisan et al. 1990; Hammami and 
Siiteri 1991; Liu et al. 1996; Jamieson et al. 1999; Nwe et al. 2000; Sandeep et al. 
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2005; Kim et al. 2007). This suggests that high physiological insulin levels suppress 
islet 11β-HSD1, and that insulin resistance in the β-cell may therefore contribute to 
the elevated islet 11β-HSD1 found in obese and diabetic animals. That insulin 
mediated islet 11β-HSD1 suppression is abolished by high glucose suggests a 
physiological effect such that glucose metabolism effects dominate over basal state 
effects of insulin (e.g. during a meal when glucose and insulin are both transiently 
elevated). 
 
In summary, we find the reductase is the predominant activity of 11β-HSD1 in 
pancreatic islets. The P1 and P2 promoter are involved in islet 11β-HSD1 
transcription. It is concluded that 11β-HSD1 activity is upregulated by free fatty 
acids, a proinflammatory cytokine and is inhibited by high glucose, and by insulin 
under basal glucose conditions. Further studies will be necessary to investigate the 
role of other factors which are also altered in obesity and diabetes, and perhaps more 
importantly, effects of the factors in combination. In addition, detailed mechanistic 
links between the regulatory factors identified in this chapter and the molecular 




Chapter 4  
 
β-cell-specific Overexpression of 
11β-HSD1 Reverses High-fat Diet 
Induced β-cell Failure 
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4 β-cell-specific overexpression of 11β-HSD1 reverses 
high-fat diet induced β-cell failure  
4.1 Introduction 
4.1.1 Type 2 diabetes and the role of the β-cell 
Diabetes has become a worldwide disease of ‘epidemic’ proportions (Wild et al. 
2004). Type 2 diabetes (T2D) is characterised by apoptotic β-cell death and a lack of 
responsiveness of the β-cell to secrete appropriate amounts of insulin after a meal. 
This usually occurs after a prolonged period of insulin resistance; a generalised lack 
of responsiveness of glucose consumption and storage in tissues (Martin et al. 1992). 
Furthermore, T2D often occurs in parallel with obesity and metabolic syndrome 
(Huang et al. 2009) suggesting the pathogenesis of insulin resistance originates at 
least in part from excessive adipose tissue or its dysfunction.  
 
The β-cell is remarkable in its ability to synthesise and release insulin in a very 
precise manner to maintain glucose homeostasis (Described in 1.3.2). Changes in 
glucose levels are the main regulator of insulin secretion and are exquisitely sensed 
across a physiological range by β-cells (Maechler et al. 2006). In T2D, a period of 
prolonged hyperglycaemia caused by muscle and liver insulin resistance initially 
provokes increased insulin secretion to maintain normal glycaemia (β-cell 
compensation). Rodent studies show two important mechanisms, expansion of the 
β-cell mass (Steil et al. 2001; Liu et al. 2002; Jetton et al. 2005) and enhanced β-cell 
function (Chen et al. 1994; Liu et al. 2002) are involved in this process. However, 
type 2 diabetes later ensues due to a progressive deterioration in β-cell function 
(Jetton et al. 2005) associated with β-cell loss by apoptosis (β-cell failure) (Butler et 
al. 2003; Yoon et al. 2003). Recent genetic studies in large human populations 
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(genome wide association) have begun to identify several candidate genes of diabetes, 
the majority of which are associated with β-cell function, such as DGKB/TMEM195 
and MADD which contribute to β-cell mass and insulin secretion (Dupuis et al. 
2010). 
 
4.1.2 11β-HSD1 in metabolic disorders 
Excess plasma GCs (described in 1.4.3.3) exacerbate hyperglycaemia (Larsson and 
Ahren 1996) and insulin resistance (Sakoda et al. 2000; Smith and Muscat 2005), as 
evidenced by rare conditions such as Cushing syndrome. However, during the more 
prevalent idiopathic human metabolic disease development, elevated tissue 
11β-HSD1, which mainly converts inactive GC (cortisone, 
11β-dehydrocorticosterone) to active GC (cortisol, corticosterone) (Bush et al. 1968; 
Seckl and Walker 2001), rather than increasing circulating GC levels (Morton and 
Seckl 2008) appears to underlie the pathogenesis. This has been supported by several 
transgenic mouse models. Transgenic overexpression of 11β-HSD1 in adipose tissue 
caused visceral obesity, insulin resistance, type 2 diabetes and hypertension in mice 
(Masuzaki et al. 2001) recapitulating the elevation of adipose 11β-HSD1 observed in 
human obesity and metabolic syndrome (Morton and Seckl 2008). A high level of 
11β-HSD1 in liver leads to mild insulin resistance and dyslipideamia (Paterson et al. 
2004), which mimicked perhaps rarer instances of metabolic disturbance. Conversely, 
11β-HSD1 knock out mice proved to be resistant to high fat diet induced type 2 
diabetes, and had increased hepatic and adipocyte insulin sensitivity (Morton et al. 
2001; Morton et al. 2004), an observation that has also been indicated by 
pharmacological studies using 11β-HSD1 inhibitors (Walker et al. 1995; Livingstone 
et al. 2000; Alberts et al. 2002; Barf et al. 2002; Alberts et al. 2003; 
Hermanowski-Vosatka et al. 2005; Webster et al. 2007; Boyle 2008; Bujalska et al. 
2008; Boyle and Kowalski 2009; Rosenstock et al. 2010). 
4.1.3 The effects of glucocorticoids and 11β-HSD1 on insulin 
secretion 
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A high level of 11β-HSD1 activity was found in pancreatic islets from obese diabetic 
rodent models (Duplomb et al. 2004; Ortsater et al. 2005). Incubation of islets from 
obese (Lepob/ob) mice with the 11β-HSD1 substrate 11DHC suppressed GSIS in vitro 
(Davani et al. 2000; Ortsater et al. 2005), leading the authors to hypothesise that high 
islet 11β-HSD1 was suppressive for GSIS. However, incubation of islets from 
Lepob/ob with relatively low 5nM 11DHC showed an initial stimulatory effect on 
GSIS (Ortsater et al. 2005). These findings open up a wider controversy in the 
literature concerning the effects of GCs on islet function. Thus, although several 
studies have investigated GCs effects on β-cell GSIS, inconsistencies due to different 
species and methods are found (details in 1.4.3.3.4). In general, high-dose and 
long-term GCs exert inhibitory effects on GSIS in vitro (Billaudel and Sutter 1979; 
Barseghian et al. 1982; Pierluissi et al. 1986; Gremlich et al. 1997; Lambillotte et al. 
1997; Davani et al. 2000; Jeong et al. 2001; Ortsater et al. 2005; Swali et al. 2008); 
while low-dose (Ortsater et al. 2005) or short-term GCs increase (Hult et al. 2009) 
and physiological concentration of GCs have no effect on GSIS (Jeong et al. 2001). 
Isolated islets from dexamethasone treated rats display an increase of GSIS (Karlsson 
et al. 2001; Choi et al. 2006; Rafacho et al. 2008; Rafacho et al. 2010). In contrast in 
mice, GCs reduce GSIS in vivo (Khan et al. 1992; Delaunay et al. 1997; Ling et al. 
1998). The consequence of chronic elevation of 11β-HSD1 activity on β-cell 
function was therefore not straight forward to predict, although one could aruge the 
weight of evidence was for an inhibitory action of GCs on GSIS.  
 
Given that inhibition of 11β-HSD1 is now advocated as a therapeutic treatment for 
obesity (reviewed in Hughes et al. 2008), we aimed to more fully understand the 
relationship between β-cell 11β-HSD1 and β-cell function. To do this we created a 
β-cell-specific 11β-HSD1 overexpression model in the C57BL/KsJ mouse genetic 
background strain that was prone to develop β-cell failure when fed high fat diets 
(Korsgren et al. 1990).  
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4.2 Hypothesis 
We hypothesized that increased glucocorticoid action mediated by increased 
11β-HSD1 expression may accelerate hyperglycaemia and diabetes by amplifying 
the inhibitory effects of glucocorticoids in β-cells.  
4.3 Aims 
1. To validate the β-cell specific 11β-HSD1 overexpression model. 
2. To test the effects of β-cell specific 11β-HSD1 overexpression on a 
diet-induced T2D in vivo and in vitro. 
3. To determine the effect of diet on expression of islet 11β-HSD1 in models with 
varying susceptibly to β-cell failure. 
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4.4 Experimental design 
4.4.1 Creation of a β-cell-specific 11β-HSD1 overexpressing 
transgenic mouse model  
As described in 2.1.1, the β-cell specific 11β-HSD1 overexpression mice model was 
created by using a β-cell specific mouse insulin promoter (MIP, 8.3kb) (Hara et al. 
2003) from HindIII (-8280) and Not I (+12) upstream of the rat 11β-HSD1 cDNA 
(1.265bp) containing EcoRI fragment. The construct-mediated 11β-HSD1 activity 
and its glucose-inducibility was tested in clonal β-cells in vitro (Turban et al. 
unpublished), micro-injected into blastocysts from the C57BL/KsJ line and 
implanted in pseudo-pregnant females. Control C57BL/KsJ mice were bred in house. 
The microinjection was performed by the University of Edinburgh GIST Unit. 
4.4.2 Genotyping of MIP-HSD1 transgenic mice 
The genotype was determined by extracting the genomic DNA from mice tail tips 
(Described in 2.8.1), followed by PCR using primers specific to the upstream MIP 
promoter and an internal sequence of the rat cDNA transgene, which includes one 
diagnostic EcoR I site which we used to confirm transgene integration. This PCR 
product (650bp) was digested by restriction enzyme EcoR I to give two bands at 
430bp and 220bp which were resolved in a 2% agarose gel. The MIP-HSD1 plasmid 
vector was used as a positive control (Described in 2.8.2).  
 
To determine copy number, genomic DNA was digested with the infrequent cutter 
Afl III (the enzyme cuts at 6.897kb of the MIP-r11β-HSD1 transgene) followed by 
Southern blotting was performed with the rat 11β-HSD1 gene cDNA (1.265kb) as a 
probe to recognize both the endogenous and transgenic bands. Signal intensity was 
used to determine copy number to distinguish the heterozygous and homozygous 
mice. We used this method to screen all the generations of transgenic mice 
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(Described in 2.8.3).  
4.4.3 11β-HSD1 activity in MIP-HSD1 transgenic mice 
11β-HSD1 possesses both reductase and dehydrogenase activities (Low et al. 1994; 
Jamieson et al. 1995). As we have found that the reductase activity of 11β-HSD1 is 
predominant in pancreatic islets (Described in chapter 3), it was essential to find out 
whether reductase remains the main activity with overexpression in transgenic 
MIP-HSD1 mice, and whether it is glucose inducible as a result of being linked with 
the insulin promoter regulatory elements. Batches of 100 islets were isolated from 
KsJ and MIP-HSD1 mice and incubated with [3H] labelled 11-dehydrocorticosterone 
(A compound) to measure reductase activity; while [3H] labelled corticosterone (B 
compound) was incubated to test the dehydrogenase activity. All islets were 
incubated in either 2.8mM low glucose concentrations or 16.8mM high glucose 
concentrations. Activities were measured by TLC methods (Described in 2.9).  
4.4.4 β-cell specificity of MIP-HSD1 transgene expression 
To further investigate whether the 11β-HSD1 transgene was highly expressed within 
the β-cell of MIP-HSD1 transgenic mice, KsJ control and MIP-HSD1tg/+ mice 
pancreas was stained with 11β-HSD1 antibody by immunohistochemistry. 
4.4.5 The effect of the MIP-HSD1tg/+ transgene on intraperitoneal 
glucose tolerance  
GTT is widely used to determine how quickly glucose can be cleared from the blood 
after glucose administration. IpGTT was performed as described in 2.3.1. Insulin 
evolution curves (an indicator of β-cell responsiveness to glucose load in vivo), were 
also determined. Both KsJ and MIP-HSD1tg/+ mice were on chow diet, and 
age-matched. 
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4.4.6 Induction of glucose intolerance with chronic high fat feeding 
To induce glucose intolerance, mice were fed a hypercaloric (high-fat) diet (58 
kcal% fat w/sucrose Surwit Diet) (Surwit et al. 1998) for 12 weeks, or a low fat 
control diet (11 kcal% fat w/cornstarch Surwit Diet). Body weight was measured 
every three days and fat mass, pancreas and liver mass were measured at necropsy. 
4.4.7 Assessment of plasma corticosterone level in MIP-HSD1 mice 
To find out whether MIP-HSD1 transgenic mice have altered at the 
plasmacorticosterone level. The mice were single-housed and after a two-day 
acclimation, blood samples were taken at the nadir (8am) by venesection within 1min 
of disturbing the animal to avoid confounding elevation of corticosterone 
stress-responses (≥1min in mice). Plasma corticosterone was measured by a RIA 
method using 3H-corticosterone label and a polyclonal anti-corticosterone antibody 
(Described in 2.6.4).  
4.4.8 Investigation of islet insulin secretion in vivo  
To more rigorously test whether chronic elevation of β-cell 11β-HSD1 affected the 
islet GSIS of MIP-HSD1 transgenic mice in vivo, intravenous glucose tolerance test 
(ivGTT) was used. This method can be used to more closely monitor early 
first-phase (1 to 3 minutes) as well as second phase of insulin secretion after glucose 
challenge compared to intraperitoneal GTT and oral GTT which can exhibit marked 
variation in time of glucose absorption, especially in obese compared to lean animals 
(Cobelli et al. 2007). Furthermore, by applying a continuous bolus over a one hour 
period independently of glucose uptake, we were able to assess continuous and 
maximal β−cell responses. As described in 2.3.2, mice were administered glucose 
intravenously and plasma glucose level was measured by glucose meter (Details in 
2.1.6.1). Blood samples were collected for further insulin ELISA assay (Details in 
2.1.6.2). 
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4.4.9 Investigation of MIP-HSD1 islet insulin secretion in vitro  
The islet autonomous insulin secretion was measured, as it is a way of assessing islet 
function independent of potentially altered islet number. Islets were isolated from all 
genotypes (Details in 2.7), and ten comparably sized islets were cultured in one well 
of a 24-well plate. High glucose (25mM) was used to stimulate islet insulin secretion 
(Details in 2.10). Medium was collected to measure insulin concentration by RIA 
(Details in 2.6.3). 
4.4.10 The effects of high fat diet on islet 11β-HSD1 activity 
Unlike the C57BL/KsJ strain, C57BL/6J mice are an obesity-prone model that can 
sustain a high level of insulin secretion to compensate for hyperglycaemia (Korsgren 
et al. 1990). C57BL/6J is widely used for metabolic studies and is the genetic 
background strain of the 11β-HSD1 knock out mice (Kotelevtsev et al. 1997; Morton 
et al. 2001; Morton et al. 2004). To begin to explore the concept that strain 
differences in islet 11β-HSD1 expression might be related to the β-cell compensatory 
capacity in response to high fat diet-induced insulin resistance, we compared the islet 
11β-HSD1 activity levels in KsJ (non-compensating) with C57BL/6J (robustly 
compensating) after 12 weeks of high fat diet. 
4.4.11 11β-HSD1 activity in islets from diabetic Lepdb/db mice 
Pancreatic islet 11β-HSD1 expression and activities were elevated in some 
obesity/diabetic rodent models (Duplomb et al. 2004; Ortsater et al. 2005). Another 
commonly used diabetic rodent model, Lepdb/db mice, had increased 11β-HSD1 
activity in liver (Liu et al. 2005) but this has not been addressed in islets. Islets were 
extracted from the appropriate KsJ wide type mice and Lepdb/db mice. Batches of 100 
islets per well were incubated at normal glucose concentration for 24 hours. TLC 




4.5.1 Creation of a β-cell specific 11β-HSD1 overexpressing 
transgenic mouse  
MIP-HSD1 transgenic mice were made in-house using the mouse insulin promoter 
upstream of the rat cDNA 22 founder mice were viable after KsJ blastocyst injection 
into pseudopregnant females. 4 mice were found to be positive for the transgene but 
only one transmitted it to the next generation. Genomic DNA was extracted from the 
tail of each mouse and used to determine its genotype (as seen in figure 4-1, 4-2).  
4.5.2 Genotyping of MIP-HSD1 transgenic mice 
4.5.2.1 Identification of MIP-HSD1 transgenic mice by PCR  
As shown in Figure 4-1, KsJ mice presented no band at 650bp, or the predicted bands 
after enzyme digestion, while MIP-HSD1 transgenic mice showed the same specific 
bands as the MIP-HSD1 plasmid vector positive control. 
4.5.2.2 Distinguishing heterozygous and homozygous MIP-11β-HSD1 
transgenic mice by Southern blot 
As shown in Figure 4-2 the lower three bands are the wild type (endogenous 
11β-HSD1) bands, present in DNA of all mice. The upper four bands are the 
transgenic bands which are specific to DNA of transgenic mice after Afl III digestion, 
heterozygous 11β-HSD1 (MIP-HSD1tg/+) had approximately 2-fold the gene dose 




Figure 4-1. Genotyping MIP-HSD1 transgene by PCR. A. A schematic diagram of 
the MIP-HSD1 transgene. B. EcoRI digestion of the MIP-HSD1 plasmid control with 
characteristic restriction fragment pattern. C. The restriction fragment pattern 
observed after EcoRI digestion of KsJ genomic DNA and MIP-HSD1 genomic DNA. 
U-uncut, C-cut, M-100 base pair ladder. 
 
 
















Figure 4-2. Genotyping transgenic mice by Southern. A. Southern blot pattern of 
KsJ wild type showing three lower bands of genomic 11β-HSD1. B. Southern blot 
pattern showing transgenic MIP-HSD1tg/+ which also shows the upper four 
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4.5.3 11β-HSD1 activity in MIP-HSD1 pancreatic islets 
4.5.3.1 11β-HSD1 reductase activity in MIP-HSD1 islets 
Islets were isolated from KsJ (n=7), MIP-HSD1tg/+ (n=5) transgenic mice and 
MIP-HSD1tg/tg (n=4). Reductase activity of 11β-HSD1 was measured after 24h 
incubation in media at low glucose or high glucose concentration in order to activate 
the insulin promoter which should drive increased transcription of 11β-HSD1. As 
expected 11β-HSD1 reductase activity and induction with glucose was higher in 
MIP-HSD1 transgenic mice with a gene-dose-dependent increase in the 
MIP-HSD1tg/tg mice. The reductase activity of 11β-HSD1 was not glucose inducible 
in KsJ mice in vitro (Figure 4-3). 
4.5.3.2 11β-HSD1 dehydrogenase activity is low in MIP-HSD1tg/+ islets  
11β-HSD1 is a bidirectional enzyme, so the dehydrogenase activity of 11β-HSD1 
was also measured in KsJ and MIP-HSD1tg/+ mice. There is little dehydrogenase 
activity of 11β-HSD1 in islets. After 24h incubation in media at low glucose or high 
glucose concentration, as expected 11β-HSD1 dehydrogenase activity was near 10 
fold lower compared to the reductase and there was no differences between 
MIP-HSD1tg/+ mice and the KsJ mice. Further the dehydrogenase activity of 














Figure 4-3. 11β-HSD1 reductase activity in different genotypes and glucose 
conditions. MIP-HSD1 11β-HSD1 reductase activity is increased and is glucose 
inducible. Values represented the mean ± S.E.M, *** P<0.001, (* versus KsJ 
16.8mM glucose), §§§ P<0.01 (§ versus MIP-HSD1tg/+), # P<0.05 (# versus 












Figure 4-4. 11β-HSD1 dehydrogenase activity of KsJ and MIP-HSD1tg/+ in 
different glucose conditions. 11β-HSD dehydrogenase activity, which is ten fold 
lower than reductase, was comparable in both genotype, and not affected by glucose. 
Values represented the mean ± S.E.M, not significant, One-way ANOVA, Tukey’s 
Multiple Comparison Test, n=4-6. 
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4.5.4 Basal insulin secretory profile of MIP-HSD1tg/+ mice 
IpGTTs (2g/kg glucose) were performed on KsJ and heterozygous MIP-HSD1tg/+ 
mice. Analysis of the glucose tolerance tests (Figure 4-5) showed similar increases of 
plasma glucose level in response to glucose injection between both groups. Moreover 
the glucose disposal represented by disappearance of blood glucose over the time, 
was comparable between KsJ and MIP-HSD1tg/+ mice. Similarly plasma insulin 
concentrations rose normally after the increase of glucose in the blood and decreased 
at a normal rate while the body cleared the glucose (Figure 4-6). 
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Figure 4-5. IpGTT plasma glucose levels for KsJ and MIP-HSD1tg/+. The glucose 
load was administered shortly after time 0, and blood was sampled at 0, 5, 10, 15, 30, 
60 and 120min. Values represent the mean ± S.E.M, Repeated measures ANOVA, 
n=6, not significant. 







Figure 4-6. IpGTT plasma insulin levels for KsJ and MIP-HSD1tg/+. The glucose 
load was administered at shortly after time 0, and blood sampled at 0, 5, 10, 15, 30, 
60 and 120min. Values represent the mean ± S.E.M, Repeated measures ANOVA, 





























4.5.5 The effects of high fat feeding on MIP-HSD1 mice 
Physiological characteristics of MIP-HSD1 mice were determined after 12 weeks of 
high fat feeding. MIP-HSD1 mice appeared grossly normal and the MIP-HSD1 mice 
showed a small but significant increase of weight gain (Table 4-1). The weight of the 
individual fat pads, pancreas and liver was not different between genotypes. Fasting 
plasma insulin and glucose was comparable between genotypes on chow diet and HF 




Table 4-1. Physiological characteristics of MIP-HSD1 mice 














29.1±0.36 30.0±0.38 30.0±0.39 29.5±0.42 30.2±0.4 29.2±0.3 
Weight 
gain (g) 
0.21±0.31 1.66±0.28* 1.01±0.25 2.41±0.32*§ 1.21±0.35 2.84±0.23*# 
Epidydimal 
mass (g) 
0.53±0.06 0.93±0.07* 0.47±0.03 0.7±0.06 0.37±0.03 0.59±0.04 
Pancreas 
(g) 
0.29±0.04 0.30±0.04 0.34±0.02 0.29±0.05 0.28±0.01 0.29±0.02 
Liver mass 
(g) 








0.85±0.33 0.48±0.27 0.56±0.11 0.74±0.33 0.56±0.35 0.43±0.17 
 
Table 4-1. Physiological parameters of KsJ and MIP-HSD1 mice after high fat 
feeding for 12 weeks. Plasma and body weight data were collected on the first day, 
and at the end of the study, the tissues were collected. * P<0.05 (versus KsJ CD), §
P<0.05 (versus MIP-HSD1tg/+ CD), # P<0.05 (versus MIP-HSD1tg/tg CD). Values 











4.5.6 The effects of high fat feeding on plasma corticosterone 
levels in MIP-HSD1 mice  
Plasma corticosterone levels were measured by RIA to determine if the MIP-HSD1 
transgene effects, if any, might affect the HPA function. The plasma corticosterone  



















Figure 4-7. Plasma corticosterone levels in different genotypes and diets. No 
difference was observed between genotypes and diets. Values represented the mean ± 
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KsJ MIP-HSD1tg/+ MIP-HSD1tg/tg 
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4.5.7  The effects of high fat feeding on MIP-HSD1 insulin 
secretion in vivo: Intravenous glucose tolerance 
In order to investigate the potentially pathogenic effects of high β-cell 11β-HSD1 in 
diabetes, glucose intolerance and weight gain were induced in the mice by feeding a 
high fat diet for 12 weeks. A high glucose concentration (3mg/g BW, 25% glucose at 
a rate 0.83μg/min/g) was constantly infused intravenously to stimulate maximal 
insulin secretion for one hour with blood sampling at 0, 1, 3, 5, 10, 15, 30, 60, and 
120mins in order to closely follow the first and second phases of insulin secretion. 
The KsJ high fat fed group secretes less insulin than KsJ chow diet and developed 
glucose intolerance after high dose glucose loading. However, the MIP-HSD1tg/+ 
high fat fed group secreted significantly more insulin than MIP-HSD1tg/+ chow diet 
fed and corrected glucose intolerance relative to HF fed KsJ mice as a result. 
MIP-HSD1tg/tg mice on both chow diet and high fat diet secreted significantly lower 
insulin than the KsJ control group during the first phase. However, MIP-HSD1tg/tg 
mice exhibited elevated insulin secretion compared to control diet fed MIP-HSD1tg/tg 
mice at second phase when fed a high fat diet. (Figure 4-8)    
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Figure 4-8. Plasma insulin and glucose levels in different genotypes and with 
different diets during LGTT. During one hour glucose loading, A. the plasma 
insulin levels for the high fat fed (HF) KsJ group secreted less insulin than chow diet 
fed (CD) KsJ group, whereas the glucose level was significantly higher in HF KsJ 
than CD KsJ mice. B. The plasma insulin level of the transgenic MIP-HSD1tg/+ mice 
HF group secreted clearly more insulin in both phases compared to CD group, even 
higher than KsJ CD group, and glucose level was not different between HF and CD 
groups. C. In MIP-HSD1tg/tg HF group first phase insulin secretion was lost but 
increased in the second phase; the glucose level was similar between HF and CD. 
The broken horizontal lines represent the 2.8ng/ml plasma insulin level and the mean 
peak (~21mM) KsJ CD plasma glucose level for comparison across the groups. 
Values represent the mean ± S.E.M, * P< 0.05, Student t-test, n=6-8. 
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4.5.8 The effects of high fat feeding on MIP-HSD1 islet insulin 
secretion in vitro 
To confirm a direct β-cell specific effect of 11β-HSD1 overexpression on islet 
function, we looked at insulin secretion from isolated islets. Isolated islets from KsJ 
and transgenic mice were treated with 2.8mM glucose for 30mins, then 25mM for 
the following 30mins, which caused a peak of insulin secretion, after which islets 
were restored to 2.8mM glucose to test the reversibility of glucose-stimulated insulin 
secretion (GSIS). KsJ on HF showed no compensatory insulin secretion after glucose 
stimulation. MIP-HSD1tg/+ on HF had a higher basal insulin secretion and showed 
higher insulin release compared to other groups after stimulation by a high glucose 
concentration. Insulin secretion from MIP-HSD1tg/tg HF group was higher than 
MIP-HSD1tg/tg CD group but this was sustained only for the first 20 minutes after 




Figure 4-9. Glucose stimulates insulin secretion in vitro differentially with 
genotype and diet. A. Insulin secretion of KsJ HF group was lower than KsJ CD 
group. B. Basal and high glucose stimulated insulin released was higher in 
MIP-HSD1tg/+ HF group. C. MIP-HSD1tg/tg on HF diet showed an elevated basal 
insulin secretion but impaired second phase GSIS. Values represent the mean ± 
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4.5.9 Differential islet 11β-HSD1 activity in mouse strains with 
varying susceptibility to β-cell failure 
After 12 weeks of high fat diet, islets were isolated from C57BL/6J and KsJ mice to 
evaluate 11β-HSD1 activity. High fat diet increased 11β-HSD1 activity in islets of 
the compensation-competent C57BL/6J strain while islet 11β-HSD1 activity was 
























Figure 4-10. 11β-HSD1 activity of C57BL/6J and KsJ islets after high fat feeding. 
11β-HSD1 activity significantly increased in C57BL/6J mice after 12 weeks high fat 
feeding (A), whereas there was a significant reduction in KsJ mice (B). Values 

















































4.5.10 11β-HSD1 is markedly elevated in islets from diabetic 
Lepdb/db mice 
11β-HSD1 activity was increased in pancreatic islets from Lepob/ob and Zuker (ZDF) 
rats where this was hypothesized to impair β-cell function (Duplomb et al. 2004; 
Ortsater et al. 2005). Having shown that reductase and not dehydrogenase 
predominates in islets, we wished to confirm whether this was altered in the diabetic 
model Lepdb/db mice (See 3.3.1 and 4.5.3.2). Thus, the islet 11β-HSD1 reductase 
activity of KsJ control was compared to that of diabetic Lepdb/db mice. Figure 4-11 













Figure 4-11. 11β-HSD1 reductase activity was significantly elevated in islets of 
the diabetic model Lepdb/db mice. Islets were isolated from KsJ and Lepdb/db mice. 
Values represent the mean ± S.E.M, ** P=0.0017, Student t-test, KsJ group n=4, 
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4.6 Discussion 
Unexpectedly, our transgenic model demonstrates that modestly elevated levels of 
β-cell specific 11β-HSD1 overexpression (heterozygote, MIP-HSD1tg/+) improves 
β-cell function in vitro and in vivo, counteracting the glucose intolerance caused by 
high fat feeding. This suggests increased β-cell 11β-HSD1 is a part of the 
physiological adaptive compensatory response of islets during prediabetes, revealing 
for the first time a markedly different outcome other than the diabetogenic effects 
induced by overexpression of 11β-HSD1 in adipose tissue and liver (Masuzaki et al. 
2001; Paterson et al. 2004). We have therefore rejected our original hypothesis, and 
must now refine our understanding of 11β-HSD1 action in β-cells. Homozygote 
transgenic mice (MIP-HSD1tg/tg), which have a more pronounced increase in β-cell 
11β-HSD1 levels, exhibit an attenuated second phase insulin secretory response 
compared to MIP-HSD1tg/+ mice, even on normal chow diet. Surprisingly, this was 
adequate enough to maintain glucose tolerance, presumably due to sufficient efficacy 
of the lower insulin to act upon normally sensitive peripheral tissues such as muscle. 
MIP-HSD1tg/tg models a high expression of 11β-HSD1 as found in the diabetic 
Lepdb/db islets and indicates that islet higher 11β-HSD1 expression might suppress 
β-cell insulin release. Previous studies have reported inconsistent results about GCs 
and/or 11β-HSD1 effects on islet insulin secretion, although most reports showed 
GCs either directly decreased islets GSIS of C57BL/6J (Swali et al. 2008) or showed 
this inhibitory effect indirectly by incubating islets with 11DHC, the 11β-HSD1 
substrate in Lepob/ob mice (Davani et al. 2000; Ortsater et al. 2005). A recent report 
showed that after short-term GC treatment islet GSIS was increased at first and 
second phase in vitro (Hult et al. 2009). Our data clarify the conflicting data in the 
literature suggesting there is an optimum level of 11β-HSD1 in β-cells which 
initially improves β-cell responses to glucose stimulation. Either a higher or lower 
level around this optimum level would suppresses β-cell GSIS, consistent with the 
inverted U-shaped dose response effects of GCs (Du et al. 2009). Thus, if the 
observations from our previous data can be extrapolated to the whole animal, 
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modestly elevated 11β-HSD1 in β-cells can ameliorate glucose intolerance. Beyond 
a protective threshold higher 11β-HSD1 expression (e.g. MIP-HSD1tg/tg and Lepdb/db) 
may worsen diabetes. These findings have profound implications for the potential 
use of 11β-HSD1 inhibitors clinically to prevent insulin resistance: these drugs may 
exacerbate diabetes if the β-cell effect outweighs peripheral insulin sensitisation. 
 
11β-HSD1 is a bidirectional enzyme; previous results demonstrated 11β-HSD1 
activity was predominantly reductase and was ten fold higher than dehydrogenase 
activity in islets of KsJ wild type mice (Showed in 3.4.1). Further increasing 
11β-HSD1 in MIP-HSD1tg/+ mice did not switch this, suggesting the H6PDH levels 
are sufficient to maintain GC amplification, presumably also when islets 11β-HSD1 
is elevated in the disease state, as we found the Lepdb/db mice.  
 
The activity of islet 11β-HSD1 in the MIP-HSD1 model is glucose inducible, which 
means hyperglycaemia can manifest increased β-cell 11β-HSD1 activity during the 
development of diabetes. Although we had only one transgenic line, increasing the 
glucose concentration elevated the conversion of 11-dehydrocorticosterone to 
corticosterone in isolated islets from MIP-HSD1 transgenic mice with a gene dose 
effect, confirming the utility of our model as well as its glucose-responsiveness and 
suitability for studies modelling high β-cell specific 11β-HSD1 levels.  
 
Our β-cell 11β-HSD1 overexpression model is therefore a functional and a valuable 
tool for determining the effects of β-cell 11β-HSD1 under pre-diabetic conditions. 
The MIP-HSD1tg/+ and MIP-HSD1tg/tg models the β-cell compensation or partial 
failure as found in a number of obesity and diabetes rodent models (Duplomb et al. 
2004; Ortsater et al. 2005). Notably, since plasma GC levels were not significantly 
altered, the phenotype of the MIP-HSD1 transgenic mice must be due to β-cell 
intrinsic transgene specific effects. 
 
IvGTT (LGGT) showed the KsJ mice on high fat diet developed glucose intolerance 
as a result of lower insulin output, ie. β-cell failure (reviewed in McGarry and 
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Dobbins 1999). This was confirmed by a lack of a compensatory response in the 
isolated islets. We further confirmed that MIP-HSD1tg/+ mice and to a certain extent 
MIP-HSD1tg/tg mice derive islet autonomous protection in vitro through chronic 
elevation of β-cell 11β-HSD1. This is extremely important as it demonstrates that 
individual islets (β-cell) have altered function rather than there being altered 
peripheral glucose disposal and that the in vivo effect is not simply due to increased 
β-cell number through a potential developmental effect of the MIP-HSD1 transgene. 
Furthermore from the in vitro result, MIP-HSD1tg/tg high fat fed mice did not secrete 
as much insulin as MIP-HSD1tg/+ when challenged by high glucose, which suggested 
a dose-dependent threshold for the protective effect of 11β-HSD1 expression in 
β-cell.  
 
There are two ways for β-cell to compensate hyperglycaemia, one is by enhancing 
β-cell insulin secretory function (Chen et al. 1994; Liu et al. 2002), the other is 
expansion of β-cell mass (Steil et al. 2001; Liu et al. 2002; Jetton et al. 2005). As we 
have already shown MIP-HSD1tg/+ mice had elevated autonomous islet function. 
Recent analysis of the pancreatic islet number by optical projection tomography 
(OPT) has shown increased islet number also (Turban et al. unpublished). 
 
Pancreatic islet 11β-HSD1 activity was elevated in C57BL/6J mice after 12 weeks 
high fat diet exposure, whereas it was reduced in β-cell failure-prone KsJ mice, the 
genetic background of the MIP-HSD1 mice. MIP-HSD1tg/+ mice show a comparable 
11β-HSD1 activity to C57BL/6J mice that robustly compensate (with 
hyperinsulinaemia) for insulin resistance. 
 
Others have shown that 11β-HSD1 activity mediated inhibition of islet insulin 
secretion (Davani et al. 2000; Swali et al. 2008). It has therefore been hypothesized 
that inhibition of 11β-HSD1 to decrease glucocorticoid activity in islets, will 
increased insulin release and protect against diabetes (Duplomb et al. 2004; Ortsater 
et al. 2005). Clinical studies using the prototypic drug, carbenoxolone (CBX), 
showed hepatic insulin sensitization in lean healthy subjects (Walker et al. 1995) and 
patients with type 2 diabetes (Andrews et al. 2003). It was also found that this 
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non-selective 11β-HSD1 inhibitor counteracted the suppressive effect of 11β-HSD1 
substrate provision on isolated islets of Lepob/ob mice (Davani et al. 2000; Ortsater et 
al. 2005), as did the selective inhibitor BVT. 2733 (Ortsater et al. 2005). However 
there were some conflicting results on whether there is an inhibitory effect of 
glucocorticoid on insulin secretion from isolated islets (Jeong et al. 2001; Hult et al. 
2009) which may be explained by differences in concentration of glucocorticoid or 
duration of exposure in culture. Crucially we have found that modest, chronic 
elevation of β-cell 11β-HSD1 to levels found in robustly compensating (C57BL/6J) 
mice is protective against β-cell failure. The increase islet 11β-HSD1 in C57BL/6J 
mice indicates this is a physiological mechanism, indeed the first from our 
knowledge where a beneficial metabolic effect is derived from increased levels of the 
11β-HSD1. However, the MIP-HSD1tg/tg and Lepdb/db mice show that any 
compensatory mechanism may eventually overshoot and lead to a detrimental 
suppression of β-cell function. Dissecting the suppressive from the beneficial effects 
of β-cell 11β-HSD1 overexpression may lead to the identification of novel 
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5 β-cell-specific overexpression of 11β-HSD1 reduces 
hyperglycaemia in streptozotocin-induced diabetes 
through anti-inflammatory effects 
5.1 Introduction 
Type 1 diabetes (T1D) is an autoimmune disease characterized by β-cell destruction. 
β-cell loss occurs through necrosis and apoptosis as a result of inflammation within 
islets (insulitis), which ultimately contributes to β-cell destruction. At early stages of 
T1D, inflammatory mediators induce and amplify the immune reaction against the 
β-cell. At later stages, inflammatory mediators suppress β-cell function, inhibit β-cell 
regeneration, stimulate peripheral insulin resistance and maintain insulitis (reviewed 
in Eizirik et al. 2009). 
 
A well-established rodent model for type 1 diabetes is streptozotocin (STZ) treatment. 
STZ is β-cell toxic and because its molecular structure is similar to glucose (Figure 
5.1) it is taken up selectively by the glucose transporter 2 (GLUT 2) which is highly 
expressed in the pancreatic β-cell. The mechanism of STZ induced β-cell death is 
related to its alkalising induced DNA damage. STZ also causes DNA methylation 
including N7-methylguanine (7-MeG), N3-methyladenine (3-MeA), and 
O6-methylguanine (6-MeG) (reviewed in Bolzan and Bianchi 2002). Two 
experimental methods are commonly used to induce diabetes by STZ. The first 
model uses multiple low-dose STZ for 5 consecutive days in order to cause a mild 
β-cell loss and delayed-onset mild hyperglycaemia. In this model, β-cell death is 
mainly by apoptosis (O'Brien et al. 1996) due to accumulation of 3-MeA and/or 
6-MeG (Glassner et al. 1999). The second uses a single high dose of STZ which 
causes almost complete β-cell death and a rapid onset of hyperglycaemia. Necrosis is 

















DNA adducts (3-MeA) by high dose of STZ, the Base Excision Repair (BER) 
pathway is over-activated and causes extensive activation of poly adenosine 
5’diphosphate-ribose polymerase (PARP), rapid depletion of cellular Nicotinamide 
adenine dinucleotide (NAD+) and cell death through necrosis (Murata et al. 1999). A 
















                                              
 
 
Figure 5-1. Structure of glucose and streptozotocin (STZ). The structures of 
glucose and STZ were determined by (Herr et al. 1967). Broken circle lines show the 






Under normal physiological conditions, the β-cell mass remains linear with body 
weight (Bonner-Weir 2000). β-cell mass is maintained through slow renewal and the 
β-cell half-life has been estimated at 30-60 days in young rats (Finegood et al. 1995). 
In humans stable β-cell mass is largely established by 20 years of age (Cnop et al. 
2010). The slow rate of β-cell proliferation is balanced to compensate for their low 
level of turnover (Dor et al. 2004; Teta et al. 2007). In the pre-diabetic condition, 
hyperglycaemia increases both β-cell function (Chen et al. 1994) and islet mass in 
the short-term (Bonner-Weir and Smith 1994; Alonso et al. 2007). The adult islet 
mass expansion is predominantly through hypertrophy of existing β-cells (Jonas et al. 
1999), β-cell proliferation (Dor et al. 2004; Teta et al. 2007), and neogenesis from 
progenitors also feature. Since there was a protective effect of β-cell specific 
11β-HSD1 overexpression on β-cell number, function and survival with the low 
grade inflammation of type 2 diabetes, we were also interested to look at the 
numerous cell types proposed as possible pancreatic progenitors that could support 
generating new β-cell in the type 1 diabetes model. Thus, acinar cells (Zhou et al. 
2008; Sangiorgi and Capecchi 2009); ductal epithelial cells (Bonner-Weir 2000; Xu 
et al. 2008); centroacinar cells (Rovira et al. ; Hayashi et al. 2003; Nagasao et al. 
2003); mesenchymal-like nestin-expressing cells (Zulewski et al. 2001) and 




Figure 5-2. Possible ways for survival or recovery of β-cell mass after 
STZ-induced toxicity. STZ-induced β-cell loss and hyperglycaemia can be 
compensated by increasing islet β-cell hypertrophy; neogenesis, and β-cell 
proliferation from existing β-cells. 
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Besides the potential direct diabetogenic properties of GCs on β-cells and their 
promotion of peripheral insulin resistance (details in 1.4.3.3) (Lambillotte et al. 
1997), GCs play an important part in pancreatic β-cell development (details in 
1.4.3.1). Furthermore, GCs inhibit cell replication and induce differentiation by 
arresting the cell cycle at G1-phase in vitro (Rogatsky et al. 1997) in epithelial cells 
(Goya et al. 1993; Buse et al. 1995), fibroblasts (Frost et al. 1994), hepatoma cells 
(Cook et al. 1988; Sanchez et al. 1993), lung cancer cells (Greenberg et al. 2002) and 
pancreatic AR42J cells (Eum et al. 2003). Furthermore, overexpression of human 
11β-HSD1 in osteosarcoma cells reduces their rate of replication (Rabbitt et al. 2002). 
And, high dose dexamethasone (1 and 0.5 mg/kg) and hydrocortisone (25mg/kg) 
increases rat β-cell replication in vivo (Rafacho et al. 2009; Jorns et al. 2010; 
Rafacho et al. 2010). In β-cells in vitro, GCs can induce β-cell apoptosis (Ranta et al. 
2006). Administration of hydrocortisone (25mg/kg) in vivo increases apoptosis, 
counteracting stimulated proliferation of rat β-cell (Jorns et al. 2010). However, 
contrasting evidence showed that dexamethasone reduced β-cell apoptosis in the 
presence of cytokines in vitro (Chou et al. 2010). Thus it remains unclear what the 
dominant and direct effect of altered β-cell glucocorticoid action has on the 
progression of type 1 diabetes.  
 
GCs are well known for their immunosuppressive and anti-inflammatory effects 
(Described in 1.4.3.2). This included increased macrophage-mediated ingestion of 
apoptotic leukocytes (Liu et al. 1999), induction of monocytes into highly phagocytic 
anti-inflammatory macrophages (Giles et al. 2001; Heasman et al. 2003), suppression 
of a number of transcriptional factors expressed in macrophages such as NF-κB, 
AP-1 and STAT families to alter the immune response (De Bosscher and Haegeman 
2009), and regulation of the Th1/Th2 balance (Kovalovsky et al. 2000). GCs may 
therefore improve islet function by suppressing local inflammation (Figure 5-3), as 
suggested by others who used dexamethasone treatment in islets in vitro (Hult et al. 






Figure 5-3. Regulatory influence of GCs on immune cells and cytokines found in 
STZ-induced diabetes. PARP increases through the BER pathway to repair adduct 
DNA damage caused by the alkylating effects of STZ which is taken up by GLUT2. 
The overactivated PARP rapidly depletes intracellular NAD+ leading to β-cell 
destruction. The dying β-cells and the antigen (Ag) released from them are perceived 
by dendritic cells (DC) or macrophages to secrete IL-12 that activates CD4+ Th1 
cells. The active Th1 cells produce IL-2 and IFNγ which inhibit CD4+ Th2 cells and 
its production of IL-4 and IL-10 that have protective effects. IL-2 and IFNγ also can 
activate both macrophages to synthesize β-cell toxic IL-1, TNFα, IFNγ, NO; and 
β-cell cytotoxic CD8+ cells with the additional production of IFNγ. GCs can suppress 
the immunoresponse by inactivating macrophages, CD4+ Th1, CD8+cells, along with 





































Basal plasma corticosterone level is significantly increased in STZ induced diabetic 
rats (Chan et al. 2005), with no change in GR content in the pancreas (Svec 1985; 
Ranhotra and Sharma 2000). However, whether GCs impacts upon STZ induced 
diabetes is unknown.  
 
11β-HSD1 is the enzyme that amplifies glucocorticoid action in many tissues 
(Described in Chapter 1). 11β-HSD1 is predicted to have an anti-inflammatory role 
as it is expressed in immune cells and regulates both innate and adaptive immune 
responses (reviewed in Chapman et al. 2009). 11β-HSD1 is expressed in pancreatic 






Our initial hypothesis was that elevated local GC regeneration would have a negative 
effect on GSIS, thus promoting diabetes in a model of diet-induced β-cell failure. 
However, having shown that chronically but modestly elevated β-cell 11β-HSD1 
rescued β-cell function, we went on to hypothesise that:  
 
Elevated β-cell 11β-HSD1 protects β cells from STZ induced β-cell damage. 
 
5.3 Aims 
To test the effects of β-cell-specific overexpression of 11β-HSD1 on: 
 
1. β-cell destruction of STZ-induced diabetes 
2. β-cell regeneration after STZ treatment 
3. Inflammatory responses to STZ treatment 
4. β-cell apoptosis after STZ treatment 
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5.4 Experimental Design 
5.4.1 Induction of type 1 diabetes in mice with streptozotocin 
Low-dose STZ: Mice were treated i.p. for 5 consecutive days with saline or 
40mg/kg/BW STZ dissolved in saline. Blood samples were taken from the tail vein 
at day 0, 4, 12, and 15 for glucose and insulin levels. 
 
High-dose STZ: Mice were given a single bolus i.p. injection of either 10mM citrate 
buffer (pH4.5) or STZ (180mg/kg/BW, dissolved in 10mM citrate buffer). Blood 
glucose was measured daily via tail venesection. Mice were sacrificed at 3 and 10 
days after STZ treated.  
 
Experimental mice were age matched (10-12 week). Blood samples were taken at 
day one, and trunk blood was collected on the last day. Heads of pancreata were 
harvested and frozon at -80°C and tails of pancreata were fixed in 10% formalin for 
IHC. 
5.4.2 Assessment of diabetes after streptozotocin treatment 
Plasma glucose was measured by glucose meter (Described in chapter 2.6.1.), and 
insulin level was measured by mouse insulin ELISA kit (Described in chapter 2.6.2.). 
Morphology and insulin content was assessed by IHC and H&E counterstain 
(Described in chapter 2.16) 
5.4.3 Assessment of β-cell proliferation after streptozotocin 
treatment 
Ki67 and PDX1 were co-stained by IF (Described in chapter 2.17). Ki67 is a nuclear 
protein expressed in proliferating cells and is present during all active phases of the 
cell cycle, but is absent from resting cells (G0). Ki67 is used as a cellular marker for 
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proliferation (Bullwinkel et al. 2006).. Pancreatic and duodenal homeobox1 (PDX1) 
is an important insulin gene transcription factor, and a necessary transcriptional 
factor for pancreatic development and β-cell maturation (Hui and Perfetti 2002). 
Cells co-expressing Ki67 and PDX1 thus delineate proliferation occurring in insulin 
producing cells which was interpreted as β-cells undergoing proliferation or 
replication. Quantitation for PDX1 and Ki67 positive cells was as described in 
chapter 2.2.12.  
5.4.4 Assessing the inflammatory status of the pancreas after 
streptozotocin treatment 
Mac-2 also known as Galectin-3 (Gal-3), eBP, IgE binding protein, CBP-35, CBP30, 
L-34 and L-29 is a 32-kDa β-galactosidase-binding lectin widely distributed in cells, 
but is enriched in cells of the monocyte/macrophage lineage 6. Mac-2 is widely used 
as an activated macrophage marker (Liu et al. 1995; Dumic et al. 2006) to detect 
macrophage infiltration. 
 
Foxp3 (X-linked forkhead/winged helix transcription factor) is expressed at the 
highest level in CD4+CD25+ T regulatory cells and has emerged as an important 
marker of T regulatory cells (Fontenot and Rudensky 2005). Quantitation was carried 
out for Foxp3 (Described in chapter 2.2.12). 
5.4.5 Assessment of β-cell neogenensis after streptozotocin 
treatment 
Pancreatic β-cell neogenesis was determined with Neurogenin 3 (Ngn3) and 
SRY/HMG box 9 (Sox9) within pancreatic tissue. Neurogenin 3 (Ngn3) is a basic 
helix-loop-helix protein which is detected in a currently ill-defined subpopulation of 
cells scattered within the early pancreatic region during development, and is required 
for endocrine cell development (Gradwohl et al. 2000). Ngn3 is widely used to detect 
newborn endocrine cells in injured pancreas. Sox9 is expressed in the adult 
pancreatic ductal epithelium (Akiyama et al. 2005) and is essential for pancreatic 
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development and activation of the endocrine cell differentiation program (Lynn et al. 
2007). 
5.4.6 Detection of β-cell apoptosis after streptozotocin treatment 
Apoptotic pancreatic β-cells were detected by deoxynucleotide transferase (TdT) 
mediated dUTP nick-end labeling (TUNEL) assay. The TUNEL system measures the 
fragmented DNA of apoptotic cells by catalytically incorporating 
fluorescein-12-dUTP at 3'-OH DNA ends using the enzyme terminal TdT, which 
forms a polymeric tail using the principle of the TUNEL assay. TUNEL was widely 
used to detect apoptotic β-cells in NOD mice (Kurrer et al. 1997; Augstein et al. 
1998; Augstein et al. 1998; Kim et al. 1999).  
 
Caspase-3 is a critical mediator of apoptosis, being responsible for the proteolytic 
cleavage of many key proteins in this process (Fernandes-Alnemri et al. 1994). An 
antibody to cleaved caspase-3 was used to detect pancreatic apoptosis in whole 
pancreas lysates (Aizman et al. 2010). 
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5.5 Results 
5.5.1 MIP-HSD1tg/+ mice show transiently reduced 
hyperglycaemia diabetes with high-dose STZ 
5.5.1.1 MIP-HSD1tg/+ mice show partial rescue of hyperglycaemia induced by 
high-dose of STZ 
High-dose STZ (180mg/kg/BW) causes massive β-cell destruction and leads to 
permanent and profound hyperglycaemia. All genotypes became hyperglycaemic 
within two days of high dose STZ and there was no significant difference among the 
groups suggesting equal severity of the initial insult and β cell destruction. However, 
after two days MIP-HSD1tg/+ mice exhibited a transient, small but significant 
oscillatory improvement in their hyperglycaemia. (Figure 5-4) 
 
Three days after high-dose STZ treatment, plasma insulin level was markedly 
decreased in KsJ, MIP-HSD1tg/+ and MIP-HSD1tg/tg mice (Figure 5-5). However, 
MIP-HSD1tg/+ and MIP-HSD1tg/tg mice maintained higher insulin levels than KsJ at 
day 3, consistent with their oscillatory protection from hyperglycaemia. By day 10, 
MIP-HSD1tg/+ maintained a higher insulin level than KsJ. 
 
Pancreatic tissue was stained for insulin protein by immunohistochemistry. In all 
genotypes of mice, insulin was localized specifically within the islets. Islet number 
and size was reduced at day 3 and 10 post STZ, most noticeably in KsJ mice 
compared to MIP-HSD1 mice which clearly exhibited stronger insulin staining 


















Figure 5-4. MIP-HSD1tg/+ mice exhibit a transient, oscillatory improvement in 
hyperglycaemia after high dose STZ. Age-matched mice were given a single bolus 
i.p. injection of either 10mM citrate buffer (pH4.5) or STZ (180mg/kg/BW, dissolved 
in 10mM citrate buffer). Blood glucose was measured via tail vein venesection 
everyday for 10 days. Values represent the mean ± S.E.M, **P<0.01, (One-way 


















Figure 5-5. MIP-HSD1 mice maintain a higher insulin level than KsJ after high 
dose STZ. Age-matched mice were given a single bolus i.p. injection of either 
10mM citrate buffer (pH4.5) or STZ (180mg/kg/BW, dissolved in 10mM citrate 
buffer). Plasma insulin was measured in blood samples the day before STZ injection 
and at day 3 and day 10 post STZ injections. Values represented the mean ± S.E.M, 
**P<0.01 (One-way ANOVA, Tukey's Multiple Comparison Test), control group 












































Figure 5-6. MIP-HSD1tg/+ islets exhibit higher insulin content after high dose 
STZ. Pancreas was fixed in 10% formalin and embedded in paraffin/wax. 
Immunohistochemistry staining for insulin was achieved using guinea pig 
anti-insulin (1:300 dilution) performed on 4µm section. (A-C) KsJ, (D-F) 
MIP-HSD1tg/+, (G-I) MIP-HSD1tg/tg; (A, D, G) without STZ treatment, (B, E, H) STZ 
treated for 3 days, (C, F, I) STZ treated for 10 days. Islet capsule is indicated by the 
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5.5.1.2  MIP-HSD1tg/+ mice maintain higher β-cell mass and proliferation after 
high-dose STZ 
To explore how the MIP-HSD1tg/+ could partially resist high-dose STZ induced 
hyperglycaemia, we investigated their β-cell proliferation capacity using 
immunofluorenscence by co-staining with Ki67 and PDX1 (Described in 5.3.4).  
 
Control pancreas exhibited proliferating β-cells in both KsJ and MIP-HSD1 
transgenic mice (Figure 5-7). After high dose-STZ injection, β-cell number reduced 
dramatically in all groups. We were unable to observe PDX1 staining at day 10 in 
KsJ mice. MIP-HSD1tg/+ and MIP-HSD1tg/tg had higher numbers of remaining β-cells 
(insulin) after 3 days and clearly detectable β-cells at day 10 (Figure 5-7). 
 
β-cell proliferation was comparable between KsJ and MIP-HSD1 mice in the 
vehicle-treated group (Figure 5-8). At day 3 post STZ, PDX1 staining and therefore 
β-cell number decreased in all groups, with the greatest decrease observed in KsJ 
mice. Ki67+ proliferating cells decreased from day 3 to day 10 in KsJ mice, as did 
PDX1 staining, which was absent in pancreas of KsJ mice at day 10. MIP-HSD1tg/+ 
and MIP-HSD1tg/tg mice maintained PDX1+ cells (β-cell) and higher Ki67+ cell 
numbers at day 10 than KsJ mice. MIP-HSD1tg/+ and MIP-HSD1tg/tg mice had 
detectable PDX1/Ki67 double-positive cells (proliferating β-cell) at day 10 (Figure 
5-8). Overall this suggests MIP-HSD1tg/+ and MIP-HSD1tg/tg mice retain a higher 














Figure 5-7. MIP-HSD1 mice have a higher β-cell proliferative cell number after 
STZ treatment. Pancreas sections were stained using immunofluorenscence 
co-stained by rabbit anti-Ki67 (1:3000 dilution, green), rabbit anti-PDX1 (1:1000 
dilution, red) and, DAPI (1:1000 dilution, blue) as a nuclear stain. (A-C) KsJ, (D-F) 
MIP-HSD1tg/+, (G-I) MIP-HSD1tg/tg; (A, D, G) without STZ treatment, (B, E, H) STZ 
treated for 3 days, (C, F, I) STZ treated for 10 days. Arrows indicate double positive 
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Figure 5-8. Higher double PDX-1 and Ki67 positive staining cells in islets of 
MIP-HSD1 mice. Quantitation using Image J software was employed for the light 
microscopy images. PDX1 and Ki67 positive cells were counted within the islets as 
defined morphologically by the islet capsule boundary through the section. The rate 
of proliferating β-cells was presented as ratio of PDX1, Ki67 double-positive cells to 
PDX1 positive cells in each islet then averaged for each group. PDX1 was 
undetectable for KsJ STZ treated for 3 and 10 days (n.d). Values represented the 
mean ± S.E.M, (One-way ANOVA, Tukey's Multiple Comparison Test), control 
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5.5.1.3 MIP-HSD1tg/+ mice show ameliorated islet inflammation after high-dose 
STZ 
5.5.1.3.1 MIP-HSD1tg/+ mice showed reduced macrophage infiltration after 
high-dose STZ 
Islet macrophage infiltration is an early event where inflammation is initiated in T1D 
and STZ-induced diabetes. Critically, macrophage infiltration is an absolute 
requirement for the development of T1D in animal models (Mandrup-Poulsen 1996) 
as potent and critical immune regulators (Kolb et al. 1990; Lukic et al. 1998; 
Homo-Delarche and Drexhage 2004). Locally elevating the GCs level can suppress 
inflammation by inhibiting lymphocyte proliferation and cytokine production. As a 
consequence, tissue macrophage responses are also affected (Gillis et al. 1979; 
Larsson 1980). To investigate whether MIP-HSD1 protected β-cells from 
anti-inflammatory effects, pancreatic tissue was stained with Mac-2 antibody which 
is a marker for activated macrophages (Described in 5.2.1). 
 
Before STZ injection, KsJ and MIP-HSD1 had very few macrophages within the 
islets and among the acinar tissue. On day 3 after STZ, there was an increase in the 
number of activated macrophages in KsJ islets compared to MIP-HSD1. The active 
macrophage numbers were diminished by day 10 in all genotypes (Figure 5-9). 
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Figure 5-9. MIP-HSD1 mice exhibit reduced islet macrophage infiltration at day 
3 after STZ treatment. Pancreas was fixed in 10% formalin and embedded in 
paraffin/wax. Immunohistochemistry staining for Mac-2 using rabbit anti-mac-2 
(1:150 dilution) performed on pancreas sections. (A-C) KsJ, (D-F) MIP-HSD1tg/+, 
(G-I) MIP-HSD1tg/tg; (A, D, G) without STZ treatment, (B, E, H) STZ treated for 3 
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5.5.1.3.2 MIP-HSD1tg/+ mice exhibit a pronounced Foxp3 T-regulatory cell 
infiltration after high-dose STZ 
T regulatory cells are a subpopulation of T cells that maintain immune system 
homeostasis by suppressing immune responses (Van Parijs and Abbas 1998). To test 
whether MIP-HSD1 showed evidence of immunosuppressive T regulatory cells, we 
stained with the Treg marker Foxp3 (Described in 5.2.2).  
 
Very few T regulatory cells were found in normal pancreas of all groups under 
normal conditions. Three days post STZ treatment, T regulatory cells were slightly 
increased in all genotypes, with a pronounced pattern within or surrounding the 
remaining islets. However, 10 days post STZ, MIP-HSD1tg/+ mice showed evidence 
for markedly increased T regulatory cell number relative to KsJ and MIP-HSD1tg/tg 
mice (Figure 5-10). 
 
The number of Foxp3 positive cells was quantified in all groups of mice by 
computerized image analysis. T regulatory cell content was presented as the ratio of 
Foxp3+ cells relative to the area of whole pancreas. Notably, in non-STZ treated 
pancreas, MIP-HSD1tg/tg mice showed a significantly higher T regulatory cell content 
versus KsJ. Three days post STZ treatment, all genotypes tended to increase T 
regulatory cell content but not significantly. Ten days post STZ treatment, T 
regulatory cells clearly increased in all groups compared to day 0. The greatest 
increase (10-fold) in T regulatory cell content was observed in MIP-HSD1tg/+ mice 
(Figure 5-11).  
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Figure 5-10. MIP-HSD1tg/+ mice exhibit markedly increased T-regulatory cell 
numbers ten days after STZ administration. Pancreas was fixed in 10% formalin 
and embedded by paraffin/wax. Immunohistochemistry staining for Foxp3 using rat 
anti-Foxp3 (1:150 dilution) was performed on pancreas section. (A-C) KsJ, (D-F) 
MIP-HSD1tg/+, (G-I) MIP-HSD1tg/tg; (A, D, G) without STZ treatment, (B, E, H) STZ 
treated for 3 days, (C, F, I) STZ treated for 10 days. Islet capsule is indicated by the 



























Figure 5-11. Quantitation of T regulatory cells in MIP-HSD1 pancreas with and 
without STZ. Quantitation using computerized image analysis. Foxp3 positive cells 
were counted by Zeiss (KS300, 3.0) software throughout the section; section area 
was measured by MCID Basic 7.0. Each individual mouse value was calculated from 
averaging at least three sections, which were more than 100μm apart (to avoid 
counting the same islet twice). Y-axis represents the ratio of positive Foxp3 cells to 
whole section area. Values represent mean ± S.E.M, ***P<0.0001, (vs. KsJ Day 10), 
§§§P<0.0001, §§P<0.01, §P<0.05 (vs. MIP-HSD1tg/+ Day 10), # P<0.05 (vs. 
MIP-HSD1tg/tg Day 10), ＆ P<0.05 (vs. MIP-HSD1tg/tg Day 0) (One-way ANOVA, 


























5.5.1.4 Investigation of islet neogenesis with Neurogenin 3 and Sox 9 after 
high-dose STZ 
β-cell neogenesis is considered as an important mechanism counteracting 
hyperglycaemia induced by β-cell injury. Among the progenitor markers, 
Neurogenin 3 (Ngn3) which is important for endocrine cells during pancreatic 
development has been widely used to detect β-cell neogenesis. In addition, Sox9 is a 
marker recently found to be essential for pancreatic development and the regulation 
of endocrine cell differentiation (Akiyama et al. 2005). 
 
Figure 5-12 shows that Ngn3 positive cells are scattered throughout pancreatic tissue, 
a few of them within the islets. Groups of Ngn3 positive cells are found in blood 
vessels, and are highly prevalent in spleen and stomach. Sox9 is expressed in adult 
pancreatic ductal epithelium. Therefore, the Sox9 positive cells were widely spread 
in pancreas (Figure 5-13). The computer imaging analysis method (Image Pro MC 
software) was used to quantify Sox9 positive cells by comparing the density of Sox9 
positive area on 13 to 30 random selected areas per section per mouse. There was no 
difference observed between day 0 and day 3 after STZ in KsJ mice. However 
MIP-HSD1tg/+ mice showed significantly a reduced Sox9 expression. In contrast, 




Figure 5-12. Ngn3 staining is scattered in adult pancreas compared to other 
tissues. Pancreas was fixed in 10% formalin and embedded by paraffin/wax. 
Immunohistochemistry staining for Ngn3 using rabbit anti-Ngn3 (1:1000 dilution) 
performed on pancreas section. (A-C) KsJ, (D-F) MIP-HSD1tg/+, (G-I) MIP-HSD1tg/tg; 
(A, D, G) without STZ treatment, (B, E, H) STZ treated for 3 days, (C, F, I) STZ 
treated for 10 days. Ngn3 positive cells were scattered in pancreatic tissue (A-I) or 
group appeared in blood vessels (J), or expressed in spleen (K) and stomach (L). Islet 
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Figure 5-13. Sox9 is expressed in ductal cells and widely scattered in undefined 
cells in the pancreas. Pancreas was fixed in 10% formalin and then embedded in 
paraffin/wax. Immunohistochemistry staining for Sox9 was with a rabbit anti-Sox9 
(1:8000 dilution) anti-body and was performed on pancreas sections. (A-C) KsJ, 
(D-F) MIP-HSD1tg/+, (G-I) MIP-HSD1tg/tg; (A, D, G) without STZ treated, (B, E, H) 
STZ treated for 3 days, (C, F, I) STZ treated for 10 days. Islet capsule is indicated by 
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Figure 5-14. Quantitation of Sox9 in the pancreas after 3 days of STZ treatment. 
Pancreas was fixed in 10% formalin and embedded in paraffin/wax. 
Immunohistochemistry staining for Sox9 was obtained using rabbit anti-Sox9 
(1:8000 dilution) performed on pancreas section. Quantitation was achieved using 
computerized image analysis. Sox9 positive cells area density was counted by Image 
Pro MC software throughout the section. Values represent mean ± S.E.M, * P<0.05 
(One-way ANOVA, Tukey's Multiple Comparison Test), control group n=5-7, STZ 
experiment group n=6-10. 
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5.5.1.5 Investigation of islet apoptosis after high-dose STZ 
TUNEL assay was used to detect β-cell apoptosis. Almost no apoptotic cells were 
found in the pancreatic tissues regarding the genotypes and treatments. In addition 
Western blot was used to determine the level of cleaved caspase-3 which gives an 
indication of the activation of the apoptotic pathway (apoptotic cells marker). 
Pancreatic lysates of KsJ mice at different days after STZ were blotted with cleaved 
caspase-3 antibody. Spleen was used as a positive control. Consistent with TUNEL 
results there was no specific apoptotic bands in KsJ mouse pancreas, while the 
positive control spleen had a specific band (Figure 5-15). Therefore, using whole 
pancreas resulted in a loss of sensitivity to detect apoptosis within islets by this 
method. Apoptosis levels were clearly low in the high dose STZ model and the lack 
of quantifiable cell numbers made it impossible to draw any conclusions on the 
impact of MIP-HSD1 on apoptosis in islets. The tentative conclusion is that there is 
no significant effect on this process in this model. 
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Figure 5-15. Evaluation of β-cell apoptosis after STZ treatment. TUNEL staining 
for paraffin fixed pancreas. Apoptotic cells were stained by TUNEL (green), nuclei 
were stained with DAPI (blue). No difference was found between the groups. 
Representative pictures shown above were (A-C) KsJ, (D-F) MIP-HSD1tg/+, (G-I) 
MIP-HSD1tg/tg; (A, D, G) without STZ treatment, (B, E, H) STZ treated for 3 days, 
(C, F, I) STZ treated for 10 days. Magnification ×40. Cleaved Caspase-3 (Casp-3, 1 
in 1000 dilution, 17kDa) was performed in KsJ pancreas by western blot. Spleen was 
used as a positive control, actin was used as internal loading control. No bands were 
observed for caspase-3 in KsJ whole pancreas tissue with or without STZ treatment. 
A representative image is shown (J). 
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5.5.2 MIP-HSD1tg/+ mice resist multiple low-dose STZ-induced 
mild hyperglycaemia 
Low-dose STZ causes delayed onset mild diabetes through β-cell damage and 
immunological injury. KsJ and MIP-HSD1tg/+ mice were treated with low-dose STZ 
(40mg/kg/BW) for five days. In the STZ-treated KsJ group, glycaemia increased 
from day 4. After day 12, the KsJ group became maximally hyperglycaemic for this 
dose of STZ. However, the increase of plasma glucose levels in the MIP-HSD1tg/+ 




















Figure 5-16. Plasma glucose level after multiple low-dose STZ. Mice were i.p. 
injected either with saline or STZ (40mg/kg/BW) dissolved in saline for 5 
consecutive days. Blood samples were taken from tail at day 0, 4, 12, and 15. Black 
solid line-KsJ control group; red solid line-MIP-HSD1tg/+ control group; black dots 
line-KsJ STZ group; red dots line-MIP-HSD1tg/+ STZ group. Values represented the 
mean ± S.E.M, **P<0.005, *P<0.05, (Student t-test), control group n=3, STZ 

















The present study demonstrated that chronic modest elevation 11β-HSD1 
specifically in pancreatic β-cells caused a small but significant reduction of the 
hyperglycaemia induced by high-dose and low-dose STZ treatment.  
 
The protection from diabetes was mediated by an increased number of remaining β- 
cells. Since the initial insult with high dose STZ led to similar hyperglycaemia, it 
suggests either a qualitatitive difference in the initial insult followed by an 
unmasking or improved survival of the existing MIP-HSD1 β-cells, or that the 
recovery of β-cell through other means is improved in MIP-HSD1 mice, or both. 
Methodological limitations made it impossible to formally measure any increase in 
β-cell neogenesis with the currently advocated markers Ngn3 (successfully used in a 
pancreatectomy model) and Sox9. There were greater numbers of PDX+-Ki67+ cells 
indicative of maintained β-cell proliferation in the MIP-HSD1 islets. Moreover, there 
was clear evidence for reduced pro-inflammatory macrophage infiltration and 
increased immuno-regulatory, pro-resolution mediating Foxp3+ T regulatory cells. 
 
The loss of β-cells was more rapid and severe in KsJ mice after STZ, whereas the 
number of proliferating cells (non-PDX+) which surrounded the destroyed islet 
region increased. These non-endocrine proliferating cells may consist of 
inflammatory cells and/or α-cells, which are increased in STZ-treated mice (Li et al. 
2000). 
 
Macrophage infiltration is an early response to the islet release of pro-inflammatory 
cytokines, such as IL-1, IFNγ and TNFα which are important for β-cell destruction 
(Mandrup-Poulsen 1996). Moreover, depletion or inactivation of macrophages 
prevents the development of T1D (Oschilewski et al. 1985; Hutchings et al. 1990). 
MIP-HSD1tg/+ mice had reduced macrophage infiltration three days after high-dose 
STZ. This is likely due to decreased release of pro-inflammatory cytokines resulting 
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in a lower severity β-cell destruction and death. Ten days after high-dose STZ, the 
phenomenon of macrophage infiltration was reduced in all genotypes suggesting this 
pro-inflammatory response to dying β-cells and their clearance was complete. 
Notably, the Mac-2 (galectin-3) is expressed on macrophages and monocytes and it 
regulates immunoregulatory function of macrophages. Deletion of galectin-3 
attenuated multiple low-dose STZ induced hyperglycaemia (Mensah-Brown et al. 
2006), further emphasising its expression here as a read out of the inflammatory 
macrophage response.  
 
T lymphocytes (T-cells) are also widely accepted as important effectors in T1D. It 
has been hypothesized that the pathogenic cellular immune response is mediated by 
Th1 cells, a subset of T cells characterized by secretion of IL-2 and INFγ which 
induce macrophages and CD8+ cells to secrete proinflammatory cytokines. 
Alternately, the protective humoral immune response is mediated by Th2, a subset of 
T cells that synthesize IL-4 and IL-10 which are considered as anti-inflammtory 
effectors (Rabinovitch 1994). The balance between Th1 and Th2 within the islet 
microenvironment may influence the development of T1D. CD4+CD25+ (Th2) cells 
known as T regulatory cells (Treg) constitute 5-10% of peripheral CD4+ T cells 
(Sakaguchi 2004). Although the nature and diversity of Treg cells remains unclear, 
Foxp3 which is expressed at the highest level in CD4+CD25+ T cells has emerged as 
an important marker for Tregs (Fontenot and Rudensky 2005). The MIP-HSD1tg/+ 
mice exhibited significantly increased Treg cell numbers after ten days high-dose 
STZ treatment. This could reflect the modestly higher level of active GCs which 
have known modulatory effects on induction of a Th2 response (Ramirez 1998). 
Furthermore, the high level of Tregs in MIP-HSD1tg/tg mice even in the absence of 
STZ treatment suggests that a higher level of 11β-HSD1 may affect a subtle change 
within the islet microenvironment leading to an effectively initial resistance to the 
inflammatory insult. This is consistent with a later dimunition of Tregs in 
MIP-HSD1tg/tg compared to MIP-HSD1tg/+ at ten days post-injection. However, three 
days after STZ, there was no change in Treg numbers in any genotypes, consistent 
with an early pro-inflammatory response followed by a gradual recruitment and 
replacement with resolving, immune-dampening Tregs.  
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Although neogenesis of β-cells in adult pancreas is still controversial (Dor et al. 2004; 
Teta et al. 2007), β-cell regeneration from a variety of progenitor cells occurs in 
several pancreatic injury models (Fernandes et al. 1997; Zulewski et al. 2001; 
Hayashi et al. 2003; Xu et al. 2008; Sangiorgi and Capecchi 2009). This is a potential 
mechanism whereby the pancreas regenerates insulin producing cells from other cell 
types, and therefore could mediate diabetes-resistance. However, there is currently 
no satisfactory and specific marker to detect neogenesis of β-cells in adult injury 
response to STZ. The marker widely used is Neurogenin 3 (Ngn3) which is 
important for endocrine cell differentiation during neonatal pancreatic development. 
Sox9 was also recently found to be essential for pancreatic development and 
endocrine cell differentiation: pancreatic cells from all lineages derive from 
Sox9-expressing precursors (Akiyama et al. 2005). Ngn3 positive cells were 
scattered in pancreatic tissue, with prominent staining in blood vessels in the 
pancreas, and high expression in spleen and stomach. It is concluded that this marker 
is not specific for pancreatic endocrine precursor cell staining in the adult STZ-injury 
mouse model. 
 
Sox9 changes suggested that progenitor cells are differentiated more extensively to 
endocrine cells in MIP-HSD1tg/tg after 3 days STZ treatment. However, this data 
must be interpreted with caution as the MIP-HSD1tg/+ mice that exhibit a marked 
protection from diabetes indeed greater than MIP-HSD1tg/tg in response to high-dose 
STZ, showed lower Sox9 expression 3 days after STZ treatment. Sox9 is expressed 
in adult pancreatic ductal epithelium but also in ill-defined cells throughout the 
pancreas. Therefore, the Sox9 staining requires careful further co-localisation with 
β-cell specific markers to determine cell type specific expression patterns. It is 
intriguing that the Sox9 expression shows a U-shaped dose-response opposite to that 
of the MAC2 staining pattern. This suggests an impact of the transgene induced GC 
levels, although the exact meaning of this change is unclear. 
 
Apoptosis is a major form of β-cell death in rodent T1D models, as high glucose 
contributes to β-cell apoptosis (Ohneda et al. 1995; Donath et al. 1999; Liu et al. 
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2000; Butler et al. 2003; Marchetti et al. 2004). Apoptosis is considered the main 
form of β-cell death for multiple low-dose STZ with the percentage of apoptotic 
β−cells at high levels at day 5 and 11 post-injection (O'Brien et al. 1996). Although 
apoptosis is not a major reason for high dose STZ induced β-cell death, the apoptosis 
incidence was estimated with caspase-3 western blot and TUNEL assay. Very few 
apoptotic cells were detected by the TUNEL method and there were no differences 
between the groups in different conditions. Western blot also failed to detect 
apoptotic cells in pancreatic lysates of KsJ mice using an antibody to cleaved 
caspase-3, despite a clear positive control band in equal amounts of a control tissue, 
spleen. This contrasts with the published work of others showing abundant apoptosis 
(Aizman et al. 2010). Thus, apoptosis does not play a major role for high-dose 
STZ-mediated cell destruction, at least for the time points chosen. Our data suggest 
that in vivo there is simply a low frequency of β-cell apoptosis with rapid clearance 
or disposal. Indeed this turnover has been estimated to be from 1.7min (Kurrer et al. 
1997) to 11min (Augstein et al. 1998) in vivo for NOD mice and BB rats two 
alternative models of type 1 diabetes. Alternatively, the time window chosen here 
may have missed the major wave of apoptosis. In addition to this, the infiltrating 
immune cells, rather than β-cell death could contribute to the number of apoptotic 
cells in and surrounding islets (Augstein et al. 1998). The present data do not support 
a role for GCs in β-cell apoptosis at least as a major factor underlying the difference 
in β-cell numbers in MIP-HSD1 mice basally or post-STZ. 
 
STZ induced β-cell destruction is dependent on the density of GLUT2. Although 
GCs suppress GLUT2 expression level in β-cells (Ogawa et al. 1992), our previous 
results in the high fat induced diabetes model suggest glucose is, if anything, better 
metabolized in MIP-HSD1tg/+ β-cell (Described in chapter 4). This implies glucose is 
likely efficiently taken up by GLUT2 in MIP-HSD1tg/+ mice, and strongly argues 
against the case that MIP-HSD1tg/+ β-cell sequester less STZ, as a mechanism of 
lower initial β-cell destruction. This notion is supported by the comparable initial 
high glucose levels following high dose STZ in KsJ and MIP-HSD1. GLUT2 is also 
expressed in hepatocytes and proximal renal tubules of kidney (Burcelin et al. 1992; 
Noonan et al. 2001) where STZ can transiently contribute to the hyperglycaemia. 
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Whilst we have not estimated liver and kidney GLUT2 expression, we predict that 
non-pancreatic effects for STZ are comparable in all genotypes. 
 
In conclusion, the data showed that chronic modest elevation of 11β-HSD1 
specifically in pancreatic β-cells ameliorats the hyperglycaemia induced by high and 
low dose STZ. Even though the mechanism by which high 11β-HSD1 mediates its 
effects are only partly elucidated so far, these results strongly demonstrated that 
β-cell proliferation and anti-inflammatory effects of 11β-HSD1 play a crucial role in 
protection of β-cells from STZ injury and recovery. MIP-HSD1tg/tg mice exhibited a 
less protective phenotype. This implies, as for the high fat diet induced diabetes 




Chapter 6   
 
General Discussion  
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6 General discussion and future work 
6.1 Major findings of the thesis 
The work presented in this thesis has provided new insights into both the 
physiological and pathological role of the intracellular glucocorticoid regenerating 
enzyme 11β-HSD1 in the pancreatic β-cell. 
 
Firstly, the enzyme was shown to be expressed in β-cells with a predominant role to 
amplify local glucocorticoid action. The elucidation of the major promoters in 
regulating 11β-HSD1, P1 and P2 indicate that it is likely to be regulated by the same 
factors that regulate its expression in liver and adipose tissue. This promoter pattern 
predicts that 11β-HSD1 will be sensitive to the changes of C/EBPs, metabolic 
effectors and inflammatory modulators. Indeed, the first evidence is provided that 
islet 11β-HSD1 is down-regulated by high glucose, insulin under physiological 
glucose levels and is up-regulated by free fatty acids and the proinflammatory 
cytokine TNFα. These data provide the first clue that factors involved in 
physiological regulation of obesity and/or diabetes might lead to the dysregulation of 
islet 11β-HSD1. Importantly, the synthetic glucocorticoid (dexamethasone) does not 
regulate islet 11β-HSD1 even at a supraphysiological dose, which suggests the local 
or systemic corticosterone is not a driver for altering islet 11β-HSD1 in diabetes.  
 
Having shown that β-cell 11β-HSD1 is elevated in a number of obesity models, 
including high fat diet (a modest increase with compensation in C57BL/6J, but a 
reduction in C57BL/KsJ with β-cell failure) and diabetic Lepdb/db mice (a larger 
increase with β-cell failure), it was reasoned that 11β-HSD1 might dynamically 
regulate the insulin secretory capacity of the β-cell. Given the weight of evidence to 
suggest that GCs negatively affect GSIS, but some of the conflicting data in the 
literature that GCs may also improve aspects of β-cell function (details in 1.4.3.3.4), 
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a transgenic model of β-cell specific 11β-HSD1 overexpression was therefore 
created. It was hypothesized that high level of 11β-HSD1 would amplify local GC 
action and suppress GSIS. On the contrary, as shown in chapter 4, modest elevation 
of 11β-HSD1 in the β-cells of the β-cell failure-susceptible KsJ line (MIP-HSD1tg/+) 
– to the level seen in the robustly compensating C57BL/6J line – completely reversed 
β-cell failure. Homozygote mice (MIP-HSD1tg/tg) with higher again 11β-HSD1 
overexpression tipped the islet function over a protective threshold, leading to 
suppressed basal GSIS, suggesting that the discrepancies observed in the literature 
might be reconciled as being a result of GC dose. Despite this inverted U-shaped 
dose response, a hallmark of GCs action in other systems (Du et al. 2009), the 
MIP-HSDtg/tg mice retained a partial protection from HF-induced β-cell failure. This 
suggests that the mechanisms leading to suppression or stimulation of GSIS by GCs 
can be dissected, and this may offer the potential for future exploration of β-cell 
compensatory mechanisms. Indeed, more recent work based on a microarray 
comparison on MIP-HSD1tg/+ and KsJ islets from HF fed mice suggests that protein 
kinase A, heat-shock and ERK signaling pathways may underlie the remarkable 
protection from β-cell failure in this model (Turban et al. unpublished). Of note, 
there was no major effect of the MIP-HSD1tg/+ on inflammatory signaling pathways 
that had been proposed as the protective mechanism of corticosterone-mediated 
improvement of GSIS in islets (Hult et al. 2009). It is likely that both the degree of 
inflammatory damage in the type 2 diabetes model is lower than a type 1 diabetes 
environment and that the level of GC regenerated by the modest 11β-HSD1 
overexpression (MIP-HSD1tg/+) is more physiological than that observed with a 
clearly immuno-suppressing dose of corticosterone (200nM) used by Hult et al. 
Nevertheless, it was hypothesized based on the protection from type 2 diabetes that 
MIP-HSD1 mice might be protected from the pronounced inflammatory insult 
induced by STZ-induced type 1 diabetes in chapter 5. This reversed hypothesis was 
shown to be correct. Thus it was shown the MIP-HSD1tg/+ and to a lesser extent 
MIP-HSD1tg/tg islets were protected from high and low dose STZ-induced β-cell 
damage through reduction of inflammatory cell infiltration of the innate immune 
response and increased infiltration pro-resolution T cells of the adaptive immune 
response. 
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6.2 GC action and 11β-HSD1 in islets: a new perspective 
GCs are well known for their profound physiological effects, and are used as 
effective anti-inflammation medicines at high doses. However, long-term 
corticosterone treatment and excessive endogenous glucocorticoids, as seen in 
Cushing Syndrome promotes metabolic disorders which contribute to diabetes 
(Landy et al. 1988; Chrousos 1995; Dorn et al. 1995; Reynolds et al. 2001; Andrews 
et al. 2002). There is disagreement among previous studies on the predominant direct 
effects of GCs on islet function. This may reflect the different species, dose and 
timing of exposure used (Gremlich et al. 1997; Lambillotte et al. 1997; Jeong et al. 
2001; Rafacho et al. 2008; Swali et al. 2008; Hult et al. 2009; Rafacho et al. 2010). 
Transgenic manipulation of 11β-HSD1 in the β-cell has revealed the proponents of 
both suppressive and stimulatory effects of GCs on islet function are likely correct; 
this may largely depend on the (local) dose/length of exposure level, within the 
context of altered demand on the pancreas; for example corticosterone will potently 
suppress inflammatory processes in islets (Hult et al. 2009), however, in vivo, any 
suppressive effect on GSIS might be counteracted by the increased secretory demand 
caused by muscle insulin resistance/hepatic glucose output. The findings reconcile 
the controversy in the field, with the exception of the RIP-GR model, in which 
increased β-cell glucocorticoid sensitivity by overexpression of GR in β-cell led to 
suppressed GSIS in the absence of altered systemic insulin sensitivity (Delaunay et al. 
1997; Ling et al. 1998; Davani et al. 2004). This discrepancy suggests that there are 
distinctions between the models. For example, elevated 11β-HSD1 may metabolize 
other ligands relevant to insulin secretion such as 7-oxysterols (Wamil et al. 2008) 
that can affect GSIS by activating liver X receptor (Efanov et al. 2004). RIP-GR 
mice may alter the balance of the amount of GC that activates stimulatory 
mineralocorticoid receptors in β-cells (Koizumi and Yada 2008), whereas MIP-HSD1 
mice will provide increased ligand to both. RIP-GR mice may have a detrimentally 
altered developmental impact on later adult islet function (Breant et al. 2006), 
whereas MIP-HSD1 have normal islet numbers before birth (Turban et al. 
unpublished). In any case, there is more evidence to suggest 11β-HSD1 is altered in 
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pancreatic islets in obesity and/or diabetes rather than GR (Duplomb et al. 2004; 
Ortsater et al. 2005), suggesting MIP-HSD1 mice are the more relevant model of 
physiological changes or disease. Future work will dissect out the exact molecular 
events underlying the different effects between GR and 11β-HSD1 in islet. 
 
Overall, the data point to islet 11β-HSD1 as having a physiological role in 
compensatory GSIS in the face of insulin resistance. Indeed this will be one of the 
few β-cell compensatory mechanisms described in the literature, and these 
mechanisms are highly sought after to begin the task of intervention in β-cell failure 
and diabetes prevention. Currently advocated therapeutic strategies to inhibit the 
enzyme, whilst having clearly beneficial effects on whole body insulin sensitivity 
may therefore need to be assessed cautiously for β-cell-specific effects in susceptible 
patients (Rosenstock et al. 2010). 
6.3 GC effects on β-cell development 
Our transgenic mice used the insulin promoter to drive 11β-HSD1 gene expression. 
During mouse development insulin appears at e9.5 within the developing pancreatic 
bud (Teitelman et al. 1993), which suggests the MIP-HSD1 mice would express the 
11β-HSD1 gene at this stage which is earlier than its normal expression time at e13 
(Speirs et al. 2004). GCs exert their effects by binding to GR. GR mRNA can be 
detected in foetal pancreatic region at e13.5–e14, increases at e14.5-e16.5 in both 
islet progenitor cells and the majority of ductal cells, then falls sharply (Speirs et al. 
2004). Therefore, the MIP-HSD1 mice would presumably have more GC action on 
developing pancreas since GR is expressed there. Previous reports strongly suggest 
that excessive GC exposure in the developing pancreas reduces the number and 
function of mature β-cells and causes permanently impaired glucose tolerance 
(details in 1.4.3.1). As discussed above, optical projection tomography (OPT) 
showed no difference in islet number between KsJ and MIP-HSD1tg/+ at e18 and in 
newborns (Turban et al. unpublished) which suggest the elevation of GCs in 
MIP-HSD1tg/+ mice has not affected the β-cell development, at least in the prenatal 
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period. Further work has to be done on MIP-HSD1tg/tg mice, which have an impaired 
second phase insulin secretory response even on normal chow diet. This might be 
consistent with the reports of others that excessive GCs in development reduced the 
number of functional β-cell (Garofano et al. 1997; Garofano et al. 1998; Nyirenda et 
al. 2009). 
6.4 GC effects on β-cell replication and apoptosis 
MIP-HSD1tg/+ mice exhibit more small islets than KsJ (Turban et al. unpublished). 
As 11β-HSD1 does not affect β-cell generation and maturation during development 
(Turban et al. unpublished), and there is no evidence for altered proliferation and 
apoptosis (see chapter 5), the neonatal and weaning stages may be the critical 
windows during which higher 11β-HSD1 activity might drive increased β-cell 
proliferation and/or reduced apoptosis leading to an increased pancreatic β-cell mass 
(Scaglia et al. 1995). Proliferation and apoptosis rates/markers will be assessed for 
MIP-HSD1 mice at these time periods in future work. 
6.5 Interaction between islet α-cell and β-cell 
In this thesis the effects of MIP-HSD1 mice on α-cells have not been investigated. 
The islet α-cell secretes glucagon which elevates blood glucose through 
glycogenolysis and gluconeogenesis by binding to the glucagon receptor in liver. 
Glucagon potently stimulates β-cell inulin release to maintain glucose homeostasis 
(Gromada et al. 1997). The effects of GC on glucagon secretion are not clear. 
Prednisolone increased glucagon secretion in mice in vitro (Marco et al. 1976) in 
agreement with clinical studies (Wise et al. 1973). However, 50nM corticosterone 
and 11DHC reduced mouse islet glucagon secretion in vitro (Swali et al. 2008). 
Moreover, 10nM dexamethasone decreased glucagon receptor mRNA expression in 
rat islets (Abrahamsen and Nishimura 1995). Therefore, it will be important to 
investigate whether MIP-HSD1tg/+ mice with increased islet insulin secretion, exhibit 
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altered glucagon paracrine profiles in future. The role of α-cell 11β-HSD1 
expression (Swali et al. 2008) will also be important to examine in conjunction with 
changes in the β-cell. 
6.6 Glucose metabolism and the insulin secretion mechanism 
MIP-HSD1tg/+ mice display a clearly compensatory secretory response to high levels 
of glucose stimulation after high fat feeding. This suggests an optimal concentration 
of GCs is a positive physiological adaptive response supporting hyperinsulinaemia. 
Although the mechanism is largely unknown, this may affect the factors involving in 
glucose metabolism and/or insulin secretion, such as NAD(P)H/NAD(P)+ ratio 
(Rafacho et al. 2010), intracellular Ca2+ concentration (Rafacho et al. 2010; Sood and 
Ismail-Beigi 2010) and insulin secretory granule release (Rafacho et al. 2010). 
Moreover, factors affecting GSIS can differentially regulate β-cell 11β-HSD1 
activity (see chapter 3) such as high glucose, insulin as well as palmitate and TNFα. 
Besides the preliminary identification of PKA (increasing insulin secretion (Gao et al. 
2002))/Hsp (reducing ER stress (Hult et al. 2009))/ERK pathways (enhancing 
differentiation (Ehses et al. 2002)) as underlying the beneficial changes (Turban et al. 
unpublished), future work will build upon the impact of (modest, chronically) altered 
GC exposure on the secretory machinery of the β-cell including membrane potential, 
G-protein coupled receptor signalling (e.g. GLP-1 responsiveness, a major incretin 
hormone that signals increased insulin secretion and islet survival), calcium and 
NADPH flux. In the latter case, one might expect the increased 11β-HSD1 activity to 
deplete NADPH levels, at least in the ER where the co-factor is provided by H6PDH. 
This intriguing reversal of the co-factor shuttle might be expected to reduce GSIS, as 
NADPH is a proximal stimulatory factor in this process (Ivarsson et al. 2005; 
Ronnebaum et al. 2006). Clearly, any 11β-HSD1-mediated NADPH consumption 
does not show negative impact on GSIS, at least on the heterozygote MIP-HSD1tg/+ 
mice. 
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6.7 11β-HSD1 knockout mice and implications for therapeutic 
11β-HSD1 inhibitors 
The global deletion of 11β-HSD1 and the utilization of 11β-HSD1 inhibitors showed 
protective effects in metabolic disease (see 1.5.5 and 1.5.6) in laboratory animals as 
well as in some clinical trials (details in 1.5.6). The prospects for therapeutic 
inhibition of 11β-HSD1 are therefore raised, although the effects of 11β-HSD1 in 
some tissues and systems have not been fully explored. Indeed modestly elevated 
11β-HSD1 in β-cell (MIP-HSD1tg/+) showed protective effects from high fat diet- 
and STZ-induced diabetes. Moreover, 11β-HSD1 knock out mice exhibit a mild 
β-cell insulin secretory defect (Turban et al. unpublished) although this is masked 
under normal insulin sensitivity and in particular under the dominant beneficial 
effects of peripheral insulin sensitization with HF diet (Morton et al. 2004). Whilst 
further work will be needed to confirm whether 11β-HSD1 is similarly regulated in 
human islets, and plays a functional role in GSIS, it must be concluded that 
11β-HSD1 inhibitors at least be given with caution. Close attention may have to be 
paid to those individuals who may have a genetic predisposition for β-cell failure or 
some indication of β-cell insufficiency (e.g. risk-associated HOMA-B) (Dupuis et al. 
2010). The work in this thesis therefore gives an immediately clinically relevant 
insight into the clinically effective dose of steroids or 11β-HSD1 inhibitors in 
therapeutic treatment of diabetes. 
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